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Klebsiella pneumoniae is a common cause of nosocomial and community-acquired 
infections, and the increasing incidence and prevalence of antibiotic resistant strains 
is proving to be particularly problematic to clinicians.  K. pneumoniae is capable of 
employing a multitude of mechanisms by which to confer resistance to most 
available antibiotics.  The carbapenem antibiotics are usually reserved for the 
treatment of complicated or multidrug resistant (MDR) K. pneumoniae infections.  
The recent emergence of not only MDR but also pan-drug resistant (PDR) K. 
pneumoniae strains has signified that it is now more important than ever to 
understand the mechanisms by which these strains confer resistance so that we may 
find ways to combat or hinder this progression.  This project aimed to investigate the 
regulation of the transcriptional activator RamA, its ability to confer a MDR 
phenotype, and the mechanisms employed by K. pneumoniae to confer levels of 
carbapenem resistance sufficient to result in therapy failure. 
 
The analysis of a panel of K. pneumoniae strains, containing both RamA expressers 
and non-expressers, demonstrated that the overexpression of RamA was sufficient to 
confer an MDR phenotype.  Two compounds, chlorpromazine (CPZ) and tigecycline, 
were shown to act as inducers of ramA, romA and acrA transcription.  CPZ exhibited 
synergy with the antibiotics chloramphenicol, norfloxacin and tetracycline, all of 
which are known substrates of the AcrAB efflux pump.  The current lack of novel 
classes of antimicrobials in development indicate a potential for a compound, such as 





tigecycline to cause mutations within ramR however, indicate that both compounds 
may have the ability to select for efflux mutants as a result of their ability to 
upregulate ramA, which in turn causes the upregulation of the AcrAB efflux pump. 
 
The regulation of RamA by the upstream gene ramR, which encodes a TetR family 
protein was investigated in K. pneumoniae isolates.  Sequencing of the ramR genes 
revealed that strains exhibiting an MDR phenotype commonly contained mutations 
within their gene sequences.  The complementation of a wildtype ramR into a strain 
containing a 32 amino acid deletion within its ramR, was shown to increase 
susceptibility to various antibiotics of different classes, and additionally 
downregulate the expression of ramA, romA and acrA.  CPZ, ciprofloxacin and 
tigecycline K. pneumoniae mutants were shown to exhibit increased MICs to a broad 
spectrum of antibiotics with respect to their parent strains, and possess mutations 
within their ramR genes.  Complementation of the wildtype ramR resulted in partial 
reversion to the parental phenotypes, indicating another mechanism must also be 
involved in conferring the MDR phenotypes.  These studies indicated that RamR 
plays an important role as a negative regulator of RamA, but also that it is not the 
sole regulator. 
 
The development of reduced susceptibility to the carbapenems was investigated in 
two clinical strains of K. pneumoniae, K1 and K2, isolated from the urine of a single 
patient at different stages of antibiotic therapy.  The strains were shown to exhibit 
similar resistance phenotypes with the exception of their susceptibilities to the 





any carbapenemases or AmpC enzymes, but both contained OXA-1, SHV-1 TEM-1 
and CTX-M-15.  Analysis of their OMP profiles indicated that both strains lacked 
OmpK35, and K2 additionally lacked OmpK36.  Mutation studies showed that the 
phenotype and OMP profile exhibited by K2 could be achieved in K1 via single step 
mutations using ertapenem, imipenem or meropenem.  Susceptibility testing of CTX-
M-15 clinical strains showed that strains containing CTX-M-15 showed reduced 
activity against ertapenem in the presence of clavulanic acid.  These studies indicated 
a potential role for CTX-M-15 in conferring reduced susceptibility to the 
carbapenems when found in conjunction with altered permeability and active efflux. 
 
The mechanisms of antibiotic resistance employed by K. pneumoniae are numerous 
and complex.  This work highlights several of these mechanisms and, more 
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Chapter 1: Introduction 
 
1.1  A brief history of antibiotics 
 
1.1.1  Definition of antibiotics 
 
Traditionally antibiotics are defined as natural microbial products that can kill or 
inhibit the growth of other micro-organisms, however synthetically produced 
antibiotics are now also referred to under the same heading. 
 
1.1.2  The emergence of antibiotics 
 
Antibiotics were introduced into medicine over 70 years ago, significantly altering 
life expectancy (Lesche, 2007).  Antibiotics have enabled the successful treatment of 
previously life-threatening infections and allowed for the use of interventions, such 
as surgery, for medical conditions which were previously thought to be untreatable 
due to the high risks of infection.  The first antibiotics, the sulphonamides 
(Prontosil
®
), were put into commercial use in the 1930’s (reviewed by Lesche, 2007).  
Prontosil
® 
was a man-made antibiotic with broad antimicrobial activity against 
Gram-positive bacteria but with no effect on Enterobacteriaceae (reviewed by 
Lesche, 2007).  This was quickly followed by other sulphonamide drugs prior to the 
use of the first natural antibiotic, penicillin, a β-lactam class antibiotic derived from 
the mould Penicillium chrysogenum, the discovery of which was accredited to 





penicillin was not commercially available for clinical use until the early 1950’s due 
to difficulties in its purification and production (reviewed by Quirke, 2001).  In the 
years following their initial discoveries and availability for clinical utilisation, 
antibiotic use rose exponentially and several new classes of both man-made and 
naturally occurring antibiotics were discovered including the aminoglycosides in 
1943 and tetracycline in 1955.  By the end of the 1960’s the development of new 
antibiotics had all but stopped and pharmaceutical companies instead began altering 
the molecular structure of already existing antibiotics in order to overcome bacterial 
resistance mechanisms and toxicity issues (Schlaes et al, 2004).  It was not until the 
late 1990’s and early 2000’s that any further new antibiotic classes were discovered 
and made available for clinical use; the lipopeptides (daptomycin), the glycylcyclines 
(tigecycline) and the oxazolidinones (linezolid).  Currently new antibiotics are scarce 
with few compounds making it through safety and efficacy trials to commercial 
production. 
 
1.2  Antibiotic classes 
 
1.2.1  Antibiotic mechanisms of action 
 
Antibiotics can exert their antimicrobial effects via five main mechanisms; inhibition 
of DNA synthesis, inhibition of RNA synthesis, inhibition of protein synthesis, 







Inhibition of DNA synthesis 
Example: The fluoroquinolones target DNA gyrase and topoisomerase IV, 
preventing the unwinding of supercoiled DNA and therefore 
inhibiting DNA transcription and replication. 
 
Inhibition of RNA synthesis 
Example: Rifampicin binds the β-subunit of RNA polymerase, preventing RNA 
transcription and any subsequent translation. 
 
Inhibition of protein synthesis 
Example: Tetracyclines bind to the 16S part of the 30S ribosomal RNA subunit 
preventing the binding of amino-acyl tRNA and inhibiting translation.  
 
Inhibition of cell wall synthesis 
Example: β-lactam antibiotics inhibit transpeptidase and peptidoglycan 
synthesis preventing the cross linking of the polysaccharide chains in 
the bacterial cell wall. 
 
Inhibition of tetrahydrofolate synthesis 
Example: The sulphonamides competitively inhibit dihydropteroate synthetase 
resulting in the disruption of the tetrahydrofolate synthase pathway, 






Antibiotics are typically classed as either bactericidal or bacteriostatic towards their 
targets, however some can act in either respect, usually dependent upon the 
concentration of antibiotic used and the target bacterium.  Bactericidal antibiotics are 
capable of killing the bacteria whilst bacteriostatic antibiotics inhibit bacterial 
reproduction.  Table 1.1 shows the mechanisms by which each class of antibiotic 




























Mechanism of Action Antibiotic Class Sub-Class Bacteriostatic/Bactericidal Examples 
Inhibition of DNA synthesis 
Fluoroquinolones 
  
Bactericidal Ciprofloxacin, Norfloxacin 
Metronidazole Bactericidal Metronidazole 
Quinolones Bactericidal Nalidixic acid 
Inhibition of RNA synthesis Rifampicin Bactericidal Rifampicin 
Inhibition of protein synthesis 
Aminoglycosides Bactericidal Amikacin, Gentamicin 
Chloramphenicols Bacteriostatic Chloramphenicol, Thiamphenicol 
Glycylcyclines Bacteriostatic Tigecycline 
Lincomycins Bacteriostatic Clindamycin, Lincomycin 
Macrolides  Bacteriostatic Azithromycin, Erythromycin 
Oxazolidinones Bacteriostatic Linezolid 
Tetracyclines Bacteriostatic Minocycline, Tetracycline 




  Carbapenems Ertapenem, Meropenem 
  Cephalosporins   -  1st Gen Cefazolin, Cefalexin 
                                 2nd Gen Cefoxitin, Cefuroxime 
                                 3rd Gen Cefotaxime, Cefpodoxime 
                                 4th Gen Cefepime 
                                 5th Gen Ceftobiprole 
  Monobactams Aztreonam 




Glycopeptides Bactericidal Teicoplanin, Vancomycin 
Lipopeptides Bactericidal Daptomycin 
Polypeptides Bactericidal Bacitracin, Colistin 
Inhibition of tetrahydrofolate 
synthesis 
Diaminopyrimidines Bacteriostatic Iclaprim, Trimethoprim 
Sulphonamides Bacteriostatic Sulphadiazine, Sulphamethoxazole 
 







1.2.2  Synergistic effects of antibiotic combinations 
 
In cases of difficult or highly resistant infections combinations of antibiotics, usually 
of different mechanisms of action or antibiotics which show synergy together, can be 
used to eliminate such infections.  Antibiotic synergy is defined as when the effects 
of the combination of two or more antibiotics is greater than the sum of the effects of 
the individual antibiotics (Gould et al, 1991).  
  
The aminoglycosides and β-lactams are two antibiotic classes with different 
mechanisms of action that can be more active when used together than separately 
(Gavalda et al, 2003).  Aminoglycosides are bactericidal protein synthesis inhibitors 
and are required to penetrate the bacterial cell and bind the 30S ribosome to exert 
their antimicrobial action.  The β-lactams are bactericidal cell wall inhibitors which 
bind to the penicillin binding proteins to inhibit peptidoglycan synthesis.  When used 
together, the action of the β-lactams inceases the permeability of the cell wall 
allowing a higher rate of penetration for the aminoglycosides, and a synergistic effect 
can be observed. 
 
Another common example of this is the use of clavulanic acid with cephalosporins.  
Clavulanic acid on its own shows little antimicrobial activity, however it is capable 
of competitively inhibiting some β-lactamase enzymes due to its possession of a β-
lactam ring structure similar to that found in the β-lactam class antibiotics.  This can 
allow a β-lactam antibiotic to exert antimicrobial effects against the bacterium which 





One of the first observed examples of synergy was that of the sulphonamide, 
sulfamethoxazole, and the dihydrofolate reductase inhibitor, trimethoprim.  The 
synergy between these two antibiotics was first observed in both in vivo and in vitro 
experiments in the 1960’s (Bushby and Hitchings, 1968).  Both antibiotics inhibit the 
tetrahydrofolate synthesis pathway, albeit at different steps.  Sulfmethoxazole 
competitively inhibits dihydropteroate synthetase, the enzyme responsible for 
dihydropteroic acid synthesis and trimethoprim inhibits the conversion of 
dihydrofolic acid into the end-product, tetrahydrofolic acid.  This combination is 
available as co-trimoxazole which contains a 1:5 ratio of trimethoprim to 
sulfamethoxazole. Co-trimoxazole shows activity in bacterial, protozoan and fungal 
infections, and consequently is often used as a prophylactic agent in immune 
compromised (eg HIV) patients (Walker et al, 2010). 
 
There are numerous other antibiotic combinations used clinically, even more so due 
to the ever increasing incidences of multidrug resistant (MDR) infections.  It has 
been suggested that combination therapy can also limit the development of resistance 
and this tactic has long since been utilised in the treatment of infections such as 











1.3  The early development of antibiotic resistance 
 
1.3.1  The end of bacterial infections? 
 
Following the antibiotic boom of the 1950’s and 1960’s many experts had begun to 
believe that bacterial infections were to become a problem of the past.  In 1969 the 
US Surgeon General, William Stewart, announced to the US congress that it was 
time to “close the books on infectious diseases” (Martin, 2008).  However, this 
opinion was not shared with all in the scientific and medical community.  Alexander 
Fleming had previously been quoted by the New York Times in 1945 saying, “The 
greatest possibility of evil in self-medication is the use of too small doses so that 
instead of clearing up infection the microbes are educated to resist penicillin and a 
host of penicillin-fast organisms is bred out which can be passed to other individuals 
and from then to others until they reach someone who gets a septicaemia or 
pneumonia which penicillin cannot save”.  This statement could now be considered 
to have been a fairly accurate prediction of the development of antibiotic resistance. 
 
1.3.2 The development of resistance 
 
The term antibiotic resistant is usually used to refer to an infection causing bacterium 
that cannot be successfully treated with an antibiotic at clinically achievable 
concentrations.  Susceptibility can be defined as a minimum inhibitory concentration 






Bacteria were undoubtedly exhibiting resistance to antibiotics long before humans 
utilised antibiotics for medicinal purposes, largely due to most antibiotic classes 
being produced by other micro-organisms in the environment where bacteria would 
encounter them naturally and subsequently develop resistance mechanisms as a 
means of survival.  The classic example of this is penicillin, a product of the fungus 
P. chrysogenum commonly found in soil, a habitat shared with several clinically 
relevant species of bacteria including P. aeruginosa and Acinetobacter spp.  As a 
result of their natural habitat these organisms tend be intrinsically resistant to 
penicillin due to the possession of chromosomal β-lactamases (Jacoby, 2009). 
 
Since the first discovery and utilisation of antibiotics in medicine in the 1930’s we 
have witnessed what can be described as a dual evolution.  On one hand there has 
been an increase in the number of antibiotic classes, their variants and spectrum of 
activity; whilst on the other hand there has been the emergence and dissemination of 
antibiotic resistance.  It is unknown which resistance phenotypes were pre-existing 
and which developed as a consequence of antibiotic utilisation in humans.  The effect 
on microbial populations following the first introduction of antibiotics cannot be 
determined and it is possible that some bacterial species were even completely 
eliminated as a result (Lesche, 2007).  When the first wave of resistance was detected 
(to the penicillins), the introduction of newer antimicrobials were used to counteract 
the effect.  This pattern of resistance development continued for almost all newly 
introduced antibiotics but was not disastrous for medicine due to the continuous 
discovery of newer alternatives.  However, in recent years the rate of new antibiotic 





evolving faster than ever, and consequently we are witnessing the increasing 
emergence of MDR and pandrug resistant (PDR) strains (Levy and Marshall, 2004; 
Falagas and Bliziotis, 2007).    As a result, treatment options are fast becoming 
limited and the quest for new antibiotics is of increasing importance. 
 
It should also be stated that despite the emergence of antibiotic resistant strains, not 
all species of bacteria are suited to attaining an MDR phenotype upon exposure to 
antibiotics.  The potential for the development of multidrug resistance is species-
specific.  For example Streptococcus pyogenes infections are commonly treated with 
penicillin antibiotics and yet S. pyogenes generally remains susceptible to the 
penicillins and other β-lactam antibiotics (Albrich et al, 2004). 
 
1.4  Mechanisms of resistance 
 
1.4.1  Resistance acquisition in bacteria 
 
Bacteria typically acquire resistance through the following: mutations and the 
acquisition of genes.  There are several mechanisms by which bacteria can develop 
resistance including: reduced permeability, active efflux, inactivation of the 
antibiotic via destruction or alteration, alteration of drug target, target amplification, 
and additional targets; all of which can be as a result of either resistance acquisition 







1.4.2  Mobile genetic elements 
 
There are two main categories of mobile genetic elements; those that are capable of 
horizontal transfer (moving from one cell to another), namely plasmids and 
bacteriophages, and those that can move from one genetic location to another within 
the same cell, transposons and integrons (Bennett, 2008).  Mobile genetic elements 
have been linked to the dissemination of resistance genes to several antibiotic classes 
including the fluoroquinolones, aminoglycosides and β-lactams (Bennett, 2008). 
 
1.4.2.1  Bacteriophages 
 
Bacteriophages, also known as phages, are viruses that infect bacteria.  Phages can 
undergo two types of replication, lytic or lysogenic.  Phages are capable of carrying 
and disseminating antibiotic resistance genes by transduction.  Lytic phages, such as 
T4 phage, penetrate the bacterial cell and replicate using the cells own replication 
machinery.  This results in the immediate phage-mediated lysis of the bacterial cell 
wall and the release of the new phages which can then go on to infect new hosts.  
Lysogenic phages will penetrate the bacterial cell and incorporate their DNA into the 
host chromosomal DNA.  The phage DNA will then replicate alongside the host 
DNA but cause no harm to the host.  The virus lies dormant and continues to allow 
the host to replicate as normal, producing a copy of the virus DNA in each of the 
daughter cells.  Bacteriophages are also capable of carrying plasmids, transposons 






1.4.2.2  Transposons 
 
Transposons, also known as ‘jumping genes’, are mobile genetic elements that can 
move around within a genome by transposition.  These sequences of DNA, found in 
both Gram-positive and Gram-negative bacteria, contain transposase genes and are 
identified by the presence of inverted repeated sequences at both ends of the element.  
In bacteria, transposons are capable of transposition between plasmid and 
chromosomal DNA and vice versa, often carrying genes encoding antibiotic 
resistance.  Transposons are an essential mechanism for the dissemination of 
antibiotic resistance genes amongst bacteria.  Of note, transposons that lack any 
additional genes are known as insertion sequences. 
 
1.4.2.3  Integrons 
 
Integrons are genetic elements that contain an integrase gene which mediates the 
integration of external DNA into the integron.  They can ‘poach’ external 
chromosomal or plasmid DNA, including antibiotic resistance genes, and incorporate 
the DNA into the integron.  Integrons often reside within transposons and so 
represent a mechanism by which new antibiotic resistance genes are added to the 









1.4.2.4  Plasmids 
 
Plasmids are self-replicating, circular DNA molecules that are capable of carrying a 
number of genes.  Bacterial plasmids can range in size from 1kb to >1000kb (Finan 
et al, 2001).  Bacterial plasmids act as a scaffold upon which gene arrays can be 
built, often encoding antibiotic resistance genes, by the incorporation of transposable 
elements and integron gene cassettes.  A resistance plasmid is one which encodes 
resistance genes to one or more antibiotics (Bennett, 2008).  Plasmids can provide a 
means by which bacterial species can dip into the resistance gene pool when 
necessary for their survival.  Some plasmids have a particularly broad host range, for 
example the resistance plasmid RP1, initially identified in P. aeruginosa, is capable 
of dissemination amongst most Gram-negative species of bacteria (Bennett, 2008).  
Genes encoding resistance to several families of antibiotics, particularly the β-
lactams, are commonly disseminated in this manner.   
 
1.4.3  Mutations 
 
The types of mutations resulting in resistance to antibiotics are wide and varied.  For 
example, the target site for the antibiotic may be mutated so that the antibiotic can no 
longer bind and exert its effects or alternatively, mutations can occur in the 
regulation genes of efflux pumps causing them to be over-expressed.  The mutations 
themselves may simply consist of single amino acid changes that alter the gene 
transcription, translation or efficacy of a particular protein, or alternatively may 





Mutations often occur as a direct result of antibiotic pressure, ie an adaptive response 
enabling the survival of the bacterium.  In such cases the mutations are targeted 
towards particular genes and many of these have been well characterised in bacteria.  
For example, mutations within the gyrA gene have been associated with 
fluoroquinolone resistance in members of the Enterobacteriaceae (Weigel et al, 
1998). 
   
However, the effect of spontaneous mutations, in the absence of antibiotic pressure, 
cannot be underestimated.  In Mycobacterium tuberculosis, it is a succession of such 
mutations that are thought to be responsible for the development of multidrug 
resistance rather any gene acquisition (Musser, 1995).  An example of this is 
resistance to streptomycin in the absence of any aminoglycoside modifying enzymes 
which is instead thought to be caused by mutations in the 16S ribosomal RNA genes 
to which streptomycin usually binds (Musser, 1995). 
 
1.4.4  Bacterial efflux pumps 
 
Efflux pumps are proteins involved in the transport of toxic substrates across the cell 
membrane and into the external environment.  These pumps are found extensively in 
both prokaryotic and eukaryotic organisms.  Efflux pumps are present in all studied 
bacterial genomes and so can be considered to be essential for cell survival (Webber 
and Piddock, 2003).  Such pumps are normally encoded within the bacterial 
chromosome but can also be found on plasmids, suggesting that they are capable of 





include members of several antibiotic families, can easily penetrate the bacterial cell 
membrane and so it is essential that the cell must have a mechanism with which to 
extrude unwanted and toxic compounds that may enter from the external 
environment, as well as those created within the cell by biological processes 
(Bambeke et al, 2000).  The pumps can be specific for a particular substrate or 
alternatively they can have a broad substrate range.  Efflux is an important 
mechanism of antibiotic resistance for two reasons: they allow the bacterium to cope 
and survive in a stressful environment (in the presence of antibiotics) and 
concurrently, by delaying the death of the bacterium they increase exposure time to 
the antibiotics in which the bacterium may undergo mutations in order to achieve 
higher levels of resistance.   
 
Efflux pumps are increasingly implicated in the causes of antibiotic resistance within 
numerous clinically relevant bacterial species including K. pneumoniae and P. 
aeruginosa (Webber and Piddock, 2003; Yang et al, 2003).  The presence of efflux is 
often gauged in vitro by the use of efflux pump inhibitors (EPIs) such as reserpine, 
CCCP and PABN.  These are used alongside the relevant antibiotics to result in 
increased susceptibilities, when compared to the antibiotic alone, in the presence of 
active efflux.  However EPIs are only used to gauge the presence of efflux in the 
laboratory and cannot be used clinically for treatment due to their toxicity and 
potential to interfere with other cellular functions (Garvey and Piddock, 2008).  The 
presence of active efflux therefore presents a major problem in successfully treating 
infections with the usual first line antibiotics and such infections may require 





There are several families of efflux pumps found in bacteria which are classified by 
three main criteria; their structural homology, substrate specificity, and energy 
source. 
 
1.4.5  Efflux pump families 
 
• The ATP binding cassette superfamily (ABC) 
• The multidrug and toxic compound extrusion family (MATE) 
• The major facilitator superfamily (MFS) 
• The resistance nodulation cell division superfamily (RND) 
• The small multidrug resistance family (SMR) 
 










ABC +ve/-ve LmrA, L. lactis ATP 12 P 
Bambeke et al, 
2000. 
MATE -ve YdhE, E. coli PMF 12 S 
Borges-
Walmsley et al, 
2003. 
MFS +ve/-ve NorA, S. aureus PMF 12 or 14 S Yin et al, 2000. 
RND -ve AcrAB, E. coli PMF 12 S Yang et al, 2003. 
SMR +ve/-ve QacC, S. aureus PMF 4 S 
Leelaporn et al, 
1994. 
 
Table 1.2.  Bacterial efflux pump families.  A summary of the types of efflux 
pumps found in bacteria with structural information and examples.  PMF – proton 






In Gram-negative bacteria there are structural similarities between the RND, ABC 
and MFS pumps.  All three are proposed to function with a membrane fusion protein 
(MFP) and outer membrane protein (OMP) (Paulsen et al, 1997).  Whilst the MFP 
component of the pump is often exclusive to the transporter protein (eg AcrAB, 
MexAB), the OMPs have been shown to be somewhat promiscuous (Welch et al, 
2010).  It has been shown that TolC in E. coli can function alongside a number of 
different RND transporters as well as MFS transporters in the transport of iron 
(Bleuel et al, 2005).   
 
1.4.5.1  ABC 
 
The ABC transporter family forms one of the largest protein families, within both 
eurkaryotes and prokaryotes, with a broad substrate range including the uptake of 
sugars and the extrusion of toxic substances (Borges-Walmsley et al, 2003).  These 
primary transporter systems are distinct from other efflux systems in that they source 
their energy from ATP hydrolysis for both the uptake and efflux of 
compounds/molecules.  The pumps themselves constitute two transmembrane 
domains, each containing six helices, and two cytoplasmic domains.  These pumps 
can function as either homodimers or heterodimers.   LmrA is an example of a well 
characterised member of this superfamily which has been shown to be involved in 








1.4.5.2  MATE 
 
MATE transporters comprise of a protein of approx. 450 amino acids in length 
arranged into 12 TMS.  These transporters have been implicated in multidrug 
resistance in a number of bacteria as well as yeast (Kuroda and Tsuchiya, 2009).  
YdhE has been shown to confer resistance to cationic antimicrobials in E. coli 
(Borges-Walmsley et al, 2003). 
 
1.4.5.3  MFS 
 
The MFS efflux pumps are similar in structure to the RND family in that they 
typically have 12 or 14 TMS and require the use of an OMP component to complete 
their function.  These pumps have been shown to be involved in the mediation of 
drug resistance but also in the uptake of various substrates such as sugars into the cell 
(Yin et al, 2000).  The TetA(B) protein is an example of a well characterised member 
of this family which has been shown to transport tetracycline in E. coli (Yin et al, 
2000). 
 
1.4.5.4  RND 
 
Of the five families of efflux pumps, the RND pumps are found most extensively and 
abundantly in Gram-negative bacterial species.  These pumps have a broad substrate 
range and are capable of the efflux of several families of antibiotics.  The RND 





protein consisting of 12 TMS (Figure 1.1).  Many of the RND family pumps exist as 
part of an operon containing a control mechanism, usually a repressor gene, often 
shortly upstream of the pump encoding genes.  The efflux genes are transcribed 
when the repressor is deactivated, most commonly by mutations.  The ability of these 
pumps to be switched on when the bacterium is under antibiotic stress and their 
broad substrate range can lead to cross-resistance of a bacterium to several 
structurally unrelated antibiotics that they may not have previously encountered.  The 
AcrAB pump, found in several members of Enterobacteriaceae, has been particularly 
well characterised in E. coli and shown to be capable of conferring an MDR 










Figure 1.1.  RND family efflux pump.  The typical structure of an RND family 
efflux pump found in Gram-negative bacteria. (adapted from Schneiders et al, 2009) 
 
1.4.5.5  SMR 
 
SMR efflux pumps are relatively small comprising of around 100 amino acids which 
are arranged into four transmembrane helices.  Despite their small monomeric size, 
SMR pumps are thought to function as trimers, making for a complex tertiary 
structure similar to that of the RND or MFS pumps.  The QacC proteins found in 
staphylococcal species have been shown to confer resistance to several types of 








1.5  The bacterial outer membrane 
 
1.5.1  Permeability of the outer membrane 
 
The Gram-negative bacterial membrane is made up of a bilayer consisting of 
phospholipids, lipopolysaccharides and OMPs (Domenech-Sanchez et al, 1999).  
The membrane has several functions including acting as a barrier between the 
intracellular and extracellular environment and controlling the passage of molecules 
in and out of the cell.  The porins, an OMP family of proteins, generally consist of 
two subgroups; specific, eg OprD in P. aeruginosa, and non-specific porins, eg 
OmpC and OmpF in E. coli (Domenech-Sanchez et al, 1999).  Non-specific porins 
generally allow the diffusion of small polar molecules whilst specific porins only 
allow the diffusion of specific substrates (Domenech-Sanchez et al, 1999). 
 
1.5.2  Major OMPs 
 
A major cause or contributing factor to an antibiotic resistant phenotype in bacteria, 
particularly Gram-negative species, is the alteration of outer membrane permeability.  
In a number of members of the Enterobacteriaceae, including E. coli, K. pneumoniae 
and Salmonella spp., there are three major OMPs which were initially characterised 
and named in E. coli as OmpA, OmpC and OmpF.  The primary function of these 
porins is to allow the passage of nutrients and other molecules in and out of the cell.  
This inadvertently allows the passage of several types of antibiotics.  The loss of one 





and lead to a reduction in susceptibility.  When in combination with active efflux, 
high levels of resistance to multiple antibiotics can be achieved.  In K. pneumoniae 
the loss of the OmpF homologue OmpK35 has been associated with cefoxitin 
resistance (Ananthan and Subha, 2005).  Porin loss is often due to mutations, 
insertions or deletions in the open reading frame or the promoter region of the 
encoding gene.   
 
1.5.3  The major OMPs of K. pneumoniae 
 
There are three major OMPs found in K. pneumoniae; OmpK34 (OmpA), OmpK35 
(OmpF) and OmpK36 (OmpC).  (E. coli homologues shown in brackets)   
 
1.5.3.1  OmpK34 
 
OmpK34 is a ~34kDa, monomeric, heat modifiable protein that forms a non-specific 
porin (Nikaido, 2003).  Unlike the other major porins, OmpK34 is not reported to 
play any role in antibiotic resistance.  Studies have shown in the OmpK34 
homologues, OmpA from E. coli and OprF from P. aeruginosa, that these proteins 
form ‘closed’ porins that prevent the permeation of large molecules such as 
antibiotics (Nikaido, 2003).  Comparisons with OmpC and OmpF have shown that 
solutes permeate OmpA at a rate two orders of magnitudes lower (Nikaido, 2003).  
OmpA has been indicated to be integral for the stability of the outer membrane and 






1.5.3.2  OmpK35 
 
OmpK35 is a ~40kDa, trimeric protein that forms a non-specific porin (Lee et al, 
2006).  OmpK35 has been reported to allow the penetration of several β-lactam 
antibiotics including cefotaxime, cefoxitin, and to a lesser extent imipenem and 
meropenem (Domenech-Sanchez et al, 1999).  OmpK35 is reported to allow the 
passage of slightly larger solutes than OmpK36 with a preference for cations over 
anions (Nikaido, 2003).  A study has suggested that clinical exposure to cefuroxime 
can deplete the expression of OmpK35 (Kallmann et al, 2008).  OmpK35 is classed 
as an osmoporin as evident by its reduced expression in a high osmolarity 
environment (Dutzler et al, 1999). 
 
1.5.3.3  OmpK36 
 
OmpK36 is a ~38kDa, trimeric protein that forms a non-specific porin.  Examination 
of the diffusion rates of organic molecules through the homologous porins OmpC 
and OmpF suggest that OmpC is a slightly smaller porin (Nikaido, 2003).  The loss 
of OmpK36 has been associated with resistance to the β-lactams, including the 
carbapenems.  It has been shown that in K. pneumoniae strains exhibiting resistance 
to carbapenems, OmpK36 is often absent, suggesting that the carbapenem antibiotics 








1.6  The β-lactam antibiotics 
 
1.6.1  The β-lactam class 
 
The β-lactams are a family of antibiotics that are characterised by the presence of a 
β-lactam ring (Figure 1.2).  They are a diverse and varied family which include the 
penicillins, cephalosporins and carbapenems, and are the most commonly prescribed 
antibiotics in Europe (Molstad et al, 2002).  Collectively β-lactams show activity 
against Gram-negative and Gram-positives organisms, including anaerobes.  The 
penicillins, despite being one of the first discovered antibiotics, remain one of the 
most commonly prescribed antibiotics, particularly for urinary tract infections 
(UTIs), largely due to their high absorption rates (Holten and Onsuko, 2000).  For 
more complicated or resistant infections, the cephalopsorins are often prescribed due 
to their broader spectrum of activity.  
 
 
Figure 1.2.  Primary structure of ampicillin.  The primary structure of the β-







The ever-increasing use of β-lactam antibiotics has resulted in the inevitable 
development of resistance, most of which is due to the production and dissemination 
of β-lactamases.  β-lactam resistance is widespread amongst bacteria and a 
considerable and continually growing number of β-lactamases have now been 
identified and characterised.  Two approaches have been used to overcome this 
resistance; the development of new β-lactams that are not degraded/hydrolysed by β-
lactamases, and the use of β-lactamase inhibitors, such as clavulanic acid, sulbactam 
or tazobactam, which work in synergy with the β-lactam antibiotics.   
 
1.6.2  The carbapenems 
 
Carbapenems are considered to be the most powerful of the β-lactam antibiotics and 
are often used as a last resort drug to treat infections that are resistant to the 
cephalosporins.  There are four members of the carbapenems that are used clinically: 
doripenem, ertapenem, imipenem and meropenem. 
 
1.6.2.1  Doripenem 
 
Doripenem is the most recent of the carbapenems licensed for clinical use in the UK 
in 2008 for the treatment of complicated intra-abdominal infections, nosocomial 
pneumonia and ventilator associated pneumonia (European Medicines Agency, 
2008).  It is a broad spectrum, synthetic carbapenem antibiotic reported to be β-
lactam stable and resistant to inactivation by renal enzymes.  Doripenem has been 





Gram-positive and Gram-negative organisms, but poorer activity against anaerobic 
organisms (Greer, 2008).  Despite being licensed, the few reported advantages over 
imipenem and meropenem, coupled with the increased costs have meant that this 
antibiotic is still rarely used compared with the other carbapenems (Greer, 2008). 
 
1.6.2.2  Ertapenem 
 
Ertapenem is a once daily parenteral 1-β-methyl carbapenem antibiotic licensed in 
2002 for use against intra-abdominal, gynaecological and community acquired 
pneumonia (Livermore et al, 2003).  Ertapenem has a more limited spectrum of 
activity, showing poor activity particularly against non-fermenting bacteria (eg 
Pseudomonas spp.), in respect to the other carbapenems and is largely used for the 
treatment of community acquired infections, particularly those caused by extended-
spectrum β-lactamase (ESBL) carrying bacteria (Livermore et al, 2003).   
 
1.6.2.3  Imipenem 
 
Imipenem was developed in 1985 from a naturally produced antibiotic, Thienamycin, 
from Streptomyces cattleya which itself showed broad spectrum activity against 
Gram-positive, Gram-negative and anaerobic organisms (Kahan et al, 1983; Merck, 
2010).  Unfortunately thienamycin instability meant that it was impractical for the 
clinical treatment of bacterial infections and instead a derivative of thienamycin, 
imipenem, was developed and synthesised.  Due to its instability against renal 





inhibitor, in order to prevent its degradation (Merck, 2010).   Imipenem is indicated 
for the treatment of serious and complicated infections of the respiratory tract, skin 
as well as gynaecological and intra-abdominal infections (Merck, 2010).  Compared 
with the other carbapenems, imipenem exhibits increased toxicity in adults with 
impaired renal function and as such requires careful monitoring, particularly in 
elderly patients (Merck, 2010).   
 
1.6.2.4  Meropenem 
 
Meropenem is a broad spectrum, synthetic carbapenem, licensed for use in the UK in 
1988.  Similarly to imipenem, meropenem exhibits broad activity against Gram-
positive, Gram-negative and anaerobic organisms; however unlike imipenem, 
structural differences in meropenem mean it is stable against degradation by 
dehydropeptidase.  Meropenem is indicated for the treatment of serious and 
complicated infections of the skin as well as intra-abdominal infections and bacterial 
meningitis (Astra Zeneca, 2009).    
 
1.7  β-lactamases and extended-spectrum β-lactamases (ESBL’s) 
 
1.7.1  β-lactamases 
 
β-lactamases are enzymes produced by some species of bacteria that are capable of 
conferring resistance to β-lactam antibiotics via the hydrolysis of the β-lactam ring.  





their active site, and those that require the metal ion zinc as a co-factor, known as 
metallo-β-lactamases (Jacoby and Munoz-Price, 2005).  β-lactamases can also be 
grouped into four molecular classes, A to D, based on their primary structure.  
Classes A, C, and D contain a serine residue at their active site and class B comprises 
the metallo-β-lactamases (Jacoby and Munoz-Price, 2005).  These molecular classes 
can be further split into functional groups based on their substrate spectrum and 

















Table 1.3.  β-lactamase classification.  β-lactamases as grouped by their molecular class, functional classification and substrate 





Class Preferred Substrates Enzyme Type Example 
1 C Cephalosporins not inhibited by CA* Cephalosporinases AmpC 
2a A Penicillins Penicillinases Penicillinases from Gram-positive species 
2b A Penicillins, Cephalosporins Cephalosporinase TEM-1 
2be A Penicillins, narrow and broad spectrum 
cepalosporins, monobactams 
Cephalosporinase SHV-2 
2br A Penicillins Inhibitor resistant 
penicillinases 
TEM-30 
2c A Penicillins, carbenicillin Carbenicillinase PSE-1 
2d D Penicillins, cloxacillin Cloxacillinase OXA-1 
2e A Cephalosporins   Cephalosporinase Inducible penicillinases from Proteus vulgaris 
2f A Penicillins, cephalosporins, 
carbapenems 
Carbapenemase KPC 
3 B Most β-lactams Metallo-β-lactamase VIM 








1.7.1.1  Chromosomal β-lactamases 
 
One of the most common examples of chromosomal β-lactamases are encoded by 
ampC genes found in several members of the Enterobacteriaceae and other bacterial 
species including P. aeruginosa and A. baumannii.  These class C β-lactamses can 
mediate resistance to the penicillins as well as some of the broad spectrum 
cephalosporins.  AmpC enzymes have even been associated with resistance to the 
carbapenem antibiotics when over-expressed in conjunction outer membrane porin 
loss (Jacoby, 2009).  Although they are found chromosomally in some species, ampC 
genes can additionally be plasmid encoded. 
 
The OXA β-lactamases similarly to AmpC, can be either chromosomally located (eg, 
OXA-51 in A. baumannii) or plasmid encoded (OXA-1 in E. coli).  These enzymes 
are narrow spectrum class D penicillinases although some of their derivatives are 
classed as ESBLs, some of which are capable of conferring resistance to the 
cephalosporin and carbapenem antibiotics. 
 
1.7.1.2  Plasmid encoded β-lactamases 
 
In the 1960’s the first plasmid-mediated β-lactamase in Gram-negative bacteria was 
discovered in an E. coli strain in Greece.  The enzyme was named TEM-1, after the 
patient, a Greek girl named Temoneira, from which it was isolated (reviewed by 
Blomberg et al, 2005).  Another enzyme TEM-2 was discovered shortly afterwards 





et al, 2005).  Both enzymes were shown to display similar properties in the 
hydrolysis of penicillins and the narrow spectrum cephalosporins, such as cefazolin.  
There are currently over 130 TEM variant enzymes, and still counting, based on their 
amino acid sequences that are disseminated widely amongst Enterobacteriaceae via 
the means of plasmids (Jacoby and Munoz-Price, 2005).  Presently there are 
numerous other plasmid encoded β-lactamase enzymes types with dozens of variants 
including the SHV-1 enzyme, which similarly to the TEM-1 and TEM-2, enzymes 
have a narrow spectrum of activity and have become widely spread amongst 
members of the Enterobacteriaceae (Wu et al, 2001).  Another example of plasmid 
bound β-lactamases are the OXA enzymes (molecular class D), found mainly in 
Acinetobacter spp. and P. aeruginosa, although some have also been found 
throughout members of the Enterobacteriaceae (Naas and Nordmann, 1999).  
 
1.7.2  ESBL’s 
 
ESBL’s were initially discovered in the 1980’s, primarily within Klebsiella spp., and 
found in immune compromised patients.  ESBLs can be considered the most 
significant mechanism of resistance to the oxyimino-cephalosporins, mediating 
resistance to the broad-spectrum cephalosporins including the 3
rd
 generation 
cephalosporins.  ESBLs are most commonly found on plasmids, usually alongside 
other resistance determinants (Paterson et al, 2003).  ESBL carrying strains of K. 
pneumoniae are more likely to be resistant to the fluoroquinolones and 
aminoglycosides in comparison to non-ESBL carrying strains (Paterson et al, 2003).  





found organisms such as P. aeruginosa, Enterobacter spp. and Salmonella spp. 
(Chaudhary and Aggarwal, 2004). 
 
1.7.2.1  TEM and SHV  
 
TEM and SHV enzymes share a 68% amino acid homology and have very similar 
tertiary structures (Majiduddin and Palzkill, 2003).  The majority of ESBLs stem 
from the class A narrow spectrum β-lactamases TEM-1, TEM-2 and SHV-1, via a 
series of mutations that alter the active site of these enzymes.  In the TEM enzymes 
for example, the mutations within the active site of the enzyme alter its 
conformation, allowing access to the oxyimino-β-lactams (Jacoby and Munoz-Price, 
2005).  Although these mutations allow the enzyme to exhibit a greater spectrum of 
activity against β-lactam antibiotics, the conformational change also results in the 
enzyme becoming susceptible to β-lactamase inhibitors such as clavulanic acid 
(Jacoby and Munoz-Price, 2005).  Collectively there are currently over 300 TEM and 
SHV β-lactamase derivatives (www.lahey.org/studies/webt.asp) and this number is 
increasing constantly, indicative of their rapid rate of evolution, likely in response to 
exposure to cephalosporin antibiotics.  Mutations at amino acid positions 39, 69, 104, 
164, 179, 205, 237, 238, 240, 244, 265 and 276 have been found in TEM and SHV 
variants, and are associated with their conversion into an ESBL phenotype (Knox, 
1995).  The presence of both SHV and TEM enzymes is very common in K. 
pneumoniae, particularly in clinical isolates, and these enzymes represent a means by 
which strains can potentially become resistant to the cephalosporin antibiotics.  It has 





chromosome, although they can additionally be found on plasmids (Babini and 
Livermore, 2000).   
 
1.7.2.2  CTX-M  
 
CTX-M enzymes are ESBLs that are most commonly found in members of the 
Enterobacteriaceae, particularly E. coli and K. pneumoniae.  Sequence homology 
suggests that they evolved from the chromosomal β-lactamases of Kluyvera spp. 
(Livermore and Hawkey, 2005).  There are currently over 100 CTX-M variants 
which exhibit varying levels of resistance to the oxyimino-cephalosporins 
(www.lahey.org/studies/webt.asp.).  The first CTX-M enzyme found in the UK was 
little over a decade ago in 2000, in a strain of K. oxytoca, soon followed by the first 
reported outbreak caused by K. pneumoniae (Livermore and Hawkey, 2005).  CTX-
M-15 is the predominant CTX-M variant in clinical isolates in the UK (Livermore et 
al, 2007).  It has additionally been reported that some CTX-M enzymes may be 
capable of contributing to the conferring of resistance to the carbapenem antibiotic, 
ertapenem, although this remains to be substantiated (Girlich et al, 2009). 
 
1.7.2.3  OXA 
 
OXA genes are predominantly found within Acinetobacter spp. and P. aeruginosa 
and to a lesser extent in members of the Enterobacteriaceae including E. coli and K. 
pneumoniae (Naas and Nordmann, 1999).  These molecular class D genes were 





Although the first discovered OXA genes, such as OXA-1, were only found to confer 
resistance to the penicillins and had no effect on other β-lactam antibiotics, ESBL 
OXA derivatives have arisen that are capable of conferring resistance to the 
cephalosporins and carbapenems (Naas and Nordmann, 1999).  There are currently 
over 100 OXA gene derivatives, 16 of which are ESBLs derived from OXA-2 and 
OXA-10 (www.lahey.org/studies/webt.asp.).  The OXA genes are mainly found on 
plasmids although in some cases, such as that of OXA-51 in A. baumannii, they can 
be chromosomal. 
 
1.7.3  Carbapenemases 
 
Carbapenemases are a subgroup of the β-lactamase enzymes that are considered to be 
the greatest cause for concern in Gram-negative bacteria.  Carbapenemases are 
capable of hydrolysing not only the cephalosporins and oxyimino-cephalosporins but 
also the carbapenem antibiotics.  The carbapenem antibiotics are often considered the 
last resort drugs for the treatment of complicated MDR infections caused by Gram-
negative pathogens and the increasing presence of the carbapenemase enzymes 
endangers their viability as a therapeutic option.  These genes are predominantly 
found in members of the Enterobacteriaceae, Pseudomonas spp. and Acinetobacter 
spp., and can be located on either the chromosome or on plasmids (Table 1.4).  There 
are carbapenemase members within all four molecular classes of β-lactamases, 





Class A – the Klebsiella pneumoniae carbapenemase (KPC) enzymes were first 
described in K. pneumoniae in 2001 (Yigit et al, 2001) and have since been found in 
several members of the Enterobacteriaceae (LaBombardi, 2007). 
 
Class B – metallo-carbapenemases such as the Verona integron-encoded metallo-β-
lactamase (VIM) which was first discovered in a strain of P. aeruginosa in Italy in 
1999 and is now found globally as several variants and in a number of different 
bacterial species (Lauretti et al, 1999). 
 
Class C – CMY-10, first isolated in Enterobacter aerogenes in 2003, is a plasmid 
bound carbapenemase and one of only a few that belong to β-lactamase molecular 
class C (Lee et al, 2003). 
 
Class D – members of the OXA-type (oxacillin hydrolysing) β-lactamases usually 
exhibit a limited spectrum of activity but extended activity has been observed against 
the oxyimino cephalosporins and carbapenems caused by OXA-2 and OXA-10 
























Table 1.4.  Carbapenemases.  Carbapenemase genes, their molecular class, genetic location and the organisms in which they have 
been found. 
 
Gene Class Organism(s) Location References 
GES A P. aeruginosa, Enterobacteriaceae Plasmid Queenan and Bush, 2007. 
IMI A E. cloacae Chr/Plasmid Queenan and Bush, 2007. 
KPC A K. pneumoniae, E. coli Plasmid Queenan and Bush, 2007. 
NMC A E. cloacae Chr Queenan and Bush, 2007. 
SFC-1 A S. fonticola Chr Henriques et al, 2004. 
SHV-38 A K. pneumoniae  Chr Poirel et al, 2003. 
SME A S. marcesens Chr Queenan and Bush, 2007. 
AIM B P. aeruginosa Plasmid Gupta, 2008. 
CcrA B B. fragilis Chr Rasmussen et al, 1990. 
DIM B P. stutzeri Plasmid Poirel et al, 2010. 
GIM B P. aeruginosa Plasmid Castanheira et al, 2004. 
IMP B Enterobacteriaceae, P. aeruginosa, Acinetobacter spp. Chr/Plasmid Queenan and Bush, 2007. 
KHM B C. freundii Plasmid Sekiguchi et al, 2008. 
NDM B Enterobacteriaceae Plasmid Yong et al, 2009. 
SIM B Acinetobacter spp. Chr Lee et al, 2005. 
SPM B P. aeruginosa Plasmid Toleman et al, 2002. 
VIM B P. aeruginosa, Acinetobacter spp. Chr/Plasmid Queenan and Bush, 2007. 
CMY C  Enterobacteriaceae Plasmid Lee et al, 2003. 








1.8  Gene regulation 
 
1.8.1  Bacterial transcriptional regulators 
 
In the environment bacteria are constantly exposed to any number of changing 
conditions and potential stressors such as changes in temperature, exposure to toxic 
molecules, osmotic stress and nutrient limitations.  In order to survive in such fluid 
environments, bacteria must be capable of quickly adapting via the implementation 
of the appropriate survival mechanisms.  Such adaptations often require the 
immediate regulation of specific gene sets.  Regulatory proteins are usually involved 
in the mediation of such responses in response to specific environmental and cellular 
signals (Ramos et al, 2005).  Transcriptional regulators are proteins that, as their 
name suggests, are involved in the regulation of gene transcription as either 
activators, repressors or both (Martinez-Bueno et al, 2004).  There are several 
families of transcriptional regulators found in bacteria, grouped by their sequence 
similarity, structure and function.  Table 1.5 lists the major families of transcriptional 










Position Example Function Reference 
AraC/XylS Activator  HTH C MarA Involved in conferring an MDR phenotype via 
efflux regulation in E. coli. 
Cohen et al, 1993. 
ArsR Repressor HTH Central CzrA  Repressor of the czr operon in Staphylococus 
aureus, involved in the transport of zinc and cobalt. 
Busenlehner et al, 
2003. 
AsnC Both HTH N AsnC Activator of asnA in E. coli, involved in the 
synthesis of asparagine from aspartate. 
Kolling and Lother, 
1985. 
Cold Shock Activator RNA binding 
domain 
Variable CspC Activator of the cold shock response and involved 
in RpoS regulation. 
Rath and Jawali, 2006. 
Crp Both HTH C PrfA Activator of virulence factors in Listeria 
monocytogenes. 
Uhlich et al, 2006. 
DeoR Repressor HTH N SugR Repressor of ptsG, phosphoenolpyruvate dependent 
phophotransferase. 
Engels and Wendisch, 
2007. 
GntR Repressor HTH N GntR Repressor of gluconate metabolism genes gntU and 
gntK. 
Tong et al, 1996. 
IcIR Both HTH N IcIR Repressor of the aceBAK operon in E. coli. Molina-Henares et al, 
2006. 
LacI Repressor HTH N LacI Repressor of the lac operon in E. coli. Nguyen and Saier, 
1995. 
LuxR Activator HTH C LuxR Activator of the lux system responsible for 
luminescence and polyhydroxybutyrate synthesis in 
Vibrio harveyi. 
Miyamoto et al, 1998. 
LysR Both HTH N OxyR Activator of genes involved in oxidative stress in E. 
coli. 
Maddocks and Oysten, 
2008. 
MarR Both HTH Central MarR Repressor of MDR gene marA in E. coli. Alekshun and Levy, 
1999. 
MerR Both HTH N SoxR Activator of soxS in response to oxidative stress. Brown et al, 2003. 
NirC Activator HTH C NirC Activator of genes involved in nitrogen uptake. Clegg et al, 2002. 
OmpR Activator Winged helix C OmpR Regulator of porin expression. Maedo and Mizuno, 
1988. 








1.8.2  Function  
 
Regulator family proteins that act as activators, such as members of the AraC/XylS 
family, commonly function via the enhancement of the interaction between RNA 
polymerase and the promoter of the target gene(s) thus increasing transcription.  
Those that act as repressors, such as members of the TetR family, commonly 
function via the binding and blocking of the promoter region of the target gene, thus 
preventing the binding of RNA polymerase and transcription (Ramos et al, 2005).  
Alternatively regulators, such as OmpR, can be part of a two-component regulatory 
system which consists of a membrane bound histidine kinase and a DNA binding 
protein that acts as a response regulator (Maeda and Mizuno, 1988).  Upon the 
detection of the specific signal the DNA binding protein is phosphorylated resulting 
in a conformational change and the subsequent mediation of transcription of the 
target gene. 
 
1.8.3  TetR family proteins 
 
TetR family proteins are regulatory proteins that are widely disseminated in bacteria 
and archaea.  Family members are characterised by a high degree of similarity over a 
47-residue stretch containing the DNA binding domain at their N-terminal end 
(Ramos et al, 2005).  The C-terminal of TetR proteins is typically not well conserved 
indicating that this is likely to be the region involved in binding to specific 
drug/molecule targets (Ramos et al, 2005).  TetR regulators typically act as 





Characterised family members have been shown to be involved in the regulation of a 
number of cellular functions including multidrug resistance, virulence and various 
catabolic pathways (Ramos et al, 2005).  TetR family members have been shown to 
be particularly abundant in soil micro-organisms, possibly due to the varied 
environments that such micro-organisms encounter (Ramos et al, 2005).  In contrast, 
TetR family proteins are not found in intracellular bacteria, such as Chlamydia, 
likely as a consequence of their stable environments (Ramos et al, 2001).  These 
observations suggest that many TetR family proteins are primarily involved in the 
regulation of genes that are required for rapid adaptive physiological responses to 
environmental stimuli.  A typical example of a TetR family protein can be found in 
AcrR. 
 
1.8.3.1  AcrR 
 
AcrR is one of the most well characterised members of the TetR family.  AcrR acts 
as the local repressor of the co-transcribed acrAB, an RND family efflux pump found 
in Enterobacteriaceae and associated with conferring resistance to several antibiotic 
classes.  The acrR gene is located upstream of and divergently transcribed from 
acrAB.  AcrR is thought to repress acrAB transcription by binding to the promoter 
region, blocking RNA polymerase access and preventing transcription.  acrAB is 
derepressed upon the binding of a drug at the C-terminal end of AcrR resulting in a 
conformational change at the N-terminus and subsequent release of AcrR from the 
promoter DNA (Su et al, 2007).  In the case of MDR bacterial strains of K. 





non-function, and subsequently upregulation of efflux through the AcrAB pump 
(Schneiders et al, 2003; Olliver et al, 2004). 
 
1.8.4  The AraC/XylS family 
 
The AraC/XylS family of regulators are one of the most common families of 
regulators with over 100 members identified in both Gram-positive and Gram-
negative bacteria, however to date no members have been found in archaea or in 
eukaryotes (Gallegos et al, 1997).  Members are typically around 100-350 residues 
long and are characterised by significant homology in a 100 residue section of amino 
acids containing the DNA binding domain (Gallegos et al, 1997).  Most family 
members are proposed to contain two α-helix-turn-α-helix (HTH) DNA binding 
motifs (Gallegos et al, 1997).  Homology studies revealed that the first HTH motif is 
poorly conserved indicating that it may be involved in specific target recognition 
whilst the second HTH has a high degree of conservation indicating that the proteins 
may share a common function, such as the facilitation of RNA polymerase 
recruitment (Ishihama, 1993).  It is thought that the members of the AraC/XylS 
family function by binding to the promoter regions of target genes and interacting 
with RNA polymerase in order initiate transcription (Ishihama, 1993).  All 
characterised members have been identified as either positive regulators or 
bifunctional regulators with the exception of one protein, CelD in E. coli, which acts 
as a negative regulator of the celABCF operon involved in the degradation of 
cellobiose (Gallegos et al, 1997).  Only one member has been shown to function by 





spp.) which requires the binding of urea in order to become activated (Gallegos et al, 
1997).  Members of the AraC/XylS family can be regulated themselves via two main 
mechanisms; they can contain a signal receptor directly upstream of the regulator 
which activates transcription in response to certain environmental factors or they can 
be regulated by another global regulator gene (Ishihama, 1993).  Members of this 
family have been shown to be involved in a variety of diverse regulatory functions 
such as L-arabinose catabolism (eg. AraC, E. coli) and the regulation of virulence 
genes (eg. VirF, Shigella dysenteriae) (Gallegos et al, 1997). 
 
1.9 AraC/XylS family transcriptional activators and antibiotic resistance 
in   Enterobacteriaceae 
 
1.9.1  MarA 
 
MarA is an AraC/XylS family protein that exists within the mar locus in E. coli and 
is also found within other Enterobacteriaceae members such as Salmonella spp., 
Enterobacter spp., and K. pneumoniae.  The over-expression of marA has been 
associated with the over-expression of the acrAB efflux pump in E. coli and 
subsequently the conferring of an MDR phenotype (Cohen et al, 1993; Alekshun and 
Levy, 1999).  The mar locus consists of four genes and an operator-promoter region, 
known as marO (Goldman et al, 1996).   Figure 1.3 illustrates the genomic layout, 







Figure 1.3.  Genetic organisation of the mar locus.  The genes within the 
mar locus and their corresponding protein sizes as found in E. coli. 
 
marA – over-expression of marA alone has been shown to be capable of conferring 
an MDR phenotype (Goldman et al, 1996). 
marB – over-expression of marB alone has no effect on antimicrobial susceptibility 
levels, however when over-expressed in conjunction with marA it appears to reduce 
susceptibility levels in comparison to marA over-expression alone (Goldman et al, 
1996). 
marC – this protein is of unknown function and its contribution to function of marAB 
is yet to be established (Goldman et al, 1996). 
marR – the first member of the MarR family of regulators which typically act as 
negative regulators (Goldman et al, 1996).  MarR functions by binding to sites within 
marO, preventing the initiation of transcription by RNA polymerase (Alekshun and 
Levy, 1999).  The binding of MarR – marO can be prevented or hindered by 
mutations within marR and the presence of chemicals which interfere with the 
interaction, both of which result in the upregulation of marA (Alekshun and Levy, 
1999).   
 
X-ray diffraction analyses have shown that MarA contains two HTH motifs and 





asymmetrically at a degenerate 20-bp DNA sequence deemed the ‘marbox’ (Martin 
et al, 1999).  The ‘marbox’  has been found located both upstream of the -35 
hexamer, in which case α-subunit carboxy-terminal domain (α-CTD) is required for 
activation, and also overlapping the -35 hexamer, in which case α-CTD activation is 
not required (Martin et al, 1999).  The marA promoter region marO has also been 
shown to contain a ‘marbox’ indicating that MarA may have a degree of self 
regulation (Martin et al, 1999).  Microarray analyses have identified that MarA, 
SoxS and Rob have overlapping regulons, regulating many identical genes such as 
acrAB and sodA (Martin and Rosner, 2002).  
 
1.9.2  SoxS 
 
SoxS is an AraC/XylS family protein found in E. coli and is also found within other 
Enterobacteriaceae members such as Salmonella spp., Enterobacter spp., and K. 
pneumoniae.  soxS is expressed in response to superoxides and has been shown to 
upregulate the expression of the AcrAB efflux pump, similarly to MarA (Zheng et al, 
2009). The use of redox-cycling agents, such as paraquat, have been shown in vitro 
to induce soxS expression (Liochev et al, 1999).    SoxR is a MerR family protein 
which acts as a positive regulator of soxS (Amabile and Demple, 1991) and is located 
immediately upstream of the soxS gene.  SoxR acts as an O
- 
sensor which activates 
soxS transcription upon its own oxidation (Liochev et al, 1999).  Figure 1.4 








Figure 1.4.  Genetic organisation of the sox locus.  The genes from within 
the sox locus, soxS and soxR, and their corresponding protein sizes as found in E. 
coli. 
 
Both global regulators, MarA and SoxS, have been shown to regulate a similar subset 
of genes which includes acrAB (Martin and Rosner, 2002).  Both genes have also 
been shown to diminish the influence of ompF expression upon their own expression 
resulting in similar MDR phenotypic observations, likely as a result of the small 
RNA, micF, expression and additionally, both genes are understood to be activated 
when the bacterium is subjected to particular stressors (Demple, 1991).  
 
1.9.3  Rob 
 
Rob is a protein, originally discovered in E. coli, that binds to the right arm of the 
origin of replication, oriC.  Rob is a 289 amino acid protein containing a 100 residue 
domain at its N-terminus that is characteristic of that found in AraC/XylS family 
proteins and homlogous to the domains found in marA and soxS.  However the ~175 
amino acid C-terminus of Rob bears no relation to any other AraC/XylS family 
proteins.  Rob is found to be constitutively expressed; however it has shown that 
further over-expression (in vitro) results in the conferring of an MDR phenotype 
similar to that of marA or soxS over-expression (Bennik et al, 2000).  Rob has been 





the regulation of other AraC/XylS family proteins and subsequently in mediating 
drug resistance via the expression of genes within the mar regulon (Bennik et al, 
2000).  Unlike marA and soxS, rob does not appear to have a local regulator up or 
downstream of its coding sequence and the exact role of Rob in its binding to oriC is 
unknown. 
 
1.9.4  A shared regulon 
 
All three of the AraC/XylS family transcriptional activators, MarA, Rob and SoxS, 
have been shown, by microarray analysis, to have overlapping regulons indicating a 
degree of redundancy exists (Martin and Rosner, 2002).  All three are thought to bind 
the ‘marbox’ sequence in order to exert their regulatory effects, which in turn results 
in a shared regulon, to some extent (Martin and Rosner, 2002) However their 
regulatory effects have been shown to differ between target genes and the regulators 
themselves have been shown to retain some unique target genes (Amabile-Cuevas 
and Demple, 1991; Bennik et al, 2000; Martin and Rosner, 2002).  This suggests that 
each protein is activated by a different environmental signal under conditions that are 
somewhat unique to each stimulus. 










1.10   Transcriptional regulator RamA 
 
1.10.1  The ram locus 
 
The ram locus is a group of genes found in a subgroup of Enterobacteriaceae that has 
been associated with multidrug resistance in K. pneumoniae (George et al, 1995).  
Figure 1.5 illustrates the genomic layout, orientation and sizes of genes from within 
the ram locus in K. penumoniae. 
 
 
Figure 1.5.  Genetic organisation of the ram locus in K. pneumoniae and 
Enterobacter spp.  The genes contained within the ram locus and their 
corresponding protein sizes. 
 
It is important to note that not all bacterial species containing the ram locus share the 
same genomic layout as K. pneumoniae and Enterobacter spp.  Salmonella spp. lack 
the romA gene (Figure 1.6). 
 
 
Figure 1.6.  Genetic organisation of the ram locus in Salmonella spp.  






1.10.1.1  RamA                   
 
RamA is an AraC/XylS family transcriptional activator found in Enterobacter spp., 
Salmonella spp. and K. pneumoniae.  It shares a distinct homology with the E. coli 
transcriptional activators MarA and SoxS (Figure 1.7).  Although marA and soxS are 
also present in Enterobacter spp., Salmonella spp. and K. pneumoniae, ramA is 




Figure 1.7.  Protein alignment of MarA, RamA and SoxS from K. 
pneumoniae.  A Multalin alignment of RamA, MarA and SoxS protein sequences 
obtained from the K. pneumoniae MGH 78578 genome sequence.  Highlighted in red 
are the conserved regions that characterise the proteins as members of the AraC/XylS 
family. 
 
RamA was originally discovered in K. pneumoniae by George et al (1995) where it 
was shown that when the ramA gene was transformed into to a susceptible E. coli 
strain, it conferred an MDR phenotype.  George et al (1995) also selected for ramA 
mutants (over-expressers) using chloramphenicol but found that the sequence of the 
mutant ramA was identical to that of the wild-type strain, indicating that the 
causative mutation was not within the gene itself.  A subsequent study by Schneiders 





expression.  Further studies in K. pneumoniae by Ruzin et al (2005) supported this 
hypothesis by observing that ramA over-expression correlated with acrAB over-
expression, leading to the premise that acrAB may be under the transcriptional 
control of ramA.   
 
1.10.1.2  RomA 
 
RomA is a putative outer membrane protein encoded downstream of ramA in K. 
pneumoniae and Enterobacter spp. but is notably absent from the ramA locus in 
Salmonella spp. (Komatsu et al, 1990).  Komatsu et al (1990) hypothesised that 
romA encodes an outer membrane protein and was responsible for conferring an 
MDR phenotype.  However the exact function of RomA remains elusive as it bears 
no strong homology to any other known outer membrane proteins and when its 
putative protein sequence is run through NCBI’s blast software, RomA only bears 
vague similarity to a metallo-β-lactamase.  Currently there is no solid evidence that 
supports either hypothesis for the role of RomA and its association, if any, with 
RamA remains unknown. 
 
1.10.1.3  RamR 
 
RamR is a TetR family protein, which are a family of proteins that typically act as 
transcriptional repressors.  ramR is located immediately downstream of romA, 
encoded on the opposite DNA strand.  ramR was hypothesised to encode a repressor 





deletion of ramR in Salmonella led to an increase in MICs to a broad range of 
antibiotics and the upregulation of ramA expression, as measured by RT-PCR.  The 
complementation of ramR restored the activities of the antibiotics and so RamR was 
understood to be acting as a local repressor of ramA (Abouzeed et al, 2008). 
 
1.10.1.4  YbdJ 
 
ybdJ is located immediately downstream from ramA and encodes a putative protein.  
The function of YbdJ is unknown, it is not known whether it plays a role in the 
regulation of ramA or is even included within its regulon. 
 
1.10.2  Which regulator? 
 
All four of the previously mentioned AraC/XylS regulators, MarA, SoxS, RamA and 
Rob, are capable of cross regulation of their gene sets and conferring an MDR 
phenotype (Martin and Rosner, 2002; Schneiders et al, 2003).  However this does not 
mean that all four are expressed simultaneously within a cell or by a particular 
species of bacterium.  The over-expression of these genes in vivo appears to be 
somewhat species specific; for example rob is constitutively expressed in the bacteria 
listed in Table 1.6 and, in vitro, further over-expression has been shown to confer an 
MDR phenotype (Bennik et al, 2000).  However to date there have been no reports of 
rob over-expressers found in nature.  Similarly marA or soxS over-expressers appear 





induced in vitro.  This suggests that Salmonella spp. and K. pneumoniae may favour 







Table 1.6.  AraC/XylS regulators in Enterobacteriaceae.  Shows the presence of the AraC/XylS regulators in E. coli, 
Enterobacter spp., K. pneumoniae and Salmonella spp. and whether over-expressers have been reported. + = present/over-expressed, - = 
absent/not over-expressed, -
a  









expression Reference Present 
Over-
expression Reference Present 
Over-
expression Reference Present 
Over-
expression Reference 





- N/A N/A + -
a
 N/A 
Enterobacter spp. + + Chollet et 
al, 2002. 
+ + Masi et al, 
2006. 
+ + Chollet et 
al, 2004. 
+ -a N/A 
K. pneumoniae + -
a
 N/A + -
a





Salmonella spp. + + Eaves et 
al, 2004. 
+ + Koutsolioutsou 
et al, 2001. 













1.11  Hospital acquired infections (HAIs) 
 
1.11.1  Emergence of HAIs    
 
A hospital acquired infection (HAI), also known as healthcare associated infection or 
nosocomial infection, is defined by the EU as “any disease or pathology related to 
the presence of an infectious agent or its products as a result of exposure to 
healthcare facilities or healthcare procedures”.  The majority of HAIs are caused by 
opportunistic pathogens that pose no risk to healthy individuals.  Hospitalised 
patients are of particularly high risk of contracting infections due to a high 
prevalence of pathogens, high prevalence of immunocompromised patients and the 
presence of efficient mechanisms of transmission.  Modern medicine and medical 
advances has meant that people are now living longer and surviving with medical 
conditions that would previously have been fatal and so increasing the population 
vulnerable to HAIs.  Patients within intensive care units (ICU) are at the greatest risk 
of acquiring HAIs due to both their immune compromised state and their being 
subjected to invasive medical procedures (Spencer, 1994).  Despite the highly 
publicised emergence of the Gram-positive ‘superbugs’, primarily methicillin-
resistant Staphylococcus aureus (MRSA) in hospitals, Gram-negative pathogens 
have continued to steadily increase in their incidence (Boucher et al, 2009).  Several 
Gram-negative species that were previously thought to have been of little clinical 
significance are now the cause of great concern due to their rapid development of 
antibiotic resistance, prompting a marked escalation into the research of their 





1.11.2  Incidence and costs of HAIs 
 
The reported incidences of HAIs differs between studies and geographical regions 
but have been estimated by the Center For Disease Control (CDC) to encompass 5% 
to 10% of hospitalised patients (Emori and Gaynes, 1993).  In England around 9% of 
patients are estimated to have an HAI at any one time, resulting in 300,000 infections 
and directly causing at least 5000 deaths per year (National Audit Office, 2004).  
These figures can be considered to be an underestimation of the true extent of HAIs 
as, in addition, an unknown number of discharged patients have an infection related 
to their hospital stay.  HAIs are estimated to result in a 2.5 times longer hospital stay 
with an attributable mortality of 1-2.7% (Emori and Gaynes, 1993).  The global 
incidence of HAIs appears to be on the increase; for example, in the US the rates of 
nosocomial infections, taking into account shorter hospital stays, has increased 36% 
over the past 20 years (Weinstein, 1998).  Such a high incidence of HAIs inevitably 
results in high costs including: direct costs, such as medication, diagnostic testing 
and staff costs; indirect costs, such as patient loss of income; and personal costs such 
as the physical and emotional pain and suffering of the patient.  This is estimated to 
cost the National Health Service (NHS) in excess of £1bn per year in addition to the 
costs to the patient (National Audit Office, 2004).   A study by Daxboeck et al 
(2006) performed in Vienna General Hospital, Austria, compared the attributable 
costs of infections caused by MDR Gram-negative infections against MRSA 
infections.  They reported that the median costs of a MDR Gram-negative infection 
to be £18115 with an average hospital stay of 42 days compared to £6624 and 37 





1.11.3  Transmission 
 
HAIs can be transmitted via a number of different routes including through medical 
devices and equipment (eg catheters), and between patients and hospital workers.  
Disease causing pathogens can become incorporated into the normal flora of 
hospital, thus aiding their transmission.  In recent years attempts have been made by 
numerous healthcare authorities to break the transmission and subsequently, the 
incidence of HAIs via campaigns to increase the awareness of both healthcare 
workers and the general public, to the importance of handwashing.  One study 
reported that alcohol rubs resulted in lower bacterial counts when compared to 
traditional handwashing with soap (Girou et al, 2002) and subsequently the use of 
alcohol–based rubs have now been introduced to most UK hospitals. 
 
1.11.4  Types of HAI 
 
The four major types of HAI are as follows: urinary tract infection (UTI), surgical 
site infection (SSI), respiratory tract infection (RTI) and bloodstream infections 
(BSI).  In the USA the CDC estimate that the total HAIs are comprised as follows 
(Klevens et al, 2007): 
   UTI – 32%     
   SSI – 22%      
   RTI – 15%              
   BSI – 14% 





UTIs are the most common type of HAI largely due to a combination of the urinary 
catheterisation of patients and the presence of multiple organism types in the hospital 
environment.  Around 80% of UTIs are caused by E. coli, but P. aeruginosa and K. 
pneumoniae are also common causes (Nicolle, 2008). 
 
A study by Gaynes  et al (2005) examined the incidences of bacterial infections from 
ICUs in the US over a 28 year period from 1975 to 2003.  Gram-negative pathogens 
were found to predominate total nosocomial infections comprising 53.4-79.5% of 
each type of infection in 1975 and 23.8-72.9% in 2003 (Gaynes et al, 2005).  As 
shown in Table 1.7, the incidence of Gram-negative infections appears to have 
dropped slightly for UTI, SSI and RTI over the study period, although Gram-
negative pathogens remained dominant.  However the incidence of Gram-negative 
BSIs have more than halved over the 28 year study period.  This phenomenon could 
be attributed to the emergence of MRSA as a nosocomial pathogen (Gaynes et al, 
2005).  K. pneumoniae infection rates have remained steady for each site of infection 













  1975 2003 
Gram-negative 
Pathogens 
UTI 78.5 72.9 
SSI 53.4 41.9 
RTI 79.5 66.0 
BSI 57.1 23.8 
        
K. pneumoniae 
UTI 4.6 9.8 
SSI 2.7 3.0 
RTI 6.4 7.2 
BSI 4.5 4.2 
 
Table 1.7.  Comparison of Gram-negative and K. pneumoniae infection 
rates in ICUs between 1975 and 2003.  Figures relate to the percentage of 
isolates recovered from each type of infection (adapted from Gaynes et al, 2005). 
 
1.12  Antibiotic resistant HAIs 
 
1.12.1  Antibiotic resistant infections 
 
Acquired antibiotic resistance can be considered one of the greatest problems in 
hospitals today.  It is estimated that there are over 2m nosocomial infections in the 
US each year and 50-60% of these are caused by resistant strains (Jones, 2001).   
 
1.12.2  The main culprits 
 
Six pathogens have been reported to cause the majority of antibiotic resistant hospital 
infections in the United States; Enterococcus faecium, S. aureus, K. pneumoniae, A 





resistant infections result in increased mortality rates and longer hospitals stays with 
respect to infections caused by their susceptible counterparts (Maudlin et al, 2010).  
 
1.12.3  Combating resistance 
 
Increasing reports of “hospital superbugs” in the media have led many scientists and 
clinicians to believe that modern medicine is losing the battle against antibiotic 
resistant bacteria, and current reports suggest that this view does have some basis 
(Levy and Marshall, 2004; Falagas and Bliziotis, 2007).  A study by Safdar et al 
(2002) reported a 25% rate of ESBL carrying Enterobacteriaceae for ICU patients.  
The use of antibiotics has undoubtedly caused many bacterial species to undergo 
strong evolutionary pressure and has likely to have sped up such evolutionary 
processes involved in the development of resistance mechanisms.  Studies have 
shown that the development of antibiotic resistance can be directly correlated with 
the introduction of antibiotics into medical usage and it has been shown that when 
antibiotic usage is restricted, the incidences of resistance are reduced (Struelens et al, 
1999; De Man et al, 2000).  The current limited state of antibiotic therapy indicates 
that new therapies and new drug targets are a necessity in order to ensure that many 
medical treatments and surgeries remain a viable option in the present as well as the 
future.  In the quest for new therapies it has become essential that we understand the 
molecular basis for antibiotic resistance in an effort to both overcome this phenotype 







1.12.4  Interventions 
 
In the absence of new antimicrobials, UK medical trusts have employed a number of 
measures with which they aim to exert some control over the current issues of HAIs 
and antibiotic resistance. 
 
-Infection control measures 
 
Several strategies have been put in place amongst healthcare staff with the aim of 
preventing the spread of infections in the UK.  Most of these strategies are centred 
around improving cleanliness and hygiene within the medical settings.  The 
combined use of alcohol-based hand gels and improved infection control education 
amongst are expected to limit the spread of nosocomial infections (NHS, 2003). 
 
-Resistance development control measures 
 
The large scale spread of resistance to antibiotics has been attributed, at least in part, 
to the inappropriate prescribing and administration of antibiotics.  To combat this 
problem the Health Protection Agency (HPA) have introduced antibiotic prescription 
guidelines alongside continuous monitoring of infections and resistance in order to 
detect the early development of any patterns so that appropriate interventions can be 






The employment of these strategies can help to reduce or limit infection and 
resistance rates in UK hospitals, however on their own they are inadequate measures 
for combating the ongoing evolution of bacteria.   
 
1.13  Klebsiella spp. 
 
1.13.1  The Klebsiella genus 
 
The Danish scientist Hans Christian Gram (1853-1938) developed a technique in 
1884 which could distinguish between two major types of bacteria which shared 
similar clinical symptoms; Streptococcus pneumoniae and K. pneumoniae.  This 
technique was thereafter known as the Gram stain and is still employed today as a 
basic means to distinguish between Gram-positive and Gram-negative bacteria.  The 
Klebsiella genus itself was named after the German bacteriologist/pathologist Edwin 
Klebs (1834-1913) whose earlier work with fellow German bacteriologist Friedrich 
Loeffler (1852-1915) resulted in the identification of Corynebacterium diphtheriae, 
also known as Klebs-Loffler bacillus, as the cause of diphtheria.  Trevisan (1885) 
named the genus Klebsiella after him in honour of his work. 
 
Members of the genus Klebsiella spp. are Gram-negative rods belonging to the 
Enterobacteriaceae family.  The common characteristics of Klebsiella spp. include 
that they are non-motile, oxidase negative and encapsulated.  The polysaccharide 
capsule shared by the Klebsiella genus is an important pathogenicity and virulence 





the host’s antibodies.  Klebsiella spp. are ubiquitous in nature and commonly found 
in water, soil and the mucosal membranes of both animals and humans (Gupta et al, 
2003).  There are seven recognised species within the Klebsiella genus according to 
Orskov’s classification; K. planticola, K. pneumoniae, K. ornithinolytica, K. oxytoca, 
K. ozaenae, K. rhinoscleromatis and K. terrigena although it should be noted that K. 
ozaenae and K. rhinoscleromatis are considered to be subspecies of K. pneumoniae 
by many scientists.   
 
Klebsiella spp. are considered to be opportunistic pathogens primarily causing 
infections in those who are immune compromised and those with underlying health 
conditions such as diabetes, lung disease and alcoholics (Anonymous, CDC, 2004).  
Klebsiella spp. are reported to be responsible for 7-10% of bloodstream infections in 
Europe, North America and South America according to data collected by the 
SENTRY Antimicrobial Surveillance Program (Alves et al, 2006).  The vast majority 
of human infections are caused by K. pneumoniae with K. oxytoca and K. 
rhinoscleromaitis causing a minority of infections by comparison (Podschun and 
Ullmann, 1998).  The other members of the Klebsiella genus are not thought to cause 
infections in humans with the exception of K. ozaenae which is believed to cause 
disease of the nasal passages, although has not yet been confirmed as a causative 









1.13.2  Virulence 
 
Klebsiella spp. possess a number of properties that enhance their virulence and 
pathogenicity. 
 
1.13.2.1  Polysaccharide capsule 
 
The bacterial capsular polysaccharrides are perhaps the most important virulence 
factor for Klebsiella spp.  The polysaccharide capsule consists of repeating subunits 
of sugars and uronic acids.  Capsular polysaccharide (CPS) and lipopolysaccharides 
(LPS) are the two most important components of the polysaccharide capsule.  
Klebsiella spp. express two cell surface antigens; O, a component of LPS of which 
there are 9 varieties, and K, a CPS of which there are over 80 varieties.  The 
polysaccharide capsule acts to protect the bacterium from both polymorphonuclear 





There are currently over 80 different serotypes of Klebsiella spp., although some 
have been shown to more virulent than others (Gupta et al, 2003).  K antigens 
lacking repetitive mannose and rhamnose structures have been found to exhibit 
increased virulence due to their not being recognised by the surface lectin of 





mannose and rhamnose structures, perhaps the reason why K2 is the predominant 




LPS is found in the outer membrane of all Gram-negative bacteria and comprises 
three components; the O antigen, the core oligosaccharide, and lipd A.  LPS itself is 
an endotoxin and the lipid A component has toxic properties, eliciting a potent 
immune response often causing fever in the infected host.  LPS activates the 
complement system by one of two pathways; the classical pathway via the lipid A 
component or the alternative pathway via the O antigen component.  
 
1.13.2.2  Fimbriae 
 
The ability of a bacterium to form biofilms on surfaces and medical devices is 
considered a major factor in the spread of nosocomial infections.  Adhesion is an 
essential first step for biofilm production and is mediated by fimbrial adhesins in 
Klebsiella spp.  Fimbriae allow the bacterium to adhere to the surface to cells, thus 
aiding their ability to cause disease.  Klebsiella spp. typically express two types of 
fimbriae; type 1 is the most common, found in most members of the 
Enterobacteriaceae, and is typically found in most clinical strains, type 3 is less 
common and was typically thought to only be present in plant strains, although have 
also been found in strains causing human infection (Podschun and Ullmann, 1998).  





structures.  It has been shown that type 1 fimbriae are essential virulence factors in 
causing UTIs in animal models but appear to play no role in mediating biofilm 
production, in contrast to that found in E. coli (Pratt and Kolter, 1998; Schroll et al, 
2010).  Type 3 fimbriae have been shown to have no influence on pathogencity in an 
animal UTI model but have been shown to be important for mediating biofilm 
production in in vitro studies (Schroll et al, 2010).   
 
1.13.2.3  Siderophores 
 
Siderophores are iron chelating compounds which are secreted by micro-organisms 
as a means of binding and acquiring iron, an essential element for bacterial growth.  
Klebsiella spp. produce two types of siderophores; enterobactin and aerobactin, both 
of which have been identified as important virulence factors (Podschun and Ullmann, 
1998). 
 
1.14  K. pneumoniae 
 
1.14.1  Clinical significance 
 
K. pneumoniae can be differentiated from other Klebsiella spp. by the fact that it can 
ferment lactose and is indole negative.  Identification can additionally be based upon 
the nucleotide sequences of gyrA, parC and rpoB genes, after which K. pneumoniae 
strains fall into one of four phylogenetic groups; KpI, KpII-A, KpII-B, and KpIII 





including; pneumonia, bacteriaemia, UTI, wound infections and GI infections.  
Although K. pneumoniae has been associated with community-acquired infections 
such as pneumonia, the majority of infections caused by this bacterium are associated 
with hospitalisation (Podshun and Ullmann, 1998).  K. pneumoniae is an important 
cause of HAIs, especially in the neonatal ICU where mortality rates can reach up to 
70% (Gupta et al, 2003).  A study by Jones et al (2004) examined the incidence of 
bacterial infections in ICU in five countries; the USA, Canada, Italy, Germany and 
France.  This study found that the incidence rates of K. pneumoniae infections 
differed between countries, ranging from 3.5-5.8%, but was the third most commonly 
isolated Gram-negative organism behind P. aeruginosa and E. coli across all five 
countries (Jones et al, 2004).  The incidence of K. pneumoniae infections has 
increased significantly over the past 20 years, coinciding with the spread of ESBLs, 
which are increasingly harboured in clinical strains (Gupta et al, 2003).  A study by 
the National Healthcare Safety Network in the USA over a 12 month period from 
2006-2007 revealed that K. pneumoniae comprised 5.8% of HAIs and 7.7% of 
catheter-associated UTIs (Hidron et al, 2008).  The same study showed that 21.2% of 
those K. pneumoniae isolates were resistant to cephalosporins and 10.1% exhibited 
resistance to carbapenems (Hidron et al, 2008).  This identifies that antibiotic 
resistance is a major factor in the success of K. pneumoniae as pathogens. 
 
K. pneumoniae has been identified as a primary cause of liver abscesses in Asia (Yu 
et al, 2008).  A study by Yu et al (2008) showed that 72% of strains isolated from K. 
pneumoniae caused liver abscesses were of capsular seroptype K1 or K2.  The 





underlying medical conditions, primarily diabetes mellitus, although the reasons for 
this association have not yet been identified (Lin et al, 2004).   
 
1.14.2  K. pneumoniae risk factors 
 
As with any bacterium capable of causing nosocomial infections, a number of risk 
factors are associated; in K. pneumoniae this is primarily the existence of an immune 
compromised host..  There are a number of risk factors that have been identified to 
be associated with the acquisition of ESBL-producing K. pneumoniae: invasive 
procedures including abdominal surgery, arterial and central venous catheterisation, 
urinary catheterisation, and mechanical ventilation; low birth weight in infants; 
prolonged hospital stays; prior antibiotic use, particularly cephalosporins and 
aminoglycosides; and colonisation of the GI tract (Jacoby, 1998; Lautenbach et al, 





1.15  Aims of this thesis 
 
• To examine the expression of the transcriptional activator RamA and its 
contribution to antibiotic resistance in K. pneumoniae. 
 
• To decipher the role of RamR in the regulation of ramA and acrA expression. 
 
• To examine the effect of antibiotics and other compounds on both ramA and 
ramR and their effects in conferring a multidrug resistant phenotype. 
 
• To investigate the mechanisms and development of antibiotic resistance, 

















Chapter 2: Materials and Methods 
 
2.1  Bacterial strains 
 
2.1.1  All bacterial strains used in this study 
 
K. pneumoniae strains investigated in this study were of laboratory, clinical and 
environmental origins, and are listed in Table 2.1.  Standard β-lactamase producing 
strains are listed in Table 2.2 and other standard strains used in this study are listed in 
Table 2.3.  All strains had been previously speciated by other laboratories. 
 
Table 2.1.  K. pneumoniae strains investigated in this study. 
 
Strain pI Source 
E. coli TEM-1  5.4 SGBA
1
 
E. coli TEM-2  5.6 SGBA
1
 
E. coli TEM-3 6.3 SGBA
1
 
E. coli SHV-1  7.6 SGBA1 
E. coli SHV-3 7.0 SGBA
1
 
E. coli SHV-5  8.2 SGBA1 
 
Table 2.2.  Standard β-lactamase producing strains. 
1
SGBA = Sebastian Amyes 
K. pneumoniae Strains Laboratory Clinical Environmental Reference 
K1   +   This study. 
K2   +   This study. 
Ecl8 +    George et al, 1995. 
Ecl8 Mdr1 +    George et al, 1995. 
S7   +   Schneiders et al, 2003. 
S8   +   Schneiders et al, 2003. 
CG43   +   Lai et al, 2000. 
MGH 78578   +   Ogawa et al, 2005. 
Kp342    + Fouts et al, 2008. 
S28   +   Schneiders et al, 2003. 








E. coli DH5α     SGBA
1
 
E .coli K12 MG1655     SGBA
1
 
E. coli ATCC 25922     SGBA1 
E. coli K12 J62-2 Rif
R
   SGBA
1
 







K. pneumoniae CTX-M-15 1     SGBA1 
K. pneumoniae CTX-M-15 2     SGBA
1
 
K. pneumoniae ATCC 13883     Pro-Lab Diagnostics 




Table 2.3.  Standard bacterial strains. 
1
SGBA = Sebastian Amyes; 
2
AH = Ahmed Hamouda 
 
2.1.2  Storage of strains 
 
Bacterial strains were inoculated onto MacConkey agar plates and incubated 
overnight at 37ºC.  A single colony was inoculated into vials containing 5ml of LB 
broth and incubated overnight.  900µl of strain culture was placed into a Cryovial 
with 100µl of sterile 50% glycerol to give a final volume of 5%.  The Cryovials were 
mixed by vortexing and stored at  -80ºC. 
 
2.2  Media, buffers and reagents 
 
2.2.1  Media and buffers 
 
All growth media and buffers used were sterilised by autoclaving at 15 lbs psi at 






2.2.2  Solid media 
 
LB agar, IsoSensitest (IST) agar, nutrient agar and MacConkey agar were obtained 
from Oxoid (Hampshire, UK) and prepared according to the manufacturer’s 
instructions.  Agar was cooled to 50ºC before being poured into sterile petri dishes 
(Sterilin Ltd, Staffordshire, UK) and allowed to set.  Plates were either used 
immediately or stored at 4ºC. 
 
2.2.3  Liquid media 
 
LB broth and nutrient broth were obtained from Oxoid (Hampshire, UK) and 
prepared according to the manufacturer’s instructions. 
 
2.2.4  Reagents 
 
All reagents were obtained from either Sigma Chemicals (Dorset, UK) or Fisher 
Scientific (Leicestershire, UK) unless stated otherwise. 
 
2.3  Antimicrobial agents 
 
2.3.1  Antibiotics 
 
The antimicrobial agents used in this study were obtained from suppliers as listed in 





Society for Antimicrobial Chemotherapy susceptibility testing guidelines (Andrews, 
2001). 
 
Antimicrobial Agent Supplier 
Amikacin Sigma-Aldrich (Dorset,UK) 
Ampicillin Sigma-Aldrich (Dorset,UK) 
Aztreonam Sigma-Aldrich (Dorset,UK) 
Cefoxitin Sigma-Aldrich (Dorset,UK) 
Ceftazidime Sigma-Aldrich (Dorset,UK) 
Chlorampheniciol Sigma-Aldrich (Dorset,UK) 
Ciprofloxacin Sigma-Aldrich (Dorset,UK) 
Clavulanic acid Sigma-Aldrich (Dorset,UK) 
Colistin Sigma-Aldrich (Dorset,UK) 
Ertapenem Merck (Nottingham, UK) 
Gentamicin Sigma-Aldrich (Dorset,UK) 
Imipenem Merck (Nottingham, UK) 
Kanamycin Sigma-Aldrich (Dorset,UK) 
Meropenem Astra Zeneca (London, UK) 
Norfloxacin Sigma-Aldrich (Dorset,UK) 
Piperacillin Sigma-Aldrich (Dorset,UK) 
Rifampicin Sigma-Aldrich (Dorset,UK) 
Sulbactam Sigma-Aldrich (Dorset,UK) 
Tetracycline Sigma-Aldrich (Dorset,UK) 
Tigecycline Wyeth (Maidenhead, UK) 
Tobramycin Faulding (Warwickshire, UK) 
 
Table 2.4. Antimicrobial agents used in this study. 
 
2.3.2  Antibiotic discs 
 











2.4  Antibiotic susceptibility testing 
 
2.4.1  Minimum inhibitory concentrations (MICs) 
 
MIC testing was carried out using IST agar according to BSAC guidelines (Andrews, 
2001).  Bacterial strains were grown overnight at 37°C in LB broth and diluted into 
0.9% NaCl to approximately 10
7 
cfu/ml.  A Denley multipoint inoculator (Denley, 
Surrey, UK) was used to inoculate a 1µl volume onto the surface of the agar plates to 
give a final inoculum of approximately 10
4
 cfu/spot. A plate containing no antibiotic 
was used as a positive control.  The plates were then incubated in air at 37°C for 18 
hours.  The MIC was deemed to be the lowest antibiotic concentration to inhibit all 
visible growth.  E. coli ATCC 25922 was used as a control. 
 
2.4.2  Disc sensitivity testing 
 
Disc sensitivity testing was performed on IST agar plates and interpreted as sensitive, 
intermediate or resistant according to the BSAC disc sensitivity testing guidelines 
(Andrews, 2007). 
 
2.4.3 Chlorpromazine synergy determination 
 
To determine the presence or absence of synergy between antimicrobials and 
chlorpromazine (CPZ) (Sigma-Aldrich, Dorset, UK), the fractional inhibitory 






FIC values were calculated using the following formula and interpreted according to 
Table 2.5 (Gould et al, 1991). 
 
FIC= MIC of Agent A (combination)  +  MIC of Agent B (combination) 
          MIC of Agent A (single)            +  MIC of Agent B (single) 
 
FIC Value Interpretation 
≤0.5 Synergy 
>0.5 - 1.0 Addition 
>1.0 - ≤4.0 Indifference 
>4.0 Antagonism 
 
Table 2.5. FIC interpretation. 
 
2.5  Polymerase chain reactions (PCRs) 
 
2.5.1  Primer design 
 
Primers were designed using Primer 3 software (http://frodo.wi.mit.edu/primer3) or 
otherwise were taken from previously published work.  Primers were synthesised by 
























Primers Forward Sequence (5'-3') Reverse Sequence (5'-3') Reference 
Gene Detection and Sequencing       
AmpC_F & AmpC_R ATCAAAACTGGCAGCCG GAGCCCGTTTTATGCACCCA Kaczmarek et al, 2006. 
CTX_MA & CTX_MB CGCTTTGCGATGTGCAG ACCGCGATATCGTTGGT Dutour et al, 2002. 
GES_F & GES_R ATGCGCTTCATTGACGCAC CTATTTGTCCGTGCTCAGG Park et al, 2006. 
GIM_F & GIM_R TCGACACACCTTGGTCTGAA AACTTCCAACTTTGCCATGC Ellington et al, 2007. 
IMP_F & IMP_R GGAATAGAGTGGCTTAAYTCTC CCAAACYACTASGTTATCT Ellington et al, 2007. 
KPC_F & KPC_R CAGCTCATTCAAGGGCTTTC GGCGGCGTTATCACTGTATT This work. 
NDM_F & NDM_R GAAGCTGAGCACCGCATTAG GACTTGGCCTTGCTGTCCTT This work. 
NMC/IMI_F & NMC/IMI_R ATGTCATTAGGTGATATGGC GCATAATCATTTGCCGTACC Kaczmarek et al, 2006. 
OXA_F & OXA_R TATCTACAGCAGCGCCAGTG CGCATCAAATGCCATAAGTG This work. 
PER_F & PER_R ATGAATGTCATTATAAAAGC AATTTGGGCTTAGGGCAGAA Park et al, 2005. 
SHV_F & SHV_R CTTTCCCATGATGAGCACCT CGCTGTTATCGCTCATGGTA This work. 
SIM_F & SIM_R TACAAGGGATTCGGCATCG TAATGGCCTGTTCCCATGTG Ellington et al, 2007. 
SME_F & SME_R TAGAGGAAGACTTTGATGGG GCATAATCATTCGCAGTACC Kaczmarek et al, 2006. 
SPM_F & SPM_R AAAATCTGGGTACGCAAACG ACATTATCCGCTGGAACAGG Ellington et al, 2007. 
TEM_F & TEM_R CGCCGCATACACTATTCTCA TTGCCGGGAAGCTAGAGTAA This work. 
VEB_F & VEB_R CGACTTCCATTTCCCGATGC GGACTCTGCAACAAATACGC Park et al, 2005. 
VIM_F & VIM_R GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG Ellington et al, 2007. 
OmpK35_F & OmpK35_R CAGACACCAAACTCTCATCAATGG AGAATTGGTAAACGATACCCACG Kaczmarek et al, 2006. 
OmpK36_F & OmpK36_R CAGCACAATGAATATAGCCGAC GCTGTTGTCGTCCAGCAGGTTG Kaczmarek et al, 2006. 
RamR_F & RamR_R CATCCCGGAGGCTTTATGAT CGCTCGACCTTAAACACGTC This Work. 
RT-PCR Analysis       
RamA_RTF & RTR CTGCAACGGCTGTTTTTACA GTGGTTCTCTTTGCGGTAGG This work. 
RomA_RTF & RTR GTTCACCGGGCAGAAAAATA GAGCCAGACCATCACATCCT This work. 
RamRTF & RamRTR GGCTCGTCCAAAGAGTGAAG CGTTCCACATGGCTTCAAA This work. 
AcrA_RTF & AcrA_RTR GTCCTCAGGTCAGTGGCATT GGTGCCCAACAGTTTCTGAT This work. 
OmpK34_RTF & OmpK34_RTR TAACGATCAGCTTGGTGCTG ATCGTCAGTGATCGGGTAGC This work. 
OmpK35_RTF & OmpK35_RTR AAAACGGCAACAAACTGGAC AGACGGGTTTTTGTGGTCTG This work. 
OmpK36_RTF & OmpK36_RTR GCGCTCTGTCTCCTACCAAC GGTGTACTGAGTGGCCAGGT This work. 
YbdJ_F & R TGAAACATCCACTGGAAACG GCGCTAAGAACCACAGACAA This work. 
16S_RTF & 16S_RTR CAGCCACACTGGAACTGAGA GTTAGCCGGTGCTTCTTCTG This work. 
Cloning        
RamRF2 & RamRR2 AACTGCAGTCGTCAAGACGATTTTCAATTTT AAAAGTACTAGTGTTTCCGGCGTCATTAG This work. 
RomAF2 & RomAR2 AACGAGTACTATGCCGGAAATTGATCTG AACGCTGCAGCAGCAGGCGCCACGCGCG This work. 
7
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2.5.2  Genomic DNA preparation for PCR 
 
DNA was prepared for PCR by resuspension of 1-2 colonies, picked from an agar 
plate, in 100µl of sterile distilled water.  The suspensions were then boiled in a 
waterbath for 10 mins before being chilled on ice.  1µl of this DNA preparation was 
used in each PCR reaction. 
 
2.5.3  PCR reaction components 
 
PCR reactions were performed in total volumes of 50µl.  Table 2.7 lists the reaction 
components in the order they were added to a mastermix before being aliquoted into 
a sterile 0.5ml thin walled PCR tube containing the DNA template.  A negative 
control was included which contained all reaction components minus any DNA.  The 
PCR tubes were mixed by pulsing in a microcentrifuge prior to being placed in a 
thermal cycler.  All PCRs were performed using Go-Taq polymerase (Promega, 
Southampton, UK). 
Component Stock Concentration 
Volume Added 
(µl) Final Concentration 
10x Buffer  200mM Tris-HCl,    
500mM KCl 
5 1x buffer; 20mM Tris-
HCl, 50mM KCl 
MgCl2 50mM 1.5 1.5mM 
dntp mix 1mM 1 20pM 
Forward primer 10µM 0.5 100pM 
Reverse primer 10µM 0.5 100pM 
Taq 
polymerase 
5U/µl 0.25 1.25U 
DNA template N/A 1 N/A 
SDW N/A 40.25 N/A 
 




2.5.4  PCR cycling parameters 
 
PCR cycling was performed in an GeneAmp® PCR System 9700 thermal cycler 
(Applied Biosystems, Warrington, UK).  Specific cycling parameters are given in 
Table 2.8.  The annealing temperatures and number of cycles varied depending upon 
the primer length, GC content and target gene. 
 
Step Temperature (°C) Time Cycles 
Initial Denaturation 95 5 min 1 
Denaturation 95 30s 
} Various Annealing Various 30s 
Extension 72 30s 
Final Extension 72 7 min 1 
Hold Temperature 4 Infinity   
 
Table 2.8. PCR cycling parameters.  The typical parameters used for PCR 
reactions.  The annealing temperature used was dependent upon the primer sequence.  
N/A – not applicable 
 
2.6  Agarose gel electrophoresis of DNA 
 
2.6.1  PCR amplified DNA 
 
PCR amplified DNA was electrophoresed in 1.5% w/v agarose gels made in 1X TAE 
buffer (40mM Tris-acetate, pH8.0; 2mM EDTA).  Electrophoresis was performed in 
Bio-Rad Mini Sub Cell horizontal gel units in 1X TAE running buffer, at room 






2.6.2  Plasmid DNA 
 
Plasmids preparations were electrophoresed in 0.85% w/v agarose gels made in 0.5X 
TBE buffer (89mM Tris base; 89mM Boric acid; 2mM EDTA).  Electrophoresis was 
performed in Bio-Rad Maxi Sub Cell horizontal gel units in 0.5X TBE running 
buffer, at 4°C and 90V for 15 hours. 
 
2.6.3  Sample preparation 
 
Samples were mixed with loading buffer (0.03% bromophenol blue, 0.03% xylene 
cyanol FF, 0.4% orange G, 15% Ficoll® 400, 10mM Tris-HCl (pH 7.5) and 50mM 
EDTA (pH 8.0)) in a 5:1 ratio (DNA:loading buffer) prior to loading onto the gel.  A 
100bp or 1kb DNA marker (Promega, Southampton, UK) was run on the gels 
alongside the samples to facilitate size estimation.   
 
2.6.4  Nucleic acid gel staining and photographing 
 
Gels were stained in either ethidium bromide at a concentration of 50mg/L for half 
an hour or GelRed (Biotium, Hayward, CA, USA) according to the manufacturer’s 








2.7  DNA/RNA analysis 
 
2.7.1  Purification of PCR products 
 
Purification of PCR products was performed using the QIAquick PCR Purification 
Kit (Qiagen, Sussex, UK) according to the manufacturer’s instructions.  The purified 
DNA was stored at -20°C. 
 
2.7.2  Estimation of DNA/RNA concentration 
 
The concentration of DNA and RNA were estimated by loading a 2µl sample onto 
the NanoDrop 2000 spectrophotometer (Thermo Scientific, Cramlington, UK) and 
taking the average of two independent readings.  Prior to recording the 
concentrations, the spectrophotometer was blanked with the appropriate elution 
buffer. 
 
2.7.3  Nucleic acid sequencing 
 
Nucleic acid sequencing was performed on an ABI 3730 capillary sequencing 
instrument (Applied Biosystems, Warrington, UK) by the Gene Pool (Edinburgh 
University).  DNA sequences were analysed using Chromas Lite software and 






2.8  DNA isolation 
 
2.8.1  Genomic DNA isolation 
 
Genomic DNA was isolated for the purpose of repetitive PCR analysis of strains.  
DNA was isolated using the Wizard Genomic DNA Isolation kit (Promega, 
Southampton, UK) according to the manufacturer’s instructions.  DNA preparations 
were stored at -20ºC. 
 
2.8.2  Plasmid DNA isolation 
 
Plasmid DNA was isolated using either the Qiagen Mini or Midi Prep kit according 
to the manufacturer’s instructions.  Plasmids were stored at -20ºC. 
 
2.9 Pulsed-field gel electrophoresis (PFGE) 
 
2.9.1  Agarose plugs 
 
PFGE was performed using the modified protocol of Miranda et al.  Strains were 
grown overnight in 5 ml of LB broth at 37°C and harvested by centrifugation at 
3000rpm for 20 mins.  The supernatant was discarded and the cells were resuspended 
in 2 ml of PIV buffer (1M Tris, 1M NaCl, pH7.6) and equilibrated in a waterbath to 
50°C.  Two ml of 1.6% Certified Megabase Agarose (BioRad, Hertfordshire, UK), 




into plug mould before being refrigerated at 4°C for 45 mins.  The plugs were 
removed from the moulds and incubated in 5 ml of lysis buffer (1M Tris, 1M NaCl, 
0.1M EDTA, 0.5% Brij 58, 0.2% deoxycholate, 0.5% Sodium lauryol sarcosine, 50 
mg of ribonuclease A per ml, and 1 mg of lysozyme [pH 7.6] per ml) overnight at 
37°C.  The lysis buffer was removed and replaced with 5 ml of ESP (0.4 M EDTA, 
1% sodium lauroyl sarcosine [pH 9.0] and 0.5 mg of proteinase K per ml) buffer and 
plugs were incubated overnight at 50°C.  The ESP buffer was removed and plugs 
were washed once with 1X TE (5 mM Tris, 5 mM EDTA [pH 7.5]) buffer and 3 
times with 0.1x TE buffer for at least 30 mins each wash and at 37°C.  Plugs were 
then stored in 0.5x TBE buffer (45mM tris, 45mM boric acid, 1mM EDTA, pH8.0) 
at 4°C until used. 
 
2.9.2  Agarose plug digestion 
 
Agarose plug slices of ~2mm were equilibriated at room temperature in 100µl of 1x 
restriction buffer for 30 mins.  The restriction buffer was then replaced with fresh 
buffer containing 30U of XbaI and tubes were incubated in a waterbath at 37ºC for 
18 hrs. 
 
2.9.3  Gel preparation 
 
A 1% Pulsed Field Certified Agarose (Bio-Rad, Hertfordshire, UK) gel was prepared 
in 0.5x TBE buffer.  Plugs were loaded into the gel lanes which were then overlain 




2.9.4  Running conditions 
 
Gels were run for 22 hours at 5.0 volts/cm with a pulse time of 5-35 seconds at 14ºC 
in 0.5x TBE running buffer, performed with a CHEF DRII system (Bio-Rad, 
Hertfordshire, UK).  A Lambda Ladder PFG Marker (New England Biolabs 
Hertfordshire, UK) was used as a size standard. 
 
2.9.5  Gel staining 
 
Gels were stained in ethidium bromide as described previously and destained in 
distilled water when necessary.  Gels were then visualised on the Bio-Rad GelDoc 
system. 
 
2.9.6  S1 nuclease PFGE plasmid profiling 
 
For the purpose of profiling larger plasmids, S1 nuclease (Promega, Hampshire, UK) 
was used to digest agarose plug slices that had been prepared as described previously 
for PFGE.  Plug slices were equilibrated in 100µl of 1x S1 nuclease buffer at room 
temperature for 30 mins before being replaced with fresh 1x S1 nuclease buffer 
containing 8U of S1 nuclease.  These were incubated in a waterbath for 45 mins at 
37°C before reactions were terminated by the addition of 5µl of 0.5M EDTA.  Gels 






2.10  Iso-electric focussing (IEF) 
 
2.10.1  Preparation of cell lysates 
 
Five ml of overnight cultures were harvested by centrifugation at 2000 g for 10 mins 
at 4°C.  The cell pellets were washed with 5 ml of 50mM sodium phosphate buffer, 
pH7.0 and centrifuged as before.  Cell pellets were resuspended in 2 ml of the 
sodium phosphate buffer and were sonicated, on ice, for 20 seconds at 8 microns four 
times with cooling periods in between pulses.  Cell debris was cleared by 
centrifugation at 16,000 g for 5 mins at 4°C.  The supernatant was stored at -20°C. 
 
2.10.2  Assessment of β-lactamase activity 
 
β-lactamase activity was assessed by measuring the time it took for 30µl of the 
preparation to change the colour of 100µl of a 50µg/ml nitrocephin solution.   
 
2.10.3  Gel preparation 
 
IEF gels were prepared containing a broad range of carrier ampholytes (pH3.5-10).  
The gel solution was prepared on glass plates as shown in Table 2.9.  To promote 
adhesion one plate was first submerged in a binding solution (0.5% w/v gelatine) for 
10 mins before being dried in a 55°C incubator for 20 mins.  The other plate was 




their perimeters and placed in a casting chamber.  The gel solution was poured and 
was left to polymerase in sunlight for 4 hours.   
 
Component Volume (ml) Final Concentration 
Ampholines 0.8 2% w/v 
40% acrylamide 9 9% 
Riboflavin (20mg/ml) 4 2mg/L 
Distilled water 26 N/A 
5% TEMED 0.2 0.005% (v/v) 
 
Table 2.9.  The components and composition of the IEF gels.  N/A – not 
applicable 
 
2.10.4  Running conditions 
 
β-lactamase samples of roughly equivalent activity (as determined by the results of 
2.10.2) were loaded on the gel surface close to the anode.  The gels were run under 
the following conditions: voltage = 500V (limiting), current = 20mA (limiting), 
power = 1W (constant). 
 
2.10.5  Band visualisation 
 
To visualise β-lactamases a sheet of filter paper was soaked with a 50µg/ml 
nitrocephin solution which was then placed on the gel surface.  Where the β-







2.11  Outer membrane protein (OMP) analysis 
 
2.11.1  OMP extraction 
 
OMPs were extracted according to the protocol as detailed by Bossi and Figueroa-
Bossi (2007).  Overnight cultures were inoculated 1/100 into 25mls of fresh LB broth 
in a sterile 125ml conical flask and shaken at 37°C, 180 rpm.  Cultures were grown 
to mid-exponential phase (OD600 ~ 0.5) and 10 ml was pelleted by centrifugation at 
4°C at 2000 g for 10 mins.  The supernatant was discarded and pellets were 
resuspended in 1ml of 10mM Tris-HCl pH 8.0 and sonicated (MSE Soniprep 150) on 
ice twice for 15 seconds at 10 microns.  Lysates were centrifuged for 5 mins at 4500 
g at room temperature in order to remove cell debris.  The supernatant was then 
removed to a 1.5 ml sterile microcentrifuge tube and centrifuged at 16,000 g for 45 
mins at 20°C.  Pellets were resuspended in 500µl of 10 mM Tris-HCl pH 8.0, 10 mM 
MgCl2, 2% (v/v) Triton X-100 and incubated in a waterbath at 37°C for 30 minutes.  
This was then centrifuged at 16,000 g for 45 mins at 20°C.  The residual OMP pellet 
was resuspended in 50µl of 100mM Tris-HCl pH 8.0, 2% SDS.  OMPs were stored 
at -20ºC. 
 
2.11.2  Protein concentration estimation 
 
Protein concentrations were estimated using a Pierce BCA Protein Assay kit 





2.11.3  SDS PAGE gel casting 
 
SDS PAGE gels were cast using the Bio-Rad Mini-PROTEAN® casting chambers.  
The components of the resolving and stacking gels are shown in table 2.10.  The 
resolving gel was prepared first.  Once poured the gel was quickly overlaid with 
100% ethanol and allowed to polymerise for one hour.  The ethanol was then poured 
off from the gel before the stacking layer was poured on top of the resolving gel and 
the comb inserted, ensuring a 0.5cm gap between the tips of the comb teeth and the 
resolving layer matrix.  The stacking layer was allowed to polymerise for at least one 
hour. 
 
  Resolving Stacking 
Gel Percentage 15 4 
Component     
40% polyacrylamide (ml) 3.75 0.5 
1.5M Tris-HCl, pH8.8 (ml) 2.5 N/A 
1M Tris-HCl, pH6.8 (ml) N/A 0.625 
10% SDS (µl) 100 50 
30% ammonium persulfate (µl) 20 10 
TEMED (µl) 20 10 
SDW (ml) 3.61 3.81 
Total Volume (ml) 10 5 
 
Table 2.10. SDS PAGE gel components. 
 
2.11.4  SDS PAGE running conditions 
 
SDS PAGE electrophoresis was performed using a Bio-Rad Mini-PROTEAN® II 
Cell.  Samples were boiled in Laemmili buffer (Bio-Rad, Hertfordshire, UK) for 10 
mins and chilled on ice prior to loading.  Gels were run at 150V for ~2 hours in 1X 




2.11.5  SDS PAGE gel staining 
 
SDS PAGE gels were removed from the electrophoresis cell and briefly washed with 
distilled water before Coomassie staining and destaining.  Stain/Destain; 50% 
ethanol, 7.5% acetic acid, 0.025% Coomassie R250 (stain solution only) (Bio-Rad, 
Hertfordshire UK).  Gels were stained for ~30 mins and destained for 30-60mins. 
 
2.12  Bacterial growth curves 
 
Overnight cultures were inoculated 1/100 into 25mls of fresh LB broth in a sterile 
125ml conical flask.  Flasks were incubated at 37°C and shaken at 180 rpm.  Optical 
density (OD) readings were taken in a spectrophotometer (Camspec M330) at a 
wavelength of 600nm at each hour. 
 
2.13  Biofilm assays 
 
Biofilm assays were performed according to the protocol of O’Toole and Kolter 
(1998).  Overnight cultures were inoculated 1/100 into fresh LB broth.  100µl of each 
strain was pipetted into a 96-well polystyrene plate and plates were sealed.  Plates 
were incubated at 37°C for 24, 48 and 72 hours.  Controls of just LB broth were 
included.  After the incubation period the contents of the wells were aspirated and 
each well was washed twice with sterile distilled water.  100µl of 0.1% crystal violet 
was added to each well and plates were incubated at room temperature for 15 




distilled water twice as before.  125µl of 95% ethanol was added to each well to 
solubilise the crystal violet and transferred into a 1.2ml cuvette containing 875µl of 
distilled water.  The contents of the cuvette were mixed and OD readings were taken 
in a spectrometer at a wavelength of 600nm.  Assays were performed in triplicate.  
Readings taken from the LB broth only wells were used as background readings and 
subtracted from the subsequent calculations of the levels of biofilm production. 
 
2.14  Mutation studies 
 
2.14.1  Attainment of mutants 
 





cfu/ml and spread on IST only plates and IST plates 
containing the appropriate antimicrobial or compound at 2, 4 and 8 times their 
respective MICs.  Plates were incubated in air at 37°C overnight.  Colonies were 
picked from the antibiotic containing plates and inoculated into fresh LB broth.  
Mutants were subjected to susceptibility testing and freezer stocks were prepared to 
be stored at -80ºC.  Colony counts were performed on the IST only plates in order to 
calculate mutation frequencies. 
 
2.14.2  Stability of mutants 
 
To test the stability of the phenotypes of the mutant strains, each was subcultured on 




showing the same susceptibility profile as the original mutants were considered to 
have a stable phenotype.   
 
2.15  Gene expression induction studies 
 
2.15.1  Chlorpromazine 
 
Bacterial cultures were seeded (1/100) into fresh LB broth and grown shaking at 
37ºC.  At mid-exponential growth phase (OD600 0.4-0.6) the cultures were split; 
150µg/ml CPZ was added to one half of the culture and the other half remained 
untreated.  These were then grown shaking at 37ºC for a further hour prior to cells 
being harvested for RNA extraction.   
 
2.15.2  Tigecycline 
 
Bacterial cultures were seeded (1/100) into fresh LB broth and grown shaking at 
37ºC.  At mid-exponential growth phase (OD600 0.4-0.6) the cultures were split; 
tigecycline was added to one half of the culture at 4 times the respective MIC of the 
strain and the other half remained untreated.  These were then grown shaking at 37ºC 








2.16  Gene expression analysis 
 
2.16.1  RNA extraction 
 
RNA was extracted using the RiboPure Bacteria RNA kit (Applied Biosystems, 
Warrington, UK) according to the manufacturer’s instructions and RNA was treated 
with TURBO DNA-free DNase (Applied Biosystems, Warrington, UK) to eliminate 
any contaminating DNA.  One µl of DNase digested RNA from each sample was 
used as a template for PCR amplification using primers RamAF and RamAR for 30 
cycles. If amplification was observed, TURBO DNA-free DNase treatment was 
repeated.  RNA was run on an agarose gel in order to assess integrity and check for 
degradation.  RNA was stored at -80°C. 
 
2.16.2  RNA concentration estimation 
 
The concentration of extracted RNA samples was estimated using the NanoDrop 
1000 Spectrophotometer (Thermo Scientific, Cramlington, UK).  Two µl of each 
RNA sample was read by the spectrophotometer and 260/280 absorbance readings 
were noted.  Those that fell between 1.8 and 2.1 were deemed to suitable to be 








2.16.3  cDNA synthesis 
 
cDNA synthesis was carried as detailed in manufacturer’s instructions using the 
Invitrogen First Strand cDNA Synthesis kit. (Invitrogen, Paisley, UK) Briefly, 250ng 
of total RNA, 500µM dNTPs and 50ng of random hexamers were incubated at 65ºC 
for 5 min then chilled on ice.  Reverse transcription was carried out in a total volume 
of 20µl containing; 10mM DTT, 5mM MgCl2, 1X RT buffer, 40U of RNaseOUT and 
200U of SuperScript III reverse transcriptase, for 10 min at 25ºC, 50 min at 50ºC and 
the reaction was terminated by heating for 5 min at 85ºC. 
 
2.16.4  Reverse transcription (RT) PCR 
  
RT PCR was performed on genes of interest.  PCRs for all genes were performed 
using 1µl of cDNA in a 50µl total volume for 25-30 cycles, depending upon the 
gene, with the exception of the 16S gene, which was for 12 cycles (Table 2.11)..  
Table 2.12 shows the genes for which expression was measured in the investigated 






















Table 2.11.  Cycle numbers used for PCR assessment of each gene. 
 
 
K. pneumoniae Strain Genes 
K1 ompK34, ompK35, ompK36, ramA, romA, acrA, 16S 
K2 ompK34, ompK35, ompK36, ramA, romA, acrA, 16S 
ATCC 13883 ompK34, ompK35, ompK36, ramA, romA, acrA, 16S 
Ecl8 ramA, ramR, romA, acrA, ybdJ, 16S 
Ecl8 Mdr1 ramA, ramR, romA, acrA, ybdJ, 16S 
S7 ramA, ramR, romA, acrA, ybdJ, 16S 
S8 ramA, ramR, romA, acrA, ybdJ, 16S 
CG43 ramA, ramR, romA, acrA, ybdJ, 16S 
MGH 78578 ramA, ramR, romA, acrA, ybdJ, 16S 
Kp342 ramA, ramR, romA, acrA, ybdJ, 16S 
S28 ramA, ramR, romA, acrA, ybdJ, 16S 
S29 ramA, ramR, romA, acrA, ybdJ, 16S 
 
Table 2.12.  The K. pneumoniae strains on which RT-PCR was 










2.16.5  Gel analysis 
 
RT PCR products were analysed using the Bio-Rad GelDoc 2000 software, Quantity 
One.  After being run on agarose gels and staining, Quantity One was used to semi-
quantitatively assess gene expression.  The intensities of the PCR product bands were 
measured and normalised to the intensities of the 16S bands before being used to 
compare expression levels between strains.  The following settings and conditions 
were used: manual band selection, background subtracted, peak intensity readings 
measured, rolling disc value of 10 used. 
 
2.17  Plasmid curing experiments 
 
2.17.1 Acriflavine, SDS and ethidium bromide 
 
Overnight broth cultures were inoculated into LB broth containing either doubling 
dilutions of ethidium bromide or 256µg/ml of acriflavine or SDS.  These were then 
grown shaking at 180 rpm, overnight at 37°C.  For ethidium bromide cultures 
aliquots of the dilution in which growth appeared to be visibly inhibited, 128µg/ml, 
was spread onto IST agar plates.  Aliquots of acriflavine and SDS cultures were 
similarly spread on IST agar plates.  All plates were incubated in air at 37°C for 18 
hours.  Twenty colonies were picked for each strain and each curing agent, 
inoculated into LB broth for growth overnight, and their susceptibility tested against 
ertapenem, imipenem and meropenem.  If strains showed similar susceptibility 




resistance was lost.  If strains showed reduced MICs then it was deemed that it was 
likely that a plasmid containing a β-lactamase had been lost and warranted further 
investigation. 
 
2.18  Genetic manipulations 
 
2.18.1  Preparation of chemically competent DH5α cells 
 
An overnight broth culture of E. coli DH5α was inoculated 1/100 into 50mls of fresh 
LB broth in a sterile 250ml flask.  This was then shaken at 37°C at 180rpm until the 
culture reached an OD600 of approximately 0.5.  The culture was split into two 25ml 
volumes in sterile 50 ml centrifuge tubes and the cells were pelleted by 
centrifugation at 4°C at 2000 g or 10mins.  The supernatant was removed and the cell 
pellets were resuspended in 25mls of sterile ice cold 0.1M CaCl2 then placed on ice 
for 30mins.  The tubes were centrifuged as before at 4°C at 2000 g for 10mins.  The 
supernatant was removed and the cell pellet was resuspended in 1ml of sterile ice 
cold 0.1M CaCl2 to which 200µl of 90% glycerol was added.  The cells were stored 
as 100µl aliquots at -80°C. 
 
2.18.2  Preparation of electrocompetent cells 
 
An overnight broth culture was inoculated 1/100 into 50mls of fresh LB broth in a 
sterile 250ml flask.  This was then shaken at 37°C at 180rpm until the culture 




in sterile 50ml centrifuge tubes and placed on ice for 30 mins.  Cells were pelleted by 
centrifugation at 4°C at 2000 g for 10 mins.  The supernatant was removed and the 
cell pellets were resuspended in 25mls of sterile ice cold 10% glycerol before being 
centrifuged as before.  This step was repeated twice more with the pellet being 
resuspended in reducing volumes of glycerol (15mls then 10mls).  The final pellet 
was resuspended in 1ml of sterile ice cold 10% glycerol and cells were stored as 
100µl aliquots at -80°C. 
 
2.18.3  Plasmid transformation via heatshock 
 
An aliquot of chemically competent DH5α cells were thawed on ice.  Two µl of 
purified plasmid or 5µl of ligation was added to the cells, mixed and chilled on ice 
for 30mins.  Cells were then placed in a waterbath set to 42°C for exactly 1 minute 
then immediately placed on ice for 2 mins.  One ml of fresh LB broth was added to 
the cells which were then transferred into a sterile 15 ml centrifuge tube and 
incubated at 37°C, shaking at 180rpm for 1 hour.  Cells were then spread on LB agar 
plates containing the appropriate selective antibiotics and incubated overnight at 
37°C. 
 
2.18.4  Plasmid transformation via electroporation 
 
An aliquot of electrocompetent cells were thawed on ice.  One µl of plasmid was 
pipetted into a 2 mm gap electroporation cuvette (Invitrogen, Paisley, UK).  Cells 




were electroporated at 2.5kV in a Bio-Rad Micropulser and 1 ml of LB broth was 
immediately added to the cells.  The cells were then transferred in a sterile 15 ml 
centrifuge tube and incubated at 37°C, shaking at 180 rpm for 1 hour.  Cells were 
then spread on LB agar plates containing the appropriate selective antibiotics. 
. 
2.18.5  ramR cloning and complementation 
 
The entire ramR open reading frame (ORF) was previously amplified using primers 
RamRF and RamRR, and cloned into vector pACYC177 (by T. Schneiders), 
subsequently known as pACramR.  Both pACYC177 and pACramR were 
maintained in E. coli DH5α.  pACramR and pACYC177 were transformed into 
electrocompetent Kp342 cells by electroporation and selected for using kanamycin at 
30µg/ml.  Plasmids were confirmed by performing plasmid preparations and 
subsequent restriction analysis.  Those containing pACYC177 only were restricted 
with ScaI to linearise and give a single band of approximately 3.9 kb.  Those 
containing pACramR were restricted with both ScaI and PstI to give two bands of 
approximately 3.6 kb and 0.9 kb.  ramR presence was additionally confirmed by 
PCR using primers internal to ramR.  Upon confirmation the strains were frozen 
down and stored at -80°C for further work.   
 
2.18.6  romA cloning and complementation 
 
romA was amplified from K. pneumoniae MGH 78578 with the primers RomAF2 




was cloned into the pGem T-easy plasmid using the pGem T-easy vector system 
(Promega, Hampshire UK), according to the manufacturer’s instructions.  romA was 
cut from the pGem plasmid using restriction enzymes ScaI and PstI, and ligated into 
pACYC177, also cut with the same enzymes.  The ligation was transformed via heat 
shock into E. coli DH5α cells.  After confirmation of the transformation by plasmid 
preparation and restriction in the same manner as described previously for ramR, the 
pACromA plasmid was extracted using a Qiagen Mini Prep kit and transformed into 
electrocompetent cells of E. coli MG1655 and also K. pneumoniae Ecl8, by 
electroporation.  The transformation was again confirmed by plasmid extraction and 
restriction analysis.  Strains were frozen down and stored at -80°C for further work. 
  
2.19  Phenotypic β-lactamase detection assays 
 
To detect the presence of any AmpC β-lactamases and any carbapenemases, the 
following tests were performed: a modified three dimensional test, an AmpC disc test 
and a modified Hodge test. 
 
2.19.1  The modified three dimensional test 
 
Crude enzyme extracts were prepared for strains K1 and K2 as described previously 
for IEF.  A lawn culture of E. coli ATCC 25922 was prepared on Mueller Hinton 
(MH) agar plates.  A cefoxitin disc was placed in the centre of the plate and using a 
sterile scalpel, 3cm linear slits were cut 3mm away from the disc.  At the end of the 




enzyme extract was loaded.  Plates were allowed to dry for 10 minutes before being 
incubated in air at 37°C for 24 hours.  Distortion of the zone of inhibition across the 
slits would be indicative of cefoxitin hydrolysis and possible AmpC production.  
Strains giving no visible distortion are considered non-AmpC producers. 
 
2.19.2  AmpC disc test 
 
A lawn culture of E. coli ATCC 25922 was prepared on MH agar plates.  A cefoxitin 
disc was placed in the centre of the plate.  Sterile filter paper discs (6mm) were 
moistened with 5µl of sterile saline and inoculated with several colonies of the test 
organism.  The inoculated disc was then placed next to the cefoxitin disc without 
touching.  A positive test for AmpC production appeared as a distortion or 
indentation of the zone of inhibition in the vicinity of the test disc. 
 
2.19.3  Modified Hodge test 
 
Modified Hodge tests were performed according to the protocol of Lee et al (2001).  
E. coli 25922 was used as the indicator strain and K. pneumoniae MGH 78578 was 
used as the carbapenemase –ve strain.  MH agar plates were swabbed with a 
suspension of E. coli 25922 diluted in sterile saline to the equivalent of a 0.5M 
McFarland standard.  After plates had dried a test disc, either ertpanem, imipenem or 
meropenem, was placed in the centre of the plate.  A heavy inoculum of test strain 
was then streaked from the disc, without touching, to the edge of the plate.  This was 




control), and K. pneumoniae KPC-3 (carbapenemase +ve control).  Plates were the 
incubated in air at 37°C for 18 hours.  If a cloverleaf effect was observed with the 
indicator strain then it was concluded that a carbapenemase was likely to be present 
in the test strain where this effect was observed. 
 
2.20  Transconjugation studies 
 
2.20.1  Transconjugation assays 
 
Transconjugation assays were performed as follows: overnight broth cultures of the 
recipient (E. coli J62-2) and donor strains (K1 and K2) were mixed in a 1:4 ratio, 
cells were collected by centrifugation and resuspended in 30µl of cold saline.  5 µl 
aliquots of the resuspension were spotted onto a nutrient agar plate and incubated at 
37°C for 6h.  Growth was collected and resuspended in cold saline and inoculated 
onto nutrient agar plates containing rifampicin at 16mg/L and one of the selective 
antibiotics gentamicin, ceftazidime or meropenem at a range of concentrations. 
 
2.20.2  Assessment of transconjugants 
 








Chapter 3.  Chemical induction of the Ram regulon 
 
3.1  Introduction 
 
3.1.1  The RamA regulon 
 
Although the transcriptional activator RamA was first identified in K. pneumoniae in 
1995 (George et al, 1995), its exact role in conferring antibiotic resistance and the 
scope of its regulon continue to remain elusive.  Previous studies have associated 
ramA over-expression with an increase in efflux, specifically the increased 
expression of the AcrAB efflux pump; however it is unknown whether this is an 
exclusive relationship and how this effect is activated (Kallman et al, 2008; Zheng et 
al, 2009).  It is known that mutations within acrR, the gene encoding a local 
repressor of the AcrAB efflux pump, can result in the over-expression of the pump 
and lead to an MDR phenotype (Olliver et al, 2004).  However MDR phenotypes as 
a result of acrAB over-expression are also evident in the absence of acrR mutations, 
leading to the assumption that other regulatory mechanisms are in place, such as the 
contribution of RamA (Schneiders et al, 2003).  This study looks at the ability of two 
compounds, the glycylcycline antibiotic tigecycline and the phenothiazine compound 
chlorpromazine (CPZ), in activating the expression of ramA and members of its 







3.1.2  Chlorpromazine background 
 
Chlorpromazine is an aliphatic phenothiazine antipsychotic drug initially used in the 
treatment of schizophrenia in the 1950’s (Figure 3.1) (Owens, 1996).  It acts as an 
antagonist of various postsynaptic receptors within the central nervous system 
(dopamine, serotonin, histamine, adrenergic and muscarinic acetylcholine receptors), 
however whether the antagonism is caused by the direct binding of chlorpromazine 
to the receptors or as an indirect effect is unknown (Owens, 1996).  Chlorpromazine 
has also been used in the treatment of nausea/emesis, anxiety and amphetamine 




Figure 3.1. The aliphatic side chain of chlorpromazine.  The three ring 
structure, with nitrogen and sulphur, is the defining characteristic of a phenothiazine 
compound. (adapted from Bourdon, 1961) 
 
Chlorpromazine has been noted in several studies (Amaral et al, 2000; Kaatz et al, 




use in the treatment of bacterial infections is severely limited by the severity and 
toxicity of its side effects and the high concentrations required to exert its 
antimicrobial activity.  Studies in S. aureus and Burkholderia pseudomallei have 
shown that chlorpromazine can act synergistically with certain antibiotics to lower 
their respective MICs (Kaatz et al, 2003; Chan et al, 2007), although the exact 
mechanism of this synergy is still unknown.  Chlorpromazine itself is suspected to 
act via the binding of calcium binding proteins, inhibiting calcium-dependent 
enzymatic processes and thereby impeding the proton gradient-dependent efflux of 
toxic compounds (Weiss et al, 1980).  It is because of this hypothesis that 
chlorpromazine may be referred to as an efflux pump inhibitor (EPI) in some 
scientific publications, although it is important to emphasise that this has not yet 
been confirmed experimentally.   
 
Chlorpromazine was chosen for study in K. pneumoniae because of evidence 
presented in a previous study in S. enterica that suggested chlorpromazine could 
upregulate ramA expression. Bailey et al (2008) found that chlorpromazine 
independent ramA over-expression resulted in acrB over-expression but in contrast, 
chlorpromazine dependent ramA over-expression resulted in acrB downregulation.  
It was concluded that chlorpromazine acted on acrB independently of ramA and 
subsequently the regulation of both genes following chlorpromazine exposure was 
deemed not to be linked.  Whether this effect is also true in K. pneumoniae remains 






3.1.3  Tigecycline background 
 
Tigecycline is a semisynthetic glycylcycline antibiotic, marketed by Wyeth as 
Tygacil
®
, that was approved for clinical use in 2005.  Tigecycline is actually a 
derivative of the tetracycline antibiotic, minocycline, and is currently the sole 
member of the glycylcycline class of antibiotics licensed for clinical use.  The 
glycylcyclines were initially developed in response to the increasing incidence of 
MDR bacterial infections and were designed to overcome mechanisms of resistance 
responsible for rendering other antimicrobials ineffective.  Similarly to the 
tetracyclines, tigecycline is a bacteriostatic protein synthesis inhibitor that functions 
by binding the 30S ribosomal subunit and blocking the entry of amino-acyl tRNA to 
the A site of the ribosome.  The substitution of an N-alkyl-glycylamido group at the 
9 position on the D ring allows tigecycline to evade the normal resistance 
mechanisms, such as the tet transporters, to which tetracycline is vulnerable (Noskin, 
2005) (Figure 3.2).   
 
 
Figure 3.2.  The primary structure of tigecycline.  The N-alkyl-glycylamido 




Tigecycline has been shown to have broad spectrum activity against Gram-negative, 
Gram-positive and anaerobic bacteria (Noskin, 2005).  Specifically, tigecycline has 
exhibited significant potency against particularly problematic infection causing 
bacteria such as MRSA and MDR A. baumannii (Noskin, 2005).     
 
Tigecycline was chosen for analysis in this study due to a reported correlation 





















3.2  Results 
 
3.2.1  Susceptibility testing 
 
The panel of K. pneumoniae strains were subjected to susceptibility testing against 
antibiotics from four different classes; chloramphenicol, fluoroquinolones 
(ciprofloxacin and norfloxacin), tetracyclines (minocycline and tetracycline) and 
glycylcyclines (tigecycline). The susceptibility testing results, as shown in Table 3.1, 
indicate that the strains listed as ramA over-expressers have significantly higher 
MICs to the antibiotics tested than the ramA non-expressing strains with the only 
exception being the MIC of the fluoroquinolones, ciprofloxacin and norfloxacin, for 
Kp342, which is comparable to that of the non-expressing strains.  These results 
suggest that the expression of ramA plays a role in conferring resistance to these 
antibiotics.  Note: it has previously been determined by T. Schneiders that the RamA 













  MIC (µg/ml) 
 




512 0.0625-512 0.0625-512 0.0625-32 0.0625-512 0.0625-16   
Strain             ramA Status 
S7     8   >128    >512     >32    >512       8 Expresser 
S8     0.5     4          4         4          2       0.125 Non-
expresser 
Ecl8 <0.0625 <0.0625          0.125         2          0.25       0.125 Non-
expresser 
Ecl8 Mdr1     8 128      128       32     256       4 Expresser 
Kp342     0.5     4      256     >32       16       4 Expresser 
MGH 78578     1     4    >512     >32     512       0.25 Non-
expresser 
S28   32   32    >512     >32   >512       2 Expresser 
S29   64 256    >512     >32   >512       2 Expresser 
CG43 <0.0625     0.125          2         8         1       0.5 Non-
expresser 
 
Table 3.1.  The resistance profiles of strains investigated their ramA 
expression status. 
* ramA expression status was previously determined via northern blot analysis by T. 
Schneiders: data not shown. 
 
3.2.2  Chlorpromazine and tigecycline studies 
 
The effects of chlorpromazine, a reported EPI was investigated in its capacity to 
inhibit active efflux, and both chlorpromazine and tigecycline were examined in their 








3.2.3  Synergy testing 
 
MDR ramA over-expressing strains were chosen for synergy testing with 
chlorpromazine and three structurally unrelated antibiotics that are known from 
previous literature to be efflux pump substrates; chloramphenicol (Cm), norfloxacin 
(Nor) and tetracycline (Tet) (Elkins and Nikaido, 2002).  Chlorpromazine was shown 
to act synergistically in all strains tested when used at a set concentration of 
200µg/ml (<50% of the MIC value for each strain) in combination with norfloxacin 
(Nor) (Table 3.2).  FIC values were determined and synergy was defined as a FIC 
value of ≤0.5.  Synergy with chloramphenicol and tetracycline appeared to be more 
strain dependent, with two and four strains showing synergy respectively.  Of the 
strains that did not show synergy, an additive effect was observed (Addition= FIC 
>0.5-1).  Overall, the use of chlorpromazine resulted in reductions in the MICs 
ranging from 4 – 128-fold.  These results suggest that chlorpromazine has an 
inhibitory effect on the efflux systems and that active efflux is at least partly 









Strain CPZ Cm Cm/CPZ200 FIC* 
Fold 
Decrease Nor Nor/CPZ200 FIC* 
Fold 
Decrease Tet Tet/CPZ200 FIC* 
Fold 
Decrease 
S7 512 2048      512 0.9 4 2048 16 0.4     128 1024      256 0.6 4 
Ecl8 Mdr1 512  128 8 0.5       16      8        0.25 0.4       32  4       0.25 0.5       16 
Kp342 1024  256        64 0.4 4      4 1 0.4 4      16 4 0.4 4 
S29 512 2048      512 0.9 4 256 4 0.4       64    512        64 0.5 8 
S28 512 2048      512 0.9 4   32 4 0.5 8  1024        64 0.5       16 
 
 
Table 3.2.  Chlorpromazine synergy MICs.  MIC values for tested strains with antibiotic alone and in combination.  FIC values 
and fold decreases in MIC are also shown for the testing combinations.  Values in red are deemed to show synergy. 











3.2.4  Chlorpromazine transcriptional induction of the Ram regulon 
 
Exponential growth phase cultures of a panel of ramA non-expressing K. 
pneumoniae strains (S8, Ecl8, MGH 78578 and CG43) were split; one half of each 
culture was left untreated and the other half was treated with 150µg/ml of 
chlorpormazine, before both were grown shaking at 37ºC for one further hour.  RNA 
was extracted and cDNA synthesised in order to perform RT-PCR and assess the 
transcription of genes ramA, romA, acrA, ramR and 16S.  The cultures treated with 
chlorpromazine were shown to exhibit increased transcription levels of ramA, romA 
and acrA (Figure 3.3.).  No ramR transcript could be detected in either culture in any 
of the strains. 
 
 
Figure 3.3.  Example gel showing chlorpromazine induction in strain 
MGH 78578.  An agarose gel picture showing an example of the transcriptional 
induction of genes ramA, romA and acrA by chlorpromazine in strain MGH 78578 
after one hour of chlorpromazine treatment at 200µg/ml.  - = untreated culture; + = 






Of the panel of strains treated with chlorpromazine, all appeared to exhibit the same 
effect of increased transcription of ramA, romA and acrA, albeit to varying levels 
between strains.  The levels of transcription were quantified using the GelDoc 
Quantity One software (BioRad) as shown in Figure 3.4.  In all strains, with the 
exception of MGH 78578, ramA transcription shows the greatest increase, followed 
by romA and then acrA.  Note: all transcriptional analyses are semi-quantitative and 
although background fluorescence is subtracted prior to quantification, a margin of 
error remains.  All RT-PCR analyses were performed twice on separate occasions. 
 
 
Figure 3.4.  Graph showing the levels of chlorpromazine induction of 
genes ramA, romA and acrA.  Shows the fold differences in transcription levels 
between ramA, romA and acrA following CPZ treatment; all levels were normalised 
to 16S and are relative to transcription levels detected in untreated cultures.  The data 







3.2.5  Tigecycline transcriptional induction of the Ram regulon 
 
Two ramA non-expressing K. pneumoniae strains, S8 and Ecl8, were chosen for 
tigecycline studies.  Exponential growth phase cultures were split in two; one half 
was left untreated and the other treated with 8X the MIC of tigecycline (Table 3.3) 
before being grown shaking at 37ºC for two further hours.  RNA was extracted and 
cDNA synthesised in order to perform RT-PCR. 
 
  MIC (µg/ml) 
Strain Tig 8X 
S8 0.125 1 
Ecl8 0.125 1 
 
Table 3.3. S8 and Ecl8 tigecycline MICs.  Shows the MIC for tigecycline for 
strains Ecl8 and S8 and the concentrations at which the inductions were performed. 
 
RT-PCR was performed for genes ramA, romA, acrA, ramR, ybdJ and 16S rRNA 
respectively.  Both strains S8 and Ecl8 showed increased transcription of genes 
ramA, romA and acrA following exposure to tigecycline (Figure 3.5).  No ramR or 
ybdJ transcript was detected in either strain and under either growth condition.  The 
transcription levels were quantified using GelDoc Quantity One software (BioRad) 








Figure 3.5.  Example gel showing tigecycline induction in strains S8 and 
Ecl8.  An agarose gel picture showing the effect of tigecycline on ramA, romA and 
acrA after two hours of exposure to tigecycline at 8x their respective MICs in strains 











Figure 3.6.  Graph showing the levels of tigecycine induction of ramA, 
romA and acrA.  Shows the increases in transcription level of two strains, S8 and 
Ecl8, after exposure to tigecycline for two hours.  All increases are relative to the 
transcription levels in untreated cultures and normalised to 16S levels.  Error bars 
show SEM. 
 
As Figures 3.5 and 3.6 show, the transcription of ramA, romA and acrA was 
upregulated in both S8 and Ecl8 following exposure to tigecycline.  The upregulation 
of all three genes was very similar in strains S8, whilst acrA was upregulated to a 
much lesser extent than that of ramA and romA in strain Ecl8.  All RT-PCR analyses 











3.3  Discussion 
 
The transcriptional activator RamA has been shown in previous studies (Schneiders 
et al, 2003; Kallman et al, 2008; Zheng et al, 2009) to be involved in the regulation 
of the RND family efflux pump, AcrAB, in K. pneumoniae and Salmonella spp.  The 
over-expression of such an efflux mechanism is sufficient to confer an MDR 
phenotype (Schneiders et al, 2003).  AcrAB, for example, is capable of the efflux of 
several classes of antibiotics including the fluoroquinolones and the tetracyclines 
(Elkins and Nikaido, 2002).  The consequence of this resistance mechanism is a 
severe limitation in treatment options for infections caused by such organisms and 
subsequently alternative antibiotic treatment regimens must be utilised.   
 
In the current antibiotic climate, where few new compounds are being discovered or 
developed, it is increasingly important that upon the potential release of such 
compounds for clinical use that it is anticipated how resistance is likely to arise.  
Therefore, with tigecycline for example, it is important to anticipate how resistance 
may be conferred.  The results of this may influence how the antibiotic is used 
clinically and which interventions are necessary in order to limit the development of 
resistance.  In cases where MDR and even PDR strains are becoming more common, 
clinicians and scientists are now finding it necessary to obtain alternative treatments 
to the antibiotics typically used in the clinical setting (Falagas et al, 2008).  This 
emergence has resulted in the revival of the polymyxins for the treatment of PDR 





compounds, such as the phenothiazines, as a possible supplement to the current 
antibiotic compilation (Kaatz et al, 2003). 
 
The susceptibility testing results showed that, as suggested in previous literature 
(George et al, 1995), the over-expression of ramA can be correlated with an MDR 
phenotype as shown by the elevated MICs of chloramphenicol, the fluoroquinolones, 
the tetracyclines and the glycylcycline.  The only exceptions to this trait are the 
fluoroquinolones, (ciprofloxacin and norfloxacin), MICs exhibited by Kp342, which 
were comparable to those exhibited by the ramA non-expressing strains S8 and MGH 
78578.   This effect could be for a number of reasons, for example; the other ramA 
over-expressers may carry additional mutations that contribute to fluoroquinolone 
resistance such as gyrA, gyrB, parC, or parE mutations that Kp342 does not, or 
alternatively there may be mutations present within the efflux genes of Kp342 that 
can result in the fluoroquinolones being a poor substrate for the pumps.   
 
The synergy testing results suggest that chlorpromazine may indeed be capable of 
functioning as an efflux pump inhibitor as has been suggested previously (Kaatz et 
al, 2003; Chan et al, 2007), however this effect does not appear to be consistent 
between strains and shows a variation in efficacy between antibiotics.  All of the 
ramA over-expressing strain tested with chlorpromazine and norfloxacin gave values 
that could be interpreted as showing a synergistic effect, and similar results were 
observed for chlorpromazine and tetracycline, with the exception of S7 whose FIC 
value fell into the addition category.  The greatest variation between strains was 





Ecl8 Mdr1 and Kp342 fell into the synergy category, and the remaining strains 
showed addition.  This effect could be due to other efflux systems or other 
chloramphenicol resistance mechanisms at work, which are not affected by 
chlorpromazine.  However, if we only take the fold decreases into account, rather 
than the FIC values, then the use of chlorpromazine results in respectable MIC 
decreases ranging from 4-128-fold across all antibiotics and strains tested. 
 
It appears that both chlorpromazine and tigecycline are capable of inducing the 
transcription of ramA and its associated genes, romA and acrA, as shown by the RT-
PCR studies.  Induction by chlorpromazine was exhibited in all ramA non-expressing 
strains and induction by tigecycline was exhibited in the two candidate strains Ecl8 
and S8.  Although all of the genes in question did indeed appear to be upregulated, 
the levels varied vastly between strains, suggesting that the regulation of these genes 
is a strain-dependent effect in which other unknown factors are involved. The similar 
upregulatory effect suggests that both compounds, chlorpromazine and tigecycline, 
may be capable of selecting for a MDR phenotype via the induction of ramA 
expression and subsequently acrAB upregulation.  The results of this part of the 
study contrast those found by Bailey et al (2008).  They found that whilst 
chlorpromazine upregulated ramA, they also determined that acrB was 
downregulated.  Although in this study we looked at the expression of acrA rather 
than acrB, both genes are reported to be co-transcribed and so the same 
transcriptional effect could be expected in both genes (Keeney et al, 2008).  There 
could be a number of reasons for this contrast in results.  The study by Bailey et al 





species-specific or alternatively chlorpromazine may effect the transcription of acrA 
and acrB differently.  It is possible that under certain conditions that, despite the co-
transcription of acrA and acrB, the stability of their mRNA may differ or be affected 
by chlorpromazine, resulting in the apparent up or downregulation of either gene.  
However, it remains unclear from this data whether the apparent induction of 
expression is due to true upregulation of RNA transcription or an mRNA 
stabilisation effect, and additionally whether this leads to increased translation.     
 
The lack of detection of both ramR and ybdJ by RT-PCR could be for a number of 
reasons, for example the genes may be subject to low level expression that is not 
picked up by RT-PCR analysis or that their expression could simply be repressed.  
Neither chemical caused the over-expression of these genes indicating that their 
expression is not directly affected by tigecycline or chlorpromazine in the same 
manner as was observed for ramA, romA and acrA.  Previous reports indicate that 
RamR is involved in the regulation of the ram regulon (Bailey et al, 2008; Molitor, 
2008), however ybdJ has not been previously reported to play a role in this regulon 
and the lack of induced over-expression indicates that this may indeed be the case. 
 
The first discovered phenothiazine, methylene blue, was initially demonstrated to 
exhibit activity against Plasmodium falciparum by Guttmann and Erlich in the late 
19
th
 century (Guttmann and Ehrlich, 1891).  Following this the first neuroleptic 
phenothiazine, chlorpromazine, was developed in the 1950’s and was quickly shown 
to exhibit antimicrobial activity against M. tuberculosis (Bourdon, 1961), however 





schizophrenia resulted in no further development of chlorpromazine as an 
antimicrobial drug (Amaral et al, 2001).  Chlorpromazine appears to be unsuitable 
for clinical use as even the lowest concentrations at which significant antimicrobial 
activity is exhibited are unachievable due to its toxic side effects (Amaral et al, 
2001).  However, in the current circumstances where an increasing number of PDR 
bacterial strains are being isolated (Falagas et al, 2008), the antimicrobial properties 
of phenothiazines indicate an attractive potential for their development and 
utilisation.  However, the exact nature of their interactions both within the bacterial 
cell and the human body must first be elucidated in order to achieve optimal efficacy 
and safety.  Although chlorpromazine has been shown to exhibit high levels of 
activity against M. tuberculosis, it is also amongst the most toxic of the 
phenothiazines.  Thioridazine, a much milder neuroleptic phenothiazine with fewer 
side-effects compared to chlorpromazine, has been shown to exhibit identical in vitro 
levels of activity to that of chlorpromazine in M. tuberculosis (Amaral et al, 1996).  
Another attractive property of the phenothiazines is that, since they are proposed to 
function by the irreversible binding of calcium binding proteins, no resistance 
development is anticipated.  Any gene deletions or mutations within the target 
proteins are likely to be lethal to the bacterial cell, so theoretically this should reduce 
the likelihood of the emergence of resistant strains (Amaral et al, 2001).  Whilst the 
synergy testing results shown in this study indicate a potential for phenothiazines as 
antimicrobials, the upregulation of ramA and acrA suggest that use of such 
compounds may also be selective for efflux mutants.  However, if this were the case 
it could also be argued that this point may be irrelevant as such compounds would 





This suggests that if the exact nature of the antimicrobial effects and cellular 
interactions of the phenothiazines could be elucidated, then these mechanisms could 
be exploited for the development of new antimicrobials. 
 
The presence of active efflux is increasingly thought of as an important resistance 
mechanism, particularly among members of the Enterobacteriaceae (Webber and 
Piddock, 2003).  RND family efflux pumps, the most abundant family amongst 
Gram-negative bacteria, have been shown to have a broad substrate range, 
demonstrating that the activation of a single resistance mechanism can result in 
clinical levels of resistance to several classes of antibiotics (Webber and Piddock, 
2003).  It could be argued that efflux is one of the most problematic resistance 
mechanisms and that ideally any new antibiotics under development should be able 
to evade such mechanisms.  Although only licensed in 2005, tigecycline resistance 
has quickly arisen in a number of clinically important pathogens including K. 
pneumoniae and A. baumannii, largely due to efflux mechanisms (Ruzin et al, 2005; 
Peleg et al, 2007).  It is possible that tigecycline resistance arises due to its apparent 
targeting and subsequent upregulation of regulator genes, such as ramA, or genes 
related to the regulation of the regulators as has been observed in this study.  
Tigecycline is reported to display in vitro activity against the E. coli strains over-
expressing the tet transporters (tet(B), tet(C), tet(K)), suggesting that it is capable of 
evading efflux by the tet transporters, an important mechanism of tetracycline 
resistance in both Gram-positive and Gram-negative bacteria (Hirata et al, 2004).  





transporters, they may remain viable substrates of other efflux mechanisms, such as 
the AcrAB pumps. 
 
In conclusion, the two compounds tested in this study appear to be capable of 
causing the upregulation of the transcriptional activator, ramA, and subsequently the 
efflux gene, acrA.  It remains unknown whether this is a permanent or transient 
effect, and whether both compounds exert their effects in the same manner.  It could 
be hypothesised that ramA, like other AraC/XylS family regulators, will itself be 
regulated by a local activator or repressor gene.  In this case it could be hypothesised 
that chlorpromazine or tigecycline acts upon this gene, which in turn upregulates 
ramA and causes a cascade of knock-on effects within the ramA regulon, one of 
which being the upregulation of acrA.  Alternatively, the compounds may act in 
another unforeseen manner that warrants further investigation, particularly in the 
case of tigecycline; an antibiotic currently used as a last resort for the treatment of a 
number of bacterial infections (Noskins, 2005). 













Chapter 4.  The role of RamA and RamR in Kp342 
 
4.1  Introduction 
 
4.1.1  Antibiotic resistance in endophyte strain, Kp342 
 
Kp342 is a nitrogen fixing K. pneumoniae endophytic strain, typically isolated from 
maize and wheat crops, the genome sequence of which is available on NCBI (NC 
011283) (Fouts et al, 2008).  The presence of Klebsiella spp. in plants can, in part, be 
attributed to their lack of flagella, a structure that typically induces the plant defence 
mechanisms in the cases of other bacteria.  Endophytic Klebsiella spp. have been 
reported and isolated in a number of different types of plants including sweet potato, 
rice, maize and bananas (Fouts et al, 2008).  It is thought that such species can 
promote the growth of the plant via the provision of fixed nitrogen.  Despite being a 
plant bacterial strain and therefore not exposed to antibiotics, Kp342 has been shown 
to exhibit high levels of resistance to several families of antibiotics, including the 
fluoroquinolones and tetracyclines (Fouts et al, 2008).  Kp342 has been shown to 
show limited pathogenicity in comparison to clinical isolates in studies using mouse 
models, indicating that, despite its antibiotic resistance profile, Kp342 is not well 
adapted for human infection (Fouts et al, 2008).  In comparison to the sequenced K. 
pneumoniae clinical strain MGH 78578 (NC 009648), Kp342 shows nucleotide and 
protein identities of 95% and 96% respectively (Fouts et al, 2008), indicating a high 

































4.2  Results 
 
4.2.1  Susceptibility testing 
 
Susceptibility testing showed that Kp342 exhibited resistance against norfloxacin 
(Nor), chloramphenicol (Cm), minocycline (Mino), tetracycline (Tet) and tigecycline 
(Tige), and intermediate levels of resistance against ciprofloxacin (Cip) (Table 4.1).  
This indicates that Kp342 exhibits an MDR phenotype. 
 
 MIC (µg/ml) 
  Cip Nor Cm Mino Tet Tige 
Range tested 0.0625-512 0.0625-512 0.0625-512 0.0625-32 0.0625-512 0.0625-16 
  0.5 4 256 >32 16 4 
S/I/R I R R R R R 
 
Table 4.1.  Susceptibility testing results of Kp342 against selected 
antibiotics.  Resistance break points were determined according to BSAC 
guidelines.  S= sensitive, I = intermediate, R = resistant. 
 
4.2.2  ramR sequencing 
 
As ramA was previously shown to be over-expressed in Kp342, ramR a putative 
regulator gene that lies upstream of ramA, was sequenced and compared to the ramR 
nucleotide sequence of K. pneumoniae MGH 78578 (NC 009648).  The Kp342 ramR 








Position MGH 78578 Kp342 
Amino Acid 
Change 
78 A C None 
111 C T None 
114 T G None  
126 A G None 
229 G C D77H 
312 A G None 
340-435  N/A 96nt deletion 32aa deletion 
456 C T None 
480 A G None 
556 C A H186N 
 
Table 4.2.  ramR sequences.  Differences found in the ramR nucleotide 
sequence of Kp342 compared to the sequence found in MGH 78578 and the resultant 
amino acid changes.  N/A = not applicable. 
 
The translated amino acid sequence of RamR in Kp342 was found to contain a 32 
amino acid deletion at position 114-145 as well as two single amino acid changes, 
D77H and H186N when compared again to that of MGH 78578.  Figures 4.1 and 4.2 














Figure 4.1.  The nucleotide sequence alignments of ramR from MGH 78578 and Kp342. 
 









4.2.3  ramR complementation 
 
Wild-type ramR, amplified from MGH 78578, was cloned into the plasmid vector 
pACYC177, thereafter known as pACramR, and transformed into Kp342.  
pACYC177 was also introduced into Kp342 as a vector only control.  Kp342, 
Kp342/pACYC177 and Kp342/pACramR were subject to susceptibility testing 
against ciprofloxacin (Cip), norfloxacin (Nor), tetracycline (Tet) and 
chloramphenicol (Cm).  Kp342 and Kp342/pACYC177 were shown to exhibit 
identical resistance profiles to one another, indicating that the introduction of 
pACYC177 alone had no effect on the susceptibility phenotype of Kp342, whilst 
Kp342/pACramR was shown to exhibit increased susceptibility to all of the 
antibiotics tested, ranging from 4-16-fold (Table 4.3).  The increases in susceptibility 
suggest that an attenuated or non-functioning RamR may be responsible for the 
MDR phenotype exhibited by Kp342 and it could be hypothesised that ramA and 
acrA are likely to be over-expressed. 
 
 MIC (µg/ml) 

















Kp342   0.5 N/A 4 N/A    16 N/A   256 N/A 
Kp342/pACYC177   0.5 0 4 0    16 0   256  0 
Kp342/pACramR  0.125 4 1 4 4 4 16      16 
 
Table 4.3.  Susceptibility testing results for Kp342, Kp342/pACYC177 






4.2.4  RT-PCR analysis of ramA and its associated genes 
 
RT-PCR was performed on RNA extracted from exponential growth cultures of 
Kp342, Kp342/pACYC177 and Kp342/pACramR in order to assess the transcription 
levels of ramA, romA, acrA, and 16S.  ramA, romA and acrA were found to be over-
expressed in Kp342 and Kp342/pACYC177 relative to Kp342/pACramR.  Figure 4.3 
shows the differences in expression levels of ramA, romA and acrA in Kp342 and 
Kp342/pACYC177, both of which showed very similar levels of expression, 
compared to the levels observed in Kp342/pACramR.  All PCRs were performed in 
duplicate and all calculations were normalised to 16S expression levels.  Figure 4.4 
shows the agarose gel pictures of the 16S, ramA, romA and acrA PCRs. 
 
Figure 4.3.  Expression levels of ramA, romA and acrA.  The levels 
expression of genes ramA, romA and acrA in Kp342 and Kp342/pACYC177 






Expression levels were calculated using the GelDoc Quantity One software to 
measure the intensity of the bands on the agarose gels relative to the 16S internal 
controls and then compared between strains.  Both ramA and romA did not appear to 
be expressed in Kp342/pACramR which translated to a 17.6-fold and 7.5-fold 
reduction respectively in expression compared to Kp342 and Kp342/pACYC177.  
acrA was deemed to be expressed 1.3-fold more in Kp342 and Kp342/pACYC177 
compared to Kp342/pACramR.  Although a certain degree of inaccuracy lies in the 
GelDoc Quantity One software for the calculation of transcription levels between 
these strains, the differences in expression levels can be clearly observed in the 
agarose gel picture in Figure 4.4. 
 
 
Figure 4.4.  Example gel showing expression of ramA, romA and acrA in 







These results suggest that the RamR present in wild-type Kp342 is non-functional 
and that RamR acts as a negative regulator of ramA, romA and acrA expression.  
This suggests that RamA is constitutively expressed in Kp342, resulting in the 
constant upregulation of the efflux pump, AcrAB. 
 
4.2.5  Biofilm assays 
 
Upon the growth of Kp342, Kp342/pACYC177 and Kp342/pACramR cultures in LB 
broth, it was observed that Kp342/pACramR appeared to form a biofilm around the 
edges of the glass conical flasks.  Biofilm assays were performed on all three strains 
in order to measure any differences between the levels of biofilm production.  Assays 












Figure 4.5.  Graph showing the differences in biofilm production 
between Kp342 strains.  Graph bars show the fold increase in biofilm production 
between Kp342/pACramR against averaged Kp342 and Kp342/pACYC177 biofilm 
measurements over a 72 hour period minus the background readings.  Bars show 
SEM. 
 
An increase in biofilm production was observed in Kp342/pACramR compared to 
Kp342 and Kp342/pACYC177 which showed very similar results to each other, 
indicating that the introduction of pACYC177 alone has no effect on biofilm 
production in Kp342.  The differences were shown to increase over a 72 hour period 









4.2.6 romA cloning 
 
In order to elucidate further the role of romA, the gene amplified from MGH 78578, 
was cloned into vector pACYC177, thereafter known as pACromA.  pACromA was 
transformed into K. pneumoniae strain Ecl8 and E. coli strain MG1655, as well as 
pACYC177 only as a vector only control.  The strains were subject to susceptibility 
testing against ciprofloxacin (Cip), chloramphenicol (Cm), tetracycline (Tet) and 
tigecycline (Tige).  The introduction of  both romA and the vector only control had 
no effect on the susceptibility profiles of either strain, and so no conclusions could be 
drawn from this regarding the function of romA. 
 
  MIC (µg/ml) 
  Cip Cm Tet Tige 
Range Tested 0.008-32 0.0625-128 0.0625-128 0.0625-16 
Strain         
Ecl8 0.0156           0.5         0.5 0.125 
Ecl8/pACYC177 0.0156           0.5         0.5 0.125 
Ecl8/pACromA 0.0156           0.5         0.5 0.125 
E. coli MG1655 0.0312           8 1 0.125 
E. coli MG1655/pACYC177 0.0312           8 1 0.125 
E. coli MG1655/pACromA 0.0312           8 1 0.125 
 











4.3  Discussion 
 
The Kp342 genome encodes 422 ABC family (7.3% of proteins) and 128 MFS 
transporters (2.2% of proteins), which are used in the uptake of nutrients, and the 
extrusion of waste and toxic compounds (Fouts et al, 2008).  These statistics indicate 
that Kp342 is likely to encode a number of efflux pumps which may be capable of 
the efflux of a broad range of substrates.  The levels of antibiotic resistance observed 
in Kp342 may be as a consequence for the bacteria’s need to remove toxic plant 
metabolites, most likely through efflux mechanisms, which may be similar in 
structure to many antibiotics (Fouts et al, 2008).  Although Kp342 has been indicated 
to be an unlikely cause of infection in humans according to results in mouse model 
studies (Fouts et al, 2008), it can be inferred that the mechanisms by which Kp342 
confers resistance to antibiotics are likely to be the same as those employed by 
clinical K. pneumoniae strains.  These high levels of resistance and the availability of 
the Kp342 genome sequence (NC 011283) make this strain a good candidate for the 
study of K. pneumoniae antibiotic resistance mechanisms.  
 
The high levels of antibiotic resistance exhibited to the fluoroquinolones, 
tetracyclines and chloramphenicol in Kp342 can be indicative of a number of 
mechanisms.  gyrA, gyrB, parC and parE mutations have previously been reported to 
be responsible for high levels of fluoroquinolone resistance in E. coli (Bagel et al, 
1999), whilst active efflux has been reported to be capable of conferring resistance to 
all three antibiotic classes (Elkins and Nikaido, 2002).  The susceptibility testing 





conferring such levels of resistance due to the resistance phenotype spanning at least 
three antibiotic classes, resistance to all of which has previously been associated with 
an efflux phenotype (Elkins and Nikaido, 2002).  The low levels of ciprofloxacin 
resistance can be attributed to the fact that efflux only has been reported to be 
inadequate at conferring high levels of resistance in K. pneumoniae and the addition 
of gyrA and parC mutations are also deemed necessary for high-level resistance 
(Bratu et al, 2009), and Kp342 was shown to contain no mutations within its gyrA, 
gyrB, parC or parE which have been associated with resistance (Fouts et al, 2008). 
 
It has previously been reported in K. pneumoniae that the transcriptional activator, 
RamA, plays a role in the regulation of the RND family efflux pump, AcrAB 
(Schneiders et al, 2003).  ramR, a gene encoding a TetR family protein that lies 
upstream of ramA, has been reported to act as a negative regulator of ramA 
expression in S. enterica (Abouzeed et al, 2008).  The 96 nucleotide deletion 
identified in the ramR gene of Kp342 is highly likely to result in a non-functional or 
attenuated protein.  The subsequent discovery that Kp342 over-expresses ramA can 
therefore be attributed to this defective regulatory gene.  The ramR complementation 
studies showed that RamR was responsible for the negative regulation of ramA and 
romA expression, which in turn has a regulatory role in the expression of efflux 
pump gene, acrA.  The subsequent increases in susceptibility to the fluoroquinolones, 
tetracyclines and chloramphenicol indicate that the antibiotics tested from these three 
classes of antibiotic are most likely to be substrates of the AcrAB efflux pump, in 
agreement with previous literature (Elkins and Nikaido, 2002).  Such a drastic 





of the requirement of plant K. pneumoniae strains to incessantly use efflux 
mechanisms as a means to remove toxic plant metabolites, i.e. to survive in that 
particular niche, and therefore the function of RamR as a repressor of ramA may be 
obsolete in such strains.  Alternatively, endophytic K. pneumoniae strains may 
employ another mechanism by which the expression of ramA, romA and acrAB are 
regulated, and this mutation is simply the resulting pseudogene.  It is however 
unknown whether the RamR from Kp342 is truly a pseudogene or whether it forms a 
truncated form of the protein which may or may not continue to serve a function. 
 
The role of RomA remains elusive, although its over-expression alongside ramA and 
repression upon ramR complementation, indicate that it is linked to the RamA 
regulon.  A previous study reported that romA in Enterobacter spp. encodes an outer 
membrane protein but this remains unconfirmed in K. pneumoniae (Komatsu et al, 
1990), and romA’s lack of homology to any other bacterial proteins fails to shed any 
light on its function.  Furthermore the lack of a romA gene in the genomes of 
Salmonella spp., where ramA and ramR are found as in K. pneumoniae and 
Enterobacter spp., further complicates the mystery surrounding this gene and its role.  
The cloning of romA in this study did not clarify its role, if any, in antibiotic 
resistance.  Whatever function RomA plays in K. pneumoniae and Enterobacter spp., 
it appears to be unimportant for the development of an MDR phenotype in 
Salmonella spp., which can reach levels of antibiotic resistance, comparable to those 
observed in K. pneumoniae, in the absence of a romA gene (van der Straaten et al, 





alternatively that K. pneumoniae and Enterobacter spp. have gained this gene as a 
result of evolutionary pressures.   
 
The content of bacterial genomes are shaped through a combination of events 
including gene genesis, gene loss, gene gain and horizontal gene transfer.  Many 
bacterial pathogens are thought to have initially evolved through reductive evolution, 
resulting in smaller, more efficient genomes.  Gene loss and gene gain events are 
likely to work in balance with one another resulting in stable genome sizes as the 
predominance of either would result in bacterial genomes getting either progressively 
smaller or bigger.  The gene to DNA ration is fairly stable in prokaryotes with 
roughly 1kb of DNA per gene (Kunin and Ouzounis, 2003).  It is therefore quite 
plausible that RomA may play an important role in K. pneumoniae and Enterobacter 
spp. but is not necessary for Salmonella spp. to both survive and thrive in its 
particular ecological niche.  For now the exact role of RomA will remain a mystery 
but it is evident that despite its absence from the ram locus in Salmonella spp., 
RomA can be concluded to be linked to RamA in K. pneumoniae. 
 
The increase in biofilm production observed upon ramR complementation in Kp342 
indicate that RamA and RamR may be involved in the regulation of virulence 
mechanisms, such as biofilm production, in addition to antibiotic resistance.  It 
appears that whilst RamR acts as a repressor of ramA expression, it is additionally 
involved in the activation of biofilm production.  The incidence of increased biofilm 
production upon the increased antibiotic susceptibility following the introduction of 





when expressing high levels of efflux genes.  It has previously been reported that 
upon ramA over-expression and the subsequent acrAB over-expression, the major 
OMP, OmpK35, is down-regulated in K. pneumoniae, likely as a compensatory 
mechanism to maintain the integrity of the outer membrane (George et al, 1995).  It 
is possible that the over-expression or repression of ramA also affects the expression 
of other genes associated with the outer membrane such as those involved in the 
production of biofilm.  As Kp342 is an endophytic bacterium, it remains unclear 
whether this effect is unique to this particular strain, unique to endophytic K. 
pneumoniae strains, or whether it is also observed in clinical strains.  It could be 
worthwhile to investigate whether other endophytic K. pneumoniae strains share 
similar characteristics, particularly the mutations observed in the Kp342 ramR gene. 
 
It has been suggested that the over-expression of the AcrAB efflux pump in K. 
pneumoniae can contribute to the virulence of the bacterium (Padilla et al, 2010).  
Padilla et al (2010) showed that AcrB deletion mutants exhibited increased 
susceptibility to antibiotics including the fluoroquinolones, tetracycline, 
chloramphenicol, aminoglycosides, β-lactams and erythromycin.  However lower 
bacterial loads were also observed in the mutants compared to their wild-type 
counterparts in mouse lung models, suggesting that AcrAB may play a role in 
virulence, particularly in the early stages of infection.  The authors suggest that 
AcrAB may be involved in resisting early host defence mechanisms such as 
antimicrobial peptides.  If this were the case then the AcrAB efflux system could 
play an essential role in the success of K. pneumoniae, as well as other members of 





indicates that RamA and RamR may play a role in the regulation of at least one 
virulence factor via the regulation of this efflux pump. 
 
The results of this study suggest the transcriptional activator RamA plays an 
important role in the endophytic strain Kp342.  The observed deletion in the ramA 
regulator gene ramR suggests that the constitutive expression of ramA is necessary 
for the survival of the bacterium in its ecological niche.  It would be of additional 
value to examine the sequences of the ramR genes from other K. pneumoniae strains 
in order to identify any common mutations and associated phenotypes to contrast and 
compare to those found in strain Kp342.  It would also be of interest to observe the 






















5.1.1  The ramR gene 
 
ramR, a gene encoding a TetR-family protein, is encoded upstream and in the 
opposite orientation of ramA and romA in K. pneumoniae (Figure 5.1).   
 
 
Figure 5.1.  The genetic arrangement of ramR, romA and ramA in K. 
pneumoniae. 
 
TetR-family proteins are a large and varied family of proteins, widely dispersed in 
bacteria and archaea, that typically function as regulatory proteins (Ramos et al, 
2005).  Members of the TetR-family have been shown to play roles in the regulation 
in a number of essential bacterial processes, ranging from those involved in antibiotic 
resistance to general cell metabolism (Ramos et al, 2005).  The role of ramR has 
been speculated, and shown to some extent, to be a local regulator of ramA 
(Abouzeed et al, 2008).  Abouzeed et al (2008) found that the insertional inactivation 
of ramR in S. enterica resulted in the subsequent over-expression of ramA and 
reduced susceptibilities to a number of antibiotics, presumably as a result of RamA’s 





ramR resulted in a reversion to the parental phenotype and so it was concluded that 
RamR was acting as a repressor of RamA.  Its presence, immediately upstream of 
ramA, suggests a role in regulation as the genes encoding the local regulators, MarR 
and SoxR, of two other AraC/XylS transcriptional activators, are similarly located in 
close proximity to their regulatory target genes, marA and soxS (Amabile-Cuevas 
and Demple, 1991; Alekshun and Levy, 1999).  The role and function of RamR was 






















5.2  Results 
 
5.2.1  ramR sequencing 
 
The sequencing of the entire ORFs of the ramR genes from the K. pneumoniae panel 










S7 579: C to A None Expresser 
S8 No changes None Non-Expresser 
Ecl8 422: T to C I141T Non-Expresser 
Ecl8 Mdr1 422: T to C I141T  Expresser 
Kp342 
78: A to C, 111: C to T, 
114: T to G, 126: A to 
G, 229: G to C, 312: A 
to G, ∆340-435, 456: C 
to T, 480: A to G, 556: 
C to A 
D77H; ∆114-
145; H186N Expresser 
S28 
∆440-453, 496: G to C, 
513: G to A, 514: C to 
T, 515: G to T, 523: G 
to C, 547: G to A, 572: 
C to T 
F/S and stop 




F/S from 163; 
stop codon at 183 Expresser 
CG43 No changes None Non-Expresser 
 
Table 5.1.  The results of the sequencing of ramR from the panel of K. 
pneumoniae strains. The changes observed in the nucleotide gene sequence and 
the resultant amino acid changes for each strain are listed.  The ramA expression 
status is also included.  Changes are noted in regard to the ramR gene sequence from 






All of the ramA over-expressing strains contained deletions or insertions that either 
caused frame-shifts or were likely to affect the RamA protein structure, with the 
exception of Ecl8 Mdr1 and S7, both of which had protein sequences identical to that 
of the ramA non-expressing strain MGH 78578.  Ecl8 and Ecl8 Mdr1 had identical 
sequences to one another despite Ecl8 Mdr1 being a ramA over-expresser and the 
strains being isogenic; Ecl8 Mdr1 was derived from Ecl8 via selection with 
chloramphenicol (George et al, 1995).  The change from isoleucine to threonine 
observed in Ecl8 and Ecl8 Mdr1 is unlikely to bear any affect on the function of 
RamR and ramA expression since it is found in both of the strains.  Kp342 was 
shown to contain two amino acid changes; aspartic acid to histidine at position 77 
and histidine to asparagine at position 186, additionally a 32 amino acid deletion 
from the middle of the gene toward the C-terminus, although the gene sequence 
remains in frame following the deletion.  Such a change is likely to have a significant 
effect on the structure of the RamR protein and subsequently its ability to function.  
Strain S28 contained a number of silent changes at the nucleotide level, however the 
most significant change was a 14nt deletion which resulted in a premature stop codon 
at amino acid position 147, resulting in a truncated RamR protein.  Strain S29 
contained a 7nt insertion, which resulted in a frame-shift from amino acid position 
163 and a premature stop codon at 183, causing a truncated RamR protein.  As 
expected, no major changes were observed in the ramR gene sequences of the ramA 





















5.2.2  ramR mutation studies 
 
CPZ, ciprofloxacin and tigecycline mutants of Ecl8 were obtained by culturing on 
media containing 8X the respective MICs of each compound.  Two mutants were 
selected from the ciprofloxacin and tigecycline plates and one from the 
chlorpromazine plate, and subjected to susceptibility testing against chloramphenicol 
(Cm), ciprofloxacin (Cip), norfloxacin (Nor) and tetracycline (Tet).  All of the 
mutants exhibited significantly higher MICs against the tested antibiotics compared 
to Ecl8 (Table 5.2).  The increases in MICs ranged from 8-fold to 128-fold.   
 
  MIC (µg/ml)   












256   
0.0156-
256   
0.0156-
256   
0.0156-
256   
Strain                 
Ecl8 
        
0.0156   N/A  0.0625   N/A   0.5   N/A     0.5    N/A 
Ecl8-CPZ-1 0.25   16  1   16   8   16  16    32 
Ecl8-Tig-1 0.25   16  1   16   8   16  16    32 
Ecl8-Tig-2 0.25   16  1   16   8   16  16    32 
Ecl8-Cip-1 0.5   32  4   64   4   8  64  128 
Ecl8-Cip-2 0.25   16  2   32   8   16  32    64 
 
Table 5.2.  Susceptibility testing results of Ecl8 and the Ecl8 mutants. 
NA = not applicable. 
 
5.2.3  Mutant ramR sequencing  
 
The ramR gene from the Ecl8 mutants was subsequently amplified and sequenced.  





changes at the amino acid level were found in all mutants with the exception of Ecl8-
Cip-1 which had a ramR sequence identical to that of Ecl8.  Ecl8-Cip-2 contained 
two nucleotide mutations, which resulted in two amino acid changes; glutamic acid 
to lysine at position 175 and aspartic acid to asparagine at position 192.  Ecl8-CPZ-1 
contained, potentially the most significant change, resulting in a premature stop 
codon at position 137.  The two tigecycline mutants, Tig-1 and Tig-2, contained the 
same single nucleotide and amino acid change; glycine to aspartic acid at position 
96.  All of the observed mutations could potentially hinder the function of RamR as a 





Amino Acid Position(s) 
and Changes 
Ecl8-CPZ-1 410: C to A S137stop 
Ecl8-Cip-1 No changes No changes 
Ecl8-Cip-2 523: G to A; 574: G to A E175K; D192N 
Ecl8-Tig-1 287: G to A G96D 
Ecl8-Tig-2 287: G to A G96D 
  
Table 5.3.  The nucleotide changes found in Ecl8 mutants and their 
resultant amino acid changes. 
 
Figure 5.3 shows the protein sequence alignments of the Ecl8 mutants vs Ecl8 itself.  
Although no particular mutation hot spots can be observed in the RamR sequences 
from these few mutants, it does appear that mutations appear to be directed towards 
















5.2.4  ramR complementation 
 
pACramR and pACYC177 were transformed into Ecl8, Ecl8 Mdr1 and each of the 
Ecl8 mutants.  The introduction of pACYC177 and pACramR into Ecl8 and Ecl8 
Mdr1 had no effect on their susceptibility profiles to the antibiotics tested (Table 
5.4).  This is indicative that additional ramR expression in strains already expressing 
a functional RamR has no effect on susceptibility profiles, signifying that the 
susceptibility profiles displayed by Ecl8 Mdr1 are not attributable to a non-
functioning or attenuated RamR protein.  Additionally, this suggests that the effects 
of RamR are not subject to a dose dependent effect in these strains.  It is clear from 
the data in Table 5.4 that the pACYC177, vector only control, similarly had no effect 
on the susceptibility profile of the mutants with the exception of Cip-2 where a small 
increase is susceptibility was observed to both norfloxacin and chloramphenicol, 
likely to be an insignificant effect.  The introduction of pACramR into Ecl8-CPZ-1 
increased the susceptibility of the strain to ciprofloxacin (2-fold), tetracycline (2-
fold) and chloramphenicol (4-fold), however no change was observed in the MIC of 
norfloxacin.  Ecl8-Tig-1 and Ecl8-Tig-2, unsurprisingly since they contained the 
same amino acid change, showed the same antibiotic profiles following 
transformation with pACramR.  Susceptibility was increased to ciprofloxacin (16-
fold), norfloxacin (8-fold), tetracycline (8-fold) and chloramphenicol (4-fold).  Of 
note, pACramR resulted in restoration of the wild-type, Ecl8, susceptibility profile in 
the cases of both ciprofloxacin and tetracycline.  The introduction of pACramR into 
Ecl8-Cip-1 showed little effect with the exception of a 2-fold increase in 





control strain.  Overall pACramR appears to have a negligible effect in this strain 
which is not entirely unexpected as no mutations were identified within its ramR.  
Ecl8-Cip-2 exhibited an increase in susceptibility to ciprofloxacin (2-fold), 
norfloxacin (2-4-fold, compared to both Ecl8-Cip-2P and Ecl8-Cip-2R), tetracycline 
(8-fold) and chloramphenicol (4-8-fold, compared to both Ecl8-Cip-2P and Ecl8-
Cip-2R).  Of note, the tetracycline MIC of Ecl8-Cip-2R was restored to the same as 






















 MIC (µg/ml) 
 Cip Nor Cm Tet 
Range Tested 0.0625-512 0.0625-512 0.0625-512 0.0625-16 

















Ecl8 0.0156  N/A  0.0625  N/A 0.5 N/A      0.5 N/A  
Ecl8-P 0.0156 0 0.0625 0 0.5 0     0.5 0 
Ecl8-R 0.0156 0 0.0625 0 0.5 0     0.5 0 
Ecl8 Mdr1     8 N/A  128 N/A 128 N/A 256 N/A 
Ecl8 Mdr1-P     8 N/A  128 N/A 128 N/A 256 N/A 
Ecl8 Mdr1-R     8 N/A  128 N/A 128 N/A 256 N/A 
Ecl8-CPZ-1     0.25 16      1 16   16 32     4 8 
Ecl8-CPZ-1P     0.25 16      1 16   16 32     4 8 
Ecl8-CPZ-1R     0.125 8      1 16     4 8     2 4 
Ecl8-Tig-1     0.25 16      1 16   16 32     4 8 
Ecl8-Tig-1P     0.25 16      1 16   16 32     4 8 
Ecl8-Tig-1R 0.0156 0    0.125 2     4 8     0.5 0 
Ecl8-Tig-2     0.25 16      1 16   16 32     4 8 
Ecl8-Tig-2P     0.25 16      1 16   16 32     4 8 
Ecl8-Tig-2R 0.0156 0      0.125 2     4 8     0.5 0 
Ecl8-Cip-1     0.5 32      4 64   64 128     2 4 
Ecl8-Cip-1P     0.5 32      4 64   64 128     1 2 
Ecl8-Cip-1R     0.5 32      4 64   64 128     1 2 
Ecl8-Cip-2     0.25 16      2 32   32 64     4 8 
Ecl8-Cip-2P     0.25 16      1 16   16 32     4 8 
Ecl8-Cip-2R     0.125 8      0.5 8     4 8     0.5 0 
   
Table 5.4.  Susceptibility testing results of Ecl8 and the Ecl8 mutants 
after transformation with pACYC177 and pACramR.  Fold changes in MIC 











5.3  Discussion 
 
The results of this study clearly indicate that RamR plays an important role in the 
regulation of ramA expression, however they also suggest that RamR is not the sole 
regulator of the ram regulon, but rather is acting as a local repressor. 
 
The analysis of the panel of K. pneumoniae strains showed that whilst in some strains 
ramA over-expression could be attributed to mutations within the ramR gene, in 
other strains, such as Ecl8 Mdr1 and S7, another regulatory mechanism may be 
responsible.  In the cases of strains Kp342, S28 and S29, there are significant 
mutations that are likely to result in either truncated proteins or changes in protein 
conformation that would likely hinder or completely disable the function of the 
RamR protein.  The two exceptions to this finding are the ramR sequences of Ecl8 
Mdr1 and S7, both of which are ramA over-expressers that had no significant 
changes within their ramR gene sequences.  The lack of explanation within the ramR 
gene for the over-expression of ramA in these two strains can be due to a number of 
reasons, for example, another gene may also regulate the expression of ramA or 
alternatively, ramR - which in turn affects ramA.  The capacity of the ramA regulon 
remains largely unexplored and it is unknown how far its reach extends and the 
factors involved in its regulation.  Another two members of the AraC/XylS family of 
transcriptional regulators, MarA and SoxS, were shown by microarray analysis to 
upregulate 153 genes upon their induction by chemicals in vitro, although it is 
unknown how many of these genes are directly regulated by MarA and SoxS in vivo 





ramA, it is also reasonable to expect that the expression of ramA will additionally be 
subject to regulation by other, as yet unknown, mechanisms.    
 
The mutational studies showed that mutations within the ramR gene were reasonably 
easy to obtain by the use of chlorpromazine, ciprofloxacin and tigecycline.  It 
appears as though these mutations were likely to be targeted towards the ramR gene 
as all three chemicals are plausible substrates of the AcrAB efflux pumps that are 
regulated by RamA.  The mutation found within the CPZ-1 mutant resulting in a 
premature stop codon and therefore a truncated protein, would be predicted to have 
the most prominent effect on ramA and subsequently the MICs.  In all of the mutated 
ramR strains, the MICs to the tested antibiotics increased significantly (8-128-fold) 
resulting in intermediate or resistant levels for all antibiotics except ciprofloxacin, 
which despite a significant decrease in susceptibility the mutants remained clinically 
sensitive.  This is not surprising as Bratu et al (2009) reported that fluoroquinolone 
resistance in K. pneumoniae was less commonly mediated through RamA and 
AcrAB but instead was more likely to be as a result of gyrA and parC mutations.  
However, it was observed that the Cip-1 mutant exhibited the greatest fold changes 
in MICs despite containing no mutation within its ramR gene.  This result again 
indicates that the conferring of an MDR phenotype and the regulation of ramA may 
be controlled by another regulator distinct from RamR.  The increases in MICs 
observed in all of the mutants with changes within ramR are consistent with the 






The complementation studies showed that the presence of the vector only, 
pACYC177, or the ramR complement, pACYCramR, had no effect on the MICs of 
the parent strain Ecl8.  This indicates that the excess of RamR produced by the 
plasmid vector does not further increase susceptibility to antibiotics.  This is likely to 
be due to the fact that the ramA gene is not expressed in Ecl8 and therefore the ramR 
expressed from the plasmid has no further role in regulation in this strain.  
Additionally the introduction of pACYC177 and pACramR into Ecl8 Mdr1 did not 
affect MICs indicating that any malfunction in the RamR protein is not responsible 
for ramA over-expression in Ecl8 Mdr1 and so another mechanism is responsible in 
this case.  The complementation of ramR into the Ecl8 mutants showed varying 
degrees of increased susceptibility and, in some cases, returning the mutants to its 
parental phenotype for that particular antibiotic.  This indicates that the mutations 
within ramR have a significant effect on the function of the protein, most likely 
hindering the repression of ramA.  The lack of restoration of MICs in the Cip-1 
mutant upon ramR complementation was to be expected, as this was the only mutant 
that did not have any mutations within the ramR gene and subsequently the MDR 
phenotype must be caused by an alternative mechanism.  Although ramR 
complementation resulted in the restoration of the parental phenotype in some of the 
mutants (Tig-1 and Tig-2 showed complete restoration of their MICs to ciprofloxacin 
and tetracycline, and Cip-2 also showed complete restoration of its MIC to 
tetracycline), for most there was just partial restoration.  This may indicate that the 
chemicals used to obtain the mutants are also responsible for causing other mutations 






Figure 5.4 illustrates the alignment of the RamR protein sequence from K. 
pneumoniae MGH 78578, Enterobacter aerogenes 638 and S. typhimurium LT2.  
Highlighted in the figure are mutations in RamR found in this study as well as those 
found in other studies (Abouzeed et al, 2008; Molitor, 2008; Hentschke et al, 2010).  
The figure illustrates that the majority of mutations are located towards the C-
terminus rather than around the DNA binding domain or HTHs.  As might be 
expected, the DNA binding domain and HTH motifs are well conserved in the RamR 
sequences of all three species, although it should also be noted that the levels of 
conservation between species outside of these domains is significantly lower.  Whilst 
some of the mutations may not affect the action of the RamR protein in its role as a 
regulator of RamA, particularly the mutations that occurred in residues that are not 
conserved between species, there does not seem to be one particular hotspot or 
residue that is commonly mutated.  There does, however, appear to be a higher 








Figure 5.4.  An alignment of the protein sequences of RamR from K. pneumoniae MGH 78578, S. enterica 
Typhimurium LT2 and Enterobacter 638.  The changes observed in the strains in this study are denoted in purple.  The changes in 
orange were observed by Abouzeed et al (2008) in S. typhimurium; changes in red were observed by Molitor (2008) in E. aerogenes; 










The results of this study clearly indicate that the regulation of RamA is a complex 
process.  Whilst it has been shown that RamR is responsible for RamA regulation in 
some strains of K. pneumoniae, such as Kp342, it has also been shown that in other 
strains, Ecl8, Ecl8 Mdr1 and S7, that RamR plays no obvious role.  Mutations within 
RamR are clearly associated with ramA over-expression in the panel of K. 
pneumoniae strains in this study, however it remains unclear which other factors are 
involved in conferring this effect.  It could be speculated that the ability of the 
chemicals CPZ, ciprofloxacin and tigecycline, to select for mutations within the 
ramR gene appears to be a targeted effect.  It should also be noted that the chemicals 
used for mutant selection are all plausible substrates for the AcrAB efflux pump, 
which is regulated by RamA, and so mutations that cause its over-expression could 
be interpreted as a selected and necessary survival mechanism employed by the 
bacterium. 
 
Further studies are necessary to fully understand the role of RamR and its regulation 
of RamA.  Whilst it is apparent that RamR is not the sole regulator of RamA, it is 
unknown whether RamR is also a regulator of any other genes.  It would be of 
particular value to perform microarray analyses of strains of K. pneumoniae that are 
both expressers and non-expressers of ramA, and additionally those that contain 









Chapter 6: The development of carbapenem resistance 
 
6.1  Introduction 
 
6.1.1  Clinical significance of K. pneumoniae 
 
K. pneumoniae HAI’s are common within hospitals in the USA and Europe, 
comprising around 6% of infections according to CDC data (Hidron et al, 2008).  
Although K. pneumoniae can cause infection at various sites within the body, it is 
most commonly isolated from UTIs, often as a result of patient catheterisation 
(Nicolle, 2008).  It is common practice to treat such infections with fluoroquinolones, 
aminoglycosides or third generation cephalosporins, which are usually adequate to 
combat the infection within reasonable time limits.  However, the increasing 
incidence of MDR K. pneumoniae strains often renders these classes of antibiotics 
inadequate.  The carbapenems are usually reserved for treating K. pneumoniae 
infections that are unresponsive to the aforementioned antibiotics or for more 
complicated cases, such as blood stream infections or patients with serious 
underlying medical conditions and are, as such, termed the ‘drugs of last resort’.  K. 
pneumoniae infections that do not respond to carbapenem therapy present a serious 









6.1.2  Strain background 
 
A 71 year old male was admitted to Hairmyres Hospital (East Kilbride, Lanarkshire) 
in May of 2008 with an undisclosed medical condition.  The patient was catheterised 
throughout his stay and developed a UTI soon after his admittance.  He was initially 
treated with ceftriaxone for which the UTI failed to respond.  Following this, strain 1, 
known as K1, was collected on the 8
th
 of May from the patients urine and was 
subsequently identified as K. pneumoniae.  The patient was then subjected to 
meropenem therapy, which also failed to clear the infection.  Following the 
meropenem therapy failure, the patient was then treated with fosfomycin to which he 
initially appeared to respond but the UTI recurred soon afterward.  Strain 2, known 
as K2, was subsequently collected on the 13
th
 of May, from the urine and again 
identified as K. pneumoniae.  Subsequent meropenem treatment also failed and by 
this point the patient had also developed Clostridium difficile and MRSA infections, 
all of which contributed to his eventual death in the July.  Figure 6.1 shows a 
timeline of the patient’s treatment.  K2 was sent to the HPA (Colindale, London) 
where it underwent susceptibility testing and was shown to exhibit resistance to all 
drugs tested with the exception of colistin.  The HPA reported no carbapenemase 









Figure 6.1.  A timeline showing the treatment regimen and response of 























6.2  Results 
 
6.2.1  Strain typing by PFGE 
 
Strains K1 and K2 were subject to digestion by XbaI and PFGE.  Both strains gave 
indistinguishable banding patterns, indicating that the strains are of the same clonal 
type (Figure 6.2). 
 
Figure 6.2.  The PFGE gel of K1 and K2.   Strains were digested with XbaI.  
Marker sizes are in kb. 
 
6.2.2  Growth curve 
 
Growth curves performed on both K1 and K2 in LB broth identified that K1 appears 
to initially grow significantly faster than K2, particularly in the first two hours, but 
both strains reached a similar OD600 as they approached the stationary growth phase 





readings over the 6 hours compared to strain K2.  This could be indicative of 
increased fitness in K1 compared to K2. 
 
 
Figure 6.3.  A growth curve of K1 and K2.  Strains were grown in LB broth 
over 6 hours. 
 
6.2.3  Biofilm assays 
 
It was observed when routinely growing overnight cultures of K1 and K2 in liquid 
media that K2 appeared to produce more biofilm than K1.  Biofilm production was 
measured comparatively between K1 and K2.  Strains were inoculated in LB broth 
and incubated for 24, 48 and 72 hours respectively.  As shown in Figure 6.4, K2 
produced more biofilm than K1 over the entire 72 hour time period.  K2 exhibited 
81%, 55% and 65% increases in biofilm production compared to K1.  The 




















K1 0.253 0.934 1.838 2.087 2.253 2.373 
K2 0.141 0.635 1.603 1.927 2.145 2.281 






substantial enough to be considered clinically significant, but the differences do 
show a characterised difference between the two strains. 
 
 
Figure 6.4.  Graph showing the differences in biofilm production 
between strains K1 and K2.  A comparison of biofilm production in K1 and K2 
when grown in LB broth over 72 hours.   Error bars show SEM. 
 
6.2.4  Susceptibility testing of K1 and K2 
 
Susceptibility testing was performed by the agar doubling dilution method on K1 and 
K2 against 17 antibiotics as well as an imipenem/EDTA combination, the results of 
which are shown in Table 6.1.  There was one notable difference between K1 and 
K2; K2 was resistant to meropenem and ertapenem and had an intermediate MIC to 
imipenem, whilst K1 was sensitive to all three carbapenems.  Aside from this 
difference, both strains exhibited resistance to all other antibiotics tested with the 
only other exception being sensitivity to colistin in both strains.  Additionally, whilst 






significantly higher MIC to both antibiotics (at least 4-fold higher in both cases) and 
a lower MIC than K2 to cefoxitin (at least 2-fold).   The lack of reduction in MICs 
between imipenem and the imipenem/EDTA combination indicate that there was 
unlikely to be a metallo-β-lactamase present in either strain, however the broad 
spectrum antibiotic resistance exhibited by both strains was indicative of a number of 
resistance mechanisms. 
 
  MIC (µg/ml) 
Antibiotic Range Tested K1 S/I/R K2 S/I/R 
Amikacin 0.0625-512         32 R        32 R 
Ampicillin 0.0625-512     >512 R    >512 R 
Aztreonam 0.0625-256     >256 R        64 R 
Cefoxitin 0.0625-512         64 R    >128 R 
Ceftazidime 0.0625-128     >128 R    >128 R 
Chloramphenicol 0.0625-512         64 R        64 R 
Ciprofloxacin 0.0625-256    >256 R        64 R 
Colistin 0.0625-32           1 S          1 S 
Ertapenem 0.0625-32           1 S        64 R 
Gentamicin 0.0625-512       128 R      128 R 
Imipenem 0.0625-32           0.125 S          4 I 
Imipenem/EDTA 0.0625-32           0.125 S          4 I 
Meropenem 0.0625-32           0.125 S          8 R 
Piperacillin 0.0625-512     >512 R    >512 R 
Sulbactam 0.0625-32       >32 R      >32 R 
Tetracycline 0.0625-512        16 R          8 R 
Tigecycline 0.0625-16          4 R          2 I 
Tobramycin 0.0625-512        64 R        64 R 
 
Table 6.1.  Susceptibility testing of strains K1 and K2 against a broad 
range of antibiotics.  Strains are indicated as being sensitive (S), intermediate (I) 









6.2.5  Susceptibility testing in the presence of clavulanic acid 
 
To determine the contribution of clavulanic acid sensitive β-lactamases to the 
carbapenem resistant phenotype, susceptibility testing was performed in the presence 
of clavulanic acid for the carbapenems, ertapenem and imipenem, and selected 
cephalosporins: cefotaxime, cefpodoxime and ceftazidime.  Clavulanic acid was 
incorporated into IST agar at 4µg/ml and discs were used for the antibiotics.  A 
number of strains in addition to K1 and K2 were also included were included to act 

































K1 0 0 0 26 34 
K1/Clav 18 20 0 31 38 
Difference 18 20 0 5 4 
K2 0 0 0 0 26 
K2/Clav 0 0 0 12 28 
Difference 0 0 0 12 2 
MGH 78578 (TEM-1, 
SHV-12) 35 35 0 40 40 
MGH 78578 (TEM-1, 
SHV-12)/Clav 35 35 0 40 40 
Difference 0 0 0 0 0 
EC MG1655 ND 27 ND 37 34 
EC MG1655/Clav ND 27 ND 38 36 
Difference ND 0 ND 1 2 
EC ATCC 25922 39 27 34 40 37 
EC ATCC 25922/Clav 40 27 35 39 37 
Difference 1 0 1 -1 0 
EC TEM-1  42 39 9 45 38 
EC TEM-1/Clav 47 40 15 48 44 
Difference 5 1 6 3 4 
EC SHV-1 18 8 0 43 47 
EC SHV-1/Clav 36 34 0 46 52 
Difference 8 26 0 3 4 
KP MB-CTX-M-15 0 0 0 30 30 
KP MB-CTX-M-15/Clav 31 29 0 37 35 
Difference 31 29 0 7 5 
KP 32 CTX-M-15 0 0 0 28 33 
KP 32 CTX-M-15/Clav 25 25 8 36 36 
Difference 25 25 8 8 3 
ATCC 13883 ND ND ND 38 30 
ATCC 13883/Clav ND ND ND 38 30 
Difference ND ND ND 0 0 
 
Table 6.2.  The results of disc susceptibility testing to antibiotics with 
and without clavulanic acid.  Additional strains: EC and KP strains containing 
specific β-lactamases (as indicated in strain names) and EC 25922, EC MG1655 – 
non-β-lactamase containing control strains.  Difference values are highlighted in red 





Differences in zone diameters ≥5mm were considered to be significant for the 
presence of clavulanic sensitive β-lactamases involved in the hydrolysis of that 
particular antibiotic.  The differences in disc diameter for ertapenem in K1, K2, KP 
MB-CTX-M-15 and KP 32-CTX-M-15 suggested that CTX-M-15 may be a 
contributing factor in the conferring of ertapenem resistance, showing diameter 
increases of 5mm, 12mm, 7mm and 8mm respectively.  Notably, no or negligible 
differences were observed in the non-β-lactamase containing control strains 
MG1655, ATCC 13883 and ATCC 25922 in the presence of clavulanic acid.  
Additionally MGH 78578, which according to its published genome sequence 
(NC_009648), contained the β-lactamases TEM-1 and SHV-12, showed no 
differences in zone diameters.  As expected the E. coli strains containing the TEM-1 
and SHV-1 β-lactamases exhibited increased susceptibility to the cephalosporin 
antibiotics when tested in the presence of clavulanic acid but no significant 
differences were observed for either ertapenem or imipenem. 
 
6.2.6  Stability of resistance phenotype in K1 and K2 
 
To assess the stability of the resistance phenotype exhibited by both K1 and K2, both 
strains were subcultured on nutrient agar for 10 days before subsequent susceptibility 
testing.  It was shown that the subcultured strains (K1S and K2S) exhibited an 
identical resistance phenotype to their parental counterparts, K1 and K2, with one 
exception; K2 showed altered susceptibilities to the aminoglycoside antibiotics 
amikacin, gentamicin and tobramycin (Table 6.3).  These alterations in susceptibility 





loss of an aminoglycoside resistance determinant in the absence of antibiotic 
pressure. 
 
  MIC (µg/ml) 
Strain Amikacin Gentamicin Tobramycin 
K1       32    >128      128 
K2       32    >128      128 
K1S       32    >128      128 
K2S         1        0.25          4 
 
Table 6.3.  Susceptibility testing results of K1, K2 and their subcultured 
counterparts, K1S and K2S, against the aminoglycoside antibiotics 
amikacin, gentamicin and tobramycin. 
 
6.2.7  K2 disc synergy testing 
 
Synergy disc tests were set up for K2 against ertapenem, imipenem and meropenem 
with amoxicillin/clavulanic acid.  Figure 6.5 part 1 shows synergy between 
imipenem and amoxicillin/clavulanic acid, and part 2 shows synergy between 
meropenem and amoxicillin/clavulanic acid.  These results appear to indicate that 
there is an enzyme present in K2, capable of the hydrolysis of both imipenem and 
meropenem that can be inhibited by clavulanic acid.  No synergy was observed with 
ertapenem.  Of note the observed synergy effects were subject to optimal spacing of 
the discs; 25mm in part 1 and 10mm in part 2.  The synergy effect observed for 
imipenem contrasts that of the observations in K2 where no significant difference 









Figure 6.5.  Synergy disc testing of strain K2.  Synergy disc testing with 




6.2.8  Modified Hodge test 
 
A modified Hodge test was performed for both K1 and K2.  E. coli ATCC 25922 
was used as the indicator strain.  This was performed using imipenem and 
meropenem antibiotic discs and a KPC-2 containing K. pneumoniae strain as a 
positive control.  Neither strain exhibited the classical cloverleaf effect and so there 
were no phenotypic signs of carbapenemase production. 
 
6.2.9  Phenotypic AmpC detection tests 
 
Two phenotypic tests were performed to determine the presence of any AmpC 





Both assays showed no distortion of the zones of inhibition and so no AmpC enzyme 
was detected. 
 
6.2.10  PCR screening of β-lactamases 
 
Both K1 and K2 were screened by PCR for the presence of the following β-
lactamase genes as listed in Table 6.4. 
 
Class A Found? Variant K1/K2 
CTX-M + CTX-M-15 Both 
GES -    
IMI/SME -    
KPC -    
NMC -    
PER -    
SHV + SHV-1 Both 
TEM + TEM-1 Both 
VEB -    
Class B       
GIM -    
IMP -    
NDM -    
SIM -    
SPM -    
Class C       
AmpC -    
VIM -    
Class D       
OXA + OXA-1 Both 
 
Table 6.4.  Β-lactamase genes screened for in K1 and K2, those 
detected and the variants identified by sequencing.  + = found; - = not 
found. 
 
All PCR products were sequenced and both strains were found to contain the 





OXA, SHV, TEM and AmpC, and subsequent sequencing was performed by A. 
Hamouda).  Of note, no carbapenemases were detected in either strain and the 
absence of any ampC genes, as indicated by the phenotypic tests, was confirmed. 
 
6.2.11  Iso-electric focussing (IEF) 
 
IEF was attempted in order to identify any additional β-lactamases.  The resulting 
IEF gels failed to show clearly focussed bands and so no conclusions could be 
drawn. 
 
6.2.12  OMP extraction of K1 and K2 
 
OMP extractions were performed from cultures grown in both LB broth (high 
osmolarity) and nutrient (low osmolarity) in order to distinguish between OmpK35 
and OmpK36 as the former is inhibited in a high osmolarity medium.  OMP 
extractions from K1 and K2 revealed that both strains were lacking a major band of 
~40 kDa and additionally K2 lacked a major band of ~36kDa (Figure 6.6).  These 
bands are presumed to be OmpK35 and OmpK36 respectively.  OMP profiles were 
compared to those extracted from K. pneumoniae ATCC 13883, which has 
previously been reported to exhibit the full OMP complement and so was used as a 









      
Figure 6.6.  SDS PAGE gel showing the major OMPs in strains K1, K2 
and ATCC 13883.  The section of an SDS PAGE gel shows the expression of the 
three major OMP proteins in strain K1, K2 and ATCC 13883 when grown in both 
LB broth (LB) and nutrient broth (NB). 
 
6.2.13  Sequencing of ompK35 and ompK36 
 
The entire ORFs of ompK35 and ompK36 from K1, K2 and K. pneumoniae ATCC 
13883 were amplified and sequenced.  Although the K1 and K2 OmpK35 and 
OmpK36 nucleotide and protein sequences were identical to one another, a number 
of differences were observed in the protein sequences between K1/K2 and ATCC 
13883 (Figures 6.7 and 6.8, and Table 6.5).  The differences observed in OmpK35 
could be responsible for its absence on the SDS PAGE gels for both strains; however 
the absence of OmpK36 in K2 could not be attributed to the mutations found as both 

















292 F/S  183 T → A 
  184 L insertion 
  192 G → T 
  221 H → N 
  225 N → L 
  230 S insertion 
  231 R → K 
  233-234 DK → AL 
  269-271 FSG → AGS 
  272-278 7 AA deletion 
  279 S → L 
  314 I → L 
  322 L → I 
  353 D → S 
  356-357 RR → HN 
 
Table 6.5. The changes in the OmpK35 and OmpK36 protein sequences 
from K1 and K2 relative to that observed in K. pneumoniae ATCC 13883.  








Figure 6.7A.  The nucleotide sequence of ompK35 from K1 and K2 aligned with ompK35 from ATCC 13883.  Note the 















Figure 6.7B.  The protein sequences of OmpK35 from K1 and K2 aligned with OmpK35 from ATCC 13883.  Note the 











































6.2.14  Carbapenem mutant studies 
 
Carbapenem mutants of K1 were selected for using ertapenem, imipenem and 
meropenem.  Mutant colonies were selected from plates containing the relevant 
antibiotic at 4 - 8 times their respective MICs.  Concentrations of the antibiotics used 
and their mutation frequencies are shown in Table 6.6.  Similar mutation studies 
were also attempted in K2 but failed to produce any mutants. 
 
Antibiotic MIC (µg/ml) Antibiotic Conc. Mutation Frequency 
Ertapenem 1 4 7.74 x 10-8 
Imipenem        0.125 1 8.7 x 10
-8
 
Meropenem    0.5 4 1.74 x 10-8 
 
Table 6.6.  The mutation frequencies of K1 to ertapenem, imipenem and 
meropenem at the antibiotic concentrations used.   
 
The mutation frequencies were similar for each antibiotic with ertapenem and 
imipenem showing a slightly higher mutation frequency than meropenem but no 
increase that could be considered significant.  Of the mutants obtained, four were 
chosen for each antibiotic for subsequent susceptibility testing, the results of which 
are shown in Table 6.7.  The resistance profiles of the carbapenem mutants were 
highly similar to those observed in K2 for the carbapenem antibiotics.  Additionally, 
the higher MICs of aztreonam and ciprofloxacin observed in K1 relative to K2, were 
maintained in the K1 mutants.  Cefoxitin MICs in K1 mutants increased to that of 
K2.  The only exception to this pattern was in the Imi1-2 mutant which maintained 






OMP extractions of the carbapenem mutants showed that the 36kDa porin loss, as 
observed in K2, was evident in 100% (4/4) of the picked ertapenem and meropenem 
mutants and in 75% (3/4) of the imipenem mutants.  K1 Imi1-2 was the only mutant 
that did not display the 36kDa porin loss, which was reflected in its considerably 
lower carbapenem MICs with respect to the other mutants.  This suggests that the 
most significant, and perhaps even sole difference between K1 and K2 with regard to 
the carbapenem resistance phenotype, is the absence of the 36kDa porin.  Subsequent 
attempts to select for second generation mutations were unsuccessful, suggesting that 
the levels of carbapenem resistance reached in the first generation mutants were at 











  MIC (µg/ml) 
 
Strain Amikacin Ampicillin Aztreonam Cefoxitin Ceftazidime Chloramphenicol Ciprofloxacin Colistin Ertapenem 
 
K1 16 >512      >256 64        >128 64         >256 1 1 
 
K2 16 >512 64    >128 >128 64 64 1 64 
 
Imi1-1 32 >512      >256    >128 256 64         >256 1       >16 
 
Imi1-2 32 >512      >256 32 128 64         >256 1 1 
 
Imi1-3 32 >512      >256    >128 256 64         >256 1       >16 
 
Imi1-4 32 >512      >256    >128 256 64         >256 1       >16 
 
Mero4-1 32 >512      >256    >128 256 64         >256 1       >16 
 
Mero4-2 16 >512      >256    >128 128 64         >256 1       >16 
 
Mero4-3 16 >512      >256 128 256 64         >256 2       >16 
 
Mero4-4 32 >512      >256    >128 256 64         >256 2       >16 
 
Ert4-1 32 >512      >256    >128 128 64         >256 1       >16 
 
Ert4-2 32 >512      >256    >128 256 64         >256 2       >16 
 
Ert4-3 32 >512      >256    >128 256 64         >256 2       >16 
  Ert4-4 32 >512      >256    >128 256 64         >256 2       >16 
 















  MIC (µg/ml) 
Strain Gentamicin Imipenem Imipenem/EDTA Meropenem Piperacillin Sulbactam Tetracycline Tobramycin 
K1        128         0.125         0.125    0.5 >512 >32          16 64 
K2        128 2 2 8 >512 >32 8 64 
Imi1-1        128 2 1 8 >512 >32 8         128 
Imi1-2 64 1 1         0.125 >512 >32 8         128 
Imi1-3       128 2 1 8 >512 >32 8         128 
Imi1-4       128 2 1 8 >512 >32 8         128 
Mero4-1       128 2 1 8 >512 >32          16         256 
Mero4-2       128 2 1 8 >512 >32          16         256 
Mero4-3       128 2 1 8 >512 >32          16           64 
Mero4-4       128 2 1 8 >512 >32          16         128 
Ert4-1       128 2 1 8 >512 >32          16         128 
Ert4-2       128 2 1 8 >512 >32          16         128 
Ert4-3       128 2 1 8 >512 >32          16         128 
Ert4-4       128 2 1 8 >512 >32          16         128 
 













Ertapenem and meropenem mutant studies performed in strain MGH 78578 showed 
that, whilst it was possible to deplete the 36kDa OMP to give the same OMP profile 
as observed in K2, this did not result in significant carbapenem resistance 
comparable to the levels achieved in the K1 ertapenem mutants (Table 6.8).  The 
MGH 78578 Ert mutant exhibited resistance to ertapenem, although at a much lower 
level than in the K1 Ert mutant, and just a modest reduction in susceptibility to 
meropenem.  The MGH 78578 Mero mutant exhibited modest increases in 
susceptibility to all three antibiotics but again at a far lower level than the K1 mutant 
equivalent.  This shows that the levels of resistance achieved to the carbapenems in 
K1 Ert and K1 Mero cannot be achieved in their MGH 78578 counterparts.  These 
results suggest that the 36kDa OMP loss, only, cannot result in carbapenem 
resistance observed in K2 and that MGH 78578 must lack another resistance 
mechanism necessary for the phenotype observed in both K2 and the K1 mutants. 
 
 MIC (µg/ml) 
  Imipenem S/I/R Ertapenem S/I/R Meropenem S/I/R 
MGH 78578        0.25 S      0.25 S       0.125 S 
MGH 78578 Ert      0.25 S 4 R   0.5 S 
MGH 78578 Mero    0.5 S 1 S   0.5 S 
           
K1         0.125 S 4 R        0.125 S 
K1 Ert 4 I       128 R 8 R 
K1 Mero 4 I       128 R 8 R 
 
Table 6.8.  A comparison of the carbapenem MICs of K1 ertapenem  and 
meropenem mutants against MGH 78578 ertapenem and meropenem 









6.2.15  Stability of resistance phenotype and OMP loss in K1 
carbapenem mutants 
 
To determine whether the resistant phenotype to ertapenem, imipenem and 
meropenem in the carbapenem mutant experiments was stable, the strains were 
subcultured on IST agar for 10 days.  The strains were then subject to susceptibility 
testing and their outer membrane proteins were extracted for analysis.  Tested strains 
contained representatives of each of the generated carbapenem mutants (ertapenem, 
imipenem and meropenem).  No differences were observed in the susceptibility or 
the OMP profiles of the subcultured strains and so the phenotypes were concluded to 
be stable. 
 
6.2.16  Analysis of gene expression 
 
RT-PCR was performed on strains K1, K2 and ATCC 13883 to determine the 
relative expression levels of the following: genes encoding the outer membrane 
proteins; ompA, ompC, ompF, and genes that have been associated with an MDR 
phenotype via the over-expression of the efflux pump AcrAB; ramA, romA, acrA 
and 16S, the latter gene was used as an internal control.  The strains were grown to 
exponential growth phase (OD600~0.5) in both LB broth and nutrient broth 








Figure 6.9. Gel showing the PCR products as amplified from K1, K2 and 
ATCC 13883 cDNA for the genes of interest. 
 
As shown in Figure 6.9, it appears as though ompK35 was not expressed in either K1 
or K2 which correlates with its absence in their OMP profiles.  ompK36 however 
appeared to have been expressed in both strains despite the absence of OmpK36 in 
the OMP profile of K2.  It is also evident that both genes ramA and romA are over-
expressed in K1 and K2 relative to the levels observed in ATCC 13883, and acrA 
expression also appeared to be more prominent in K1 and K2, correlating with the 
results of the earlier study on the ramA regulon.  ompK34 has not been associated 
with the conferring of antibiotic resistance and 16S is a constitutively expressed 





6.2.17  Sequencing of ramR 
 
Upon the recognition that ramA was over-expressed in both K1 and K2, its local 
regulator gene, ramR, was amplified and sequenced.  The sequence was compared to 
that of K. pneumoniae strain MGH 78578, which has previously been shown to be a 
ramA non-expresser and whose ramR can be considered to be of the wild-type 
sequence. 
 
Sequence analysis revealed that K1 and K2 had identical ramR nucleotide sequences 
and contained three changes relative to the MGH 78578 sequence (Figure 6.10A).  
The protein sequence alignments (Figure 6.10B) show that the nucleotide change at 
position 579 is silent, but the changes at positions 57 and 247 result in the following; 
A19V and E83stop.  The presence of the stop codon in the ramR of both strains can 
be presumed to result in a non-functional RamR protein resulting in the subsequent 







Figure 6.10.  The nucleotide (A) and protein sequences (B) of ramR/RamR from K1, K2 against the wild-type 









6.2.18  Plasmid profiling of K1 and K2 
 
Plasmids were extracted from K1, K2 and also K. pneumoniae MGH 78578 (which 




Figure 6.11.  An agarose gel showing the plasmid profiles of K1, K2 and 
MGH 78578.  A 1kb DNA ladder with the DNA band sizes (in bp) are noted on the 
left and the sizes of known plasmids in MGH 78578 are noted on the right. 
 
In the agarose gel both K1 and K2 appear to contain three plasmids of similar sizes, 





their native, circular forms.  No obvious differences between the two strains can be 
ascertained from these results.  Plasmids were further profiled by S1 PFGE, which 
should allow the determination of true plasmid sizes.  K1, K1S, K2 and K2S were 
analysed by this technique (Figure 6.12). 
 
K1 and K1S plasmid profiles appear to be identical, both of which showing four 
plasmids.  K2 and K2S however showed differences in their plasmid profiles: K2S 
appears to lack the plasmid of around 70kb, and instead has gained another plasmid 
of <48kb.  Additionally K1 appears to contain an extra plasmid of <48kb with regard 
to K2 (Figure 6.12 and Table 6.9)  As the only difference between K2 and K2S was 
that K2S was subject to subculturing for ten days, it is highly unlikely that this is 
truly an additional plasmid.  It is possible that the plasmid of around 70kb has instead 
lost a large section of its DNA as a result of plasmid instability and now appears 
smaller in size.  It could be hypothesised that the missing section of plasmid may 
contain an aminoglycoside resistance determinant, as resistance profiles to the 










Figure 6.12.  An agarose gel showing the plasmid profiles of K1, K1S, 
K2, K2S and AG5 (AG5 - section 6.2.19). 
 
 No of Plasmids Sizes (kb) 
K1 4 194, 97, 70, <48 
K2 3 194, 97, 70 
K1S 4 194, 97, 70, <48 
K2S 3 194, 97, <48 
AG5 1 70 
 
Table 6.9.  The number of plasmids and approximate sizes present in 
the parent, subcultured and transconjugant strains. 
 
6.2.19  Plasmid curing  
 
Plasmid curing was attempted in both K1 and K2 using the curing agents; ethidium 
bromide, SDS and acriflavine.  Curing success was assessed by susceptibility testing 





gentamicin and ceftazidime.  No changes in MICs were observed for any of the 
‘cured’ colonies and so it was concluded that no plasmid containing genes that affect 
the MICs of the tested antibiotics were lost from the strains. 
 
6.2.20  Transconjugation studies 
 
Transconjugation experiments were set up with K1 and K2 as donors and rifampicin 
resistant E. coli J62-2 as the recipient strain.  Susceptibility testing was performed on 
suspected transconjugants as shown in Table 6.10.  Carbapenem resistance was non 
transferable to J62-2.  Gentamicin, tobramycin and ceftazidime resistance were all 
successfully transferred from K1 into J62-2.  No transconjugants were obtained from 
K2. 
 
  MIC (µg/ml) 
  Ceftazidime Cefoxitin Gentamicin Imipenem Tobramycin 
Range Tested 0.0625-128 0.0625-512 0.0625-512 0.0625-32 0.0625-512 
K1        128 64       128         0.125 64 
K2        128   >128       128 2 64 
E. coli J62-2 <8 <4        0.25         0.125 <2 
AG1 64 <4 64       0.25 32 
AG2 64 <4 64       0.25 32 
AG3 64 <4 64       0.25 64 
AG4 64 <4 64       0.25        128 
AG5 64 <4 64         0.25        128 
AG6 64 <4 64      0.25 64 
AG7 64 <4 64      0.25 64 
AG8 64 <4 64      0.25 64 
AG9 64 <4 64      0.25 64 
AG10 64 <4 64      0.25 64 
 
Table 6.10.  Susceptibilities of E. coli J62-2 transconjugants (AG1-10) 






6.2.21  Transconjugant J62-2 AG5 
 
The transconjugant strain appears to have acquired just one plasmid from K1 of 
around 70 kb in size as shown by S1 PFGE (Figure 6.12).  This same plasmid 
appears to be absent from the K2S strain.  The gain of this plasmid in J62-2 AG5 and 
loss in K2S correlates with the MIC data in Table 6.9 and the assumption that the 
plasmid contains a gene capable of conferring aminoglycoside resistance. 
 
- 70kb Plasmid 
 
PCRs were performed on strains K1, K2, K1S, K2S, J62-2 and J62-2 AG5 for the 
following genes: CTX-M, OXA, SHV and TEM.   
 
 
  Genes 
Strain CTX-M OXA SHV TEM 
K1 + + + + 
K2 + + + + 
K1S + + + + 
K2S + - + + 
J62-2 - - - - 
J62-2 AG5 + + - + 
 
Table 6.11. β-lactamase genes detected by PCR.  + = found; - = not found. 
 
The data in Table 6.11 suggests that the ~70 kb plasmid contains CTXM-15, OXA-1 
and TEM-1 in addition to the gene conferring aminoglycoside resistance.  The lack 
of OXA-1 in K2S suggests that this gene is located in the same region of DNA that is 





been lost.  SHV-1 is likely to be chromosomally encoded in K1 and K2 as is found in 































6.3  Discussion 
 
6.3.1 Aim of this work 
 
The work in this chapter was performed with the purpose of characterising the strains 
K1 and K2, establishing their relationship to one another, and ascertaining the 
mechanism(s) by which they exhibit an MDR phenotype, particularly to the 
carbapenem antibiotics.   
 
6.3.2 β-lactam and carbapenem resistance mechanisms 
 
Mechanisms of carbapenem resistance have become an important area of study in 
members of the Enterobacteriaceae as well as for other species of bacteria including 
P. aeruginosa and A. baumannii.  Of particular importance is the prevalence and 
spread of carbapenem resistant strains within the hospital environment and patients.  
This causes significant problems for the success of antibiotic therapy.  Carbapenem 
resistance in K. pneumoniae is most commonly mediated by the production of 
carbapenemases, which act to facilitate the hydrolysis of the β-lactam ring and 
therefore disable the carbapenem antibiotics.  An increasing number of 
carbapenmases have been identified in K. pneumoniae, most recently the KPC and 
NDM enzymes in 2001 and 2009 respectively (Yigit et al, 2001; Yong et al, 2009).  
Since their initial discoveries in the USA and India, incidences of both enzymes have 
been reported worldwide (Struelens et al, 2010; Babouee et al, 2011; Mulvey et al, 





carbapenemase β-lactamases, particularly the ampC genes, in conjunction with major 
OMP loss and active efflux mechanisms have been associated with a carbapenem 
resistant phenotype (Kohler et al, 1999, Quale et al, 2006, Yang et al, 2010).  The 
conferring of carbapenem resistance is a complex area of research often 
incorporating a multitude of mechanisms rather than being attributable to just one. 
 
A number of factors, including the identical PFGE profiles and their isolation in 
close proximity from a single patient, make it highly likely that strains K1 and K2 
are isogenic.  The differences observed in the levels of biofilm produced and the 
growth curves may be indicative of a ‘fitness cost’ as a consequence of the levels of 
carbapenem resistance conferred by K2.  Both of these show a marked difference 
between the two strains.   
 
The levels of MDR exhibited by both strains indicate the presence of a number of 
resistance mechanisms.  The levels of resistance to the cephalosporin antibiotics 
could be attributed to the presence of the β-lactamases CTX-M-15, SHV-1 and TEM-
1, which are capable of conferring the levels of cephalosporin resistance observed.  
The over-expression of the transcriptional activator ramA, as a result of a stop codon 
within the ramR regulator gene, indicates that it is likely that the elevated expression 
of efflux pumps are, in part, responsible for the MDR phenotype.  It is plausible that 
this mutation was responsible for the resistance exhibited to the fluoroquinolones, 
tetracycline and tigecycline, as earlier studies suggest that these antibiotics are 
substrates of the RND family efflux pumps commonly associated with regulation by 





carbapenemase gene detection, despite extensive screening by PCR and a modified 
Hodge test, denotes that such a gene is unlikely to play any role in the carbapenem 
resistance phenotype.  Additionally the lack of ampC detection by both PCR and 
phenotypic assays indicate that an AmpC enzyme does not contribute to the 
carbapenem resistant phenotype. 
 
The expression of the major OMPs has been associated with resistance to the β-
lactam antibiotics and indicated as a contributory factor in carbapenem resistance 
(Yang et al, 2009; Yang et al, 2010).  The OMP profiles of K1 and K2 revealed a 
key difference between the strains; K2 did not express OmpK36.  Expression of the 
major OMPs are certainly important factors for the permeation of various classes of 
antibiotics across the bacterial cell membrane and it appears that in K. pneumoniae, 
OmpK36 is of particular importance for permeability of the carbapenems.  The 
results of the K1 carbapenem mutant studies suggest that K1 is indeed the progenitor 
of K2, and that meropenem therapy is likely to have selected for the carbapenem 
resistant phenotype in vivo.  The susceptibility testing and OMP analysis of the 
carbapenem mutants show that the levels of resistance and OMP profile exhibited by 
K2 could be achieved in K1 by using any of the three carbapenems tested as a 
selective agent.  There are however some aspects of the K2 susceptibility profile that 
could not be explained by selection with the carbapenem antibiotics.  Both aztreonam 
and ciprofloxacin MICs were >256µg/ml in K1 but 64µg/ml in K2, and the K1 
carbapenem mutants maintained the higher MICs of the K1 parent strain.  Although 





ciprofloxacin, it remains unknown what causes the reductions in MICs to these 
antibiotics that were achieved in vivo but not in vitro. 
 
The results of the carbapenem mutant studies in strain MGH 78578 suggest that the 
loss of OmpK36 affects the MICs as follows: Ertapenem > Meropenem > Imipenem.  
The greatest reductions in susceptibility following OmpK36 loss are observed for 
ertapenem (4-16-fold), then meropenem (4-fold) and modest changes for imipenem 
(2-fold).  It has been shown that imipenem is capable of penetrating the bacterial cell 
wall faster than meropenem, likely due to a combination of its zwitterionic charge 
and smaller size, and these differences may allow imipenem to penetrate other porins 
that ertapenem and meropenem cannot (Yang et al, 1995).  The results of the K1 
carbapenem mutant studies on the other hand show markedly different results.  All 
three types of mutants (ertapenem, imipenem and meropenem) exhibited the same 
reductions in susceptibility with 64-fold changes for both ertapenem and meropenem, 
and a 32-fold change for imipenem, suggesting that the porin loss has the following 
effect on MICs; ertapenem = meropenem > imipenem.  The vast difference in 
susceptibility changes between MGH 78578 and the K1 carbapenem mutants suggest 
that although OmpK36 loss is an important factor in conferring resistance, additional 
mechanisms present in K1 but absent in MGH 78578 are also necessary to confer the 
phenotype observed.  In order to decipher the causes of the carbapenem resistant 
phenotype of K2, it is essential that these additional mechanisms are identified. 
 
It has been suggested that non-carbapenemase ESBLs may play a role in conferring 





ESBLs are noted for their ability to hydrolyse cephalosporins, none have been 
definitively shown to have the ability to confer resistance to the carbapenems.  It has 
previously been suggested that CTX-M-15 may be capable of contributing towards 
carbapenem resistance through the hydrolysis of ertapenem (Girlich et al, 2008).  
Girlich et al (2008) showed that CTX-M-15 exhibited higher β-lactamase activity 
against ertapenem than other CTX-M enzymes and TEM-3, although its activity was 
still substantially lower than that of the carbapenemase KPC-2 (1.6mU/mg vs. 
98mU/mg).  Compared to the wild-type K. pneumoniae ATCC 13883, K1 exhibits 
reduced susceptibility to ertapenem (0.125µg/ml vs. 1µg/ml) indicating that K1 may 
already be predisposed to resistance even before exposure to any carbapenem 
antibiotics.  The fact that both strains K1 and K2 contain CTX-M-15, suggest that 
this enzyme may be involved in conferring ertapenem resistance, in line with the 
findings of another study (Girlich et al, 2009). The other β-lactamases identified in 
strains K1 and K2 (OXA-1, SHV-1, TEM-1) are highly unlikely to play any role in 
conferring any ertapenem resistance as none of these have ever been reported to 
possess any carbapenemase activity and additionally strain MGH 78578, which 
contains TEM-1, and E. coli control strains containing TEM-1 and SHV-1, were 
completely sensitive to ertapenem.  Similarly, the carbapenem mutants of both MGH 
78578 and K1 exhibited completely different levels of resistance to ertapenem as 
well as meropenem and imipenem, despite the same resulting OMP profiles.  It must 
also be considered that despite the detection of just one ESBL in these strains (CTX-
M-15) it is possible that they additionally contain more than one SHV or TEM-type 
β-lactamase, and that only the predominant narrow-spectrum β-lactamases (SHV-1 





The production and dissemination of carbapenemases is often seen as the primary 
cause of carbapenem resistance and subsequently the incidences of carbapenemases 
is closely monitored in the UK by the HPA.  However, this study shows that levels of 
carbapenem resistance, sufficient to result in therapy failure, are possible in the 
absence of such enzymes.  A combination of resistance mechanisms, that are 
seemingly insignificant in regard to the conferring of carbapenem resistance singly, 
can result in resistance together.  This complex interplay between different resistance 
mechanisms is a particularly worrying phenomenon as they are a great deal more 
difficult and time consuming to identify compared to the presence of single 
resistance genes such as those encoding carbapenemases.  Additionally, as was 
observed with these strains, the elevated levels of resistance observed in strain K1 
was only subtly more than that of wild-type K. pneumoniae strain, MGH 78578, and 
so the predisposition to becoming carbapenem resistant upon exposure to the 
antibiotics may not be easily phenotypically detectable.  
 
The contribution of efflux mechanisms to carbapenem resistance is currently a 
disputed topic with some studies reporting a reduction in susceptibility to the 
carbapenem antibiotics upon the activation of efflux (Kohler et al, 1999; Szabo et al, 
2006), whilst other studies report little or no effect (El Amin et al, 2005; Kaczmarek 
et al, 2006).  Despite any foregone conclusions regarding the ability of efflux to 
contribute to carbapenem resistance, it remains clear that the presence of active 
efflux diminishes the viability of other antibiotic treatment options and so the 
capacity of efflux mechanisms should not be discounted.  Whilst in this study, only 





disregard the possibility of AcrAB contributing to carbapenem resistance or the 
presence of other efflux systems, that may be involved in conferring the phenotype. 
 
6.3.3  Plasmid analysis 
 
Plasmid-mediated transfer of resistance genes can be considered to be one of the 
most important mechanisms for the spread of antibiotic resistance.  In K. 
pneumoniae, plasmid-mediated resistance has been associated with the spread of 
genes conferring resistance to several classes of antibiotics including the 
fluoroquinolones and aminoglycosides, but particularly the β-lactams via the 
dissemination of genes encoding β-lactamases.  The acquisition of resistance 
plasmids, plasmids that carry two or more resistance determinants, provide a direct 
mechanism by which a bacterium can become resistant to multiple classes of 
antibiotics.   
 
The transconjugation studies and plasmid profiling showed that the β-lactamase 
genes CTX-M-15, OXA-1, and TEM-1 are present on the same plasmid whilst SHV-
1 is likely to be chromosomally located, as is typical in K. pneumoniae (Leung et al, 
1997).  The transfer of aminoglycoside resistance indicated that this plasmid 
additionally carries an aminoglycoside resistance determinant.  The loss of 
aminoglycoside resistance in strain K2S, suggests that this gene has been lost from 
the plasmid and the results of S1 PFGE show that the plasmid is significantly smaller 





DNA can be deleted and plasmids ends can recombine to create smaller, more 
compact plasmids.   
 
The loss of plasmid-resistance markers has been documented in S. enterica, where it 
was shown that in the absence of antibiotic pressure, resistance is lost whilst the 
plasmid itself remains (Mendoza-Medellin et al, 2004).  In the case of K2 and KS it 
appears that a large section of the plasmid DNA has been lost rather than only the 
gene encoding aminoglycoside resistance.  It was also shown that OXA-1 was lost, 
indicating that it likely resided in the same region of the plasmid.  Large plasmid 
DNA losses are not an undocumented phenomenon.  Williams et al (1988) observed 
a 39kb deletion of DNA from a plasmid in P. putida that encoded genes required for 
the catabolism of toluene and xylene.  It has been shown that the maintenance of 
large plasmids incurs a fitness cost on the bacterium and strains that lose plasmids as 
a result of segregational instability, can grow more rapidly than their parental 
counterparts, eventually taking over the population (Smith and Bidochka, 1998).  It 
could be hypothesised that K2S lost a large region of its plasmid as a mechanism of 
reducing costs on fitness. 
 
6.3.4  Conclusions 
 
It could be hypothesised that reduced susceptibility to the carbapenem antibiotics can 
be achieved through a plethora of contributory mechanisms, which on their own have 
no significant effect but together can confer levels of resistance to the carbapenems 





bacterium to ertapenem, imipenem or meropenem results in a universal effect of 
OmpK36 porin loss, the result of which is reduced susceptibility across the 
carbapenem antibiotics.  As ertapenem is typically used for the treatment of 
community infections, it is important to appreciate that ertapenem usage prior to 
usage of meropenem may inadvertently select for reduced susceptibility and cause 
therapy failure in strains that are predisposed to becoming carbapenem resistant.  The 
results of this study compound the increasing threat of carbapenem resistance and 
show that it is not only carbapenemases that require close monitoring under 
resistance surveillance studies, but additionally other ESBLs, such as CTX-M-15 
(which is the most commonly isolated of the CTX-M enzymes in the UK (Livermore 
et al, 2007)), must not be forgotten or overlooked as being less of a threat.  This 
indicates that the practice of conserving the carbapenem antibiotics until absolutely 
necessary is more important than ever as the availability of other antibiotics is a 











7.  Discussion and conclusions 
 
K. pneumoniae has recently been the focus of media attention regarding the spread of 
strains containing the carbapenemase NDM-1 and the problems associated with 
treating such infections (Struelens et al, 2010).  Fortunately such strains are still 
relatively rare in the UK although their emergence does demonstrate that K. 
pneumoniae is a bacterium capable of constantly acquiring new antibiotic resistance 
mechanisms.  Since the emergence and dissemination of β-lactamases in K. 
pneumoniae, few treatment options remain viable.  Presently the carbapenem 
antibiotics are considered the ‘antibiotics of last resort’ for complicated K. 
pneumoniae infections and those that harbour ESBLs; however even these 
compounds are now in danger of becoming ineffective due to the rapid evolution and 
dissemination of carbapenemases, such as NDM-1. 
 
Treatment options for infections caused by K. pneumoniae are dependent upon a 
number of factors including: the site of infection, any current medications, and 
previous antibiotic therapy.  Typically the aminoglycosides, fluroquinolones and 
penicillins/β-lactamase inhibitor combinations are the first line antibiotics used in the 
treatment of infections followed by the cephalosporins, all of which can be utilised in 
either monotherapy or combination therapy.  In the case of ESBL-producing strains 
the carbapenem antibiotics are the preferred choice, although these can be inadequate 
in the presence of strains harbouring carbapenemases.  The glycylcycline antibiotic, 
tigecycline, can be utilised in the treatment of carbapenem-resistant infections, 





urine mean it is limited in its ability to treat these infections and as such requires 
close monitoring (Peleg and Hooper, 2010).  K. pneumoniae, however, is capable of 
conferring resistance to all of these compounds through a plethora of mechanisms 
and as such presents a dilemma. 
 
The main focus of this PhD was to investigate the mechanisms of antibiotic 
resistance employed by clinical and environmental strains of K. pneumoniae. 
 
This study has shown that the transcriptional activator RamA is an important factor 
in the conferring of resistance to antibiotics that are subject to efflux via the AcrAB 
efflux pump.  RamA over-expressing strains were shown to exhibit elevated MICs to 
various classes of antibiotics including chloramphenicol, the fluroquinolones and the 
tetracyclines.  It has previously been shown that the upregulation of ramA 
transcription is associated with the upregulation of acrA, a gene encoding a 
component of the RND family efflux pump, AcrAB (Schneiders et al, 2003).  Two 
chemicals, chlorpromazine (CPZ) and tigecycline, were shown to upregulate genes 
deemed to be within the ram regulon; ramA, romA and acrA.  These findings suggest 
that these chemicals are capable of selecting for the upregulation of ramA, which in 
turn upregulates acrA, resulting in increased efflux capabilities.  This is an important 
finding as the ‘switching on’ of this single mechanism is sufficient to lead to an 
MDR phenotype that can result in the failure of therapy to many of the first line 
antibiotics used to treat K. pneumoniae infections.  The ability of CPZ to exhibit 
synergistic effects with chloramphenicol, norfloxacin and tetracycline is contrasted 





the phenothiazines may have a potential for clinical use, it is apparent that this may 
be a double-edged sword, where they may also be detrimental to the viability of other 
antimicrobials.  The upregulation of ramA over-expression by tigecycline is a 
particularly significant and worrying finding as tigecycline is an antibiotic reserved 
to treat complicated K. pneumoniae infections and its ability to select for an MDR 
phenotype brings into question the appropriateness of its use.  The effects of both 
CPZ and tigecycline in the upregulation of ramA and acrA suggest that acrA 
upregulation by both compounds is mediated by RamA, suggesting that the 
compounds themselves directly act upon either ramA itself or indirectly act upon its 
regulator(s). 
 
The endophytic K. pneumoniae strain, Kp342 was shown to exhibit a MDR 
phenotype and analysis of its ramR gene sequence revealed a 32 amino acid deletion.  
Complementation with a wild-type ramR resulted in increased susceptibility to 
several antibiotics that are normally associated with efflux through the AcrAB efflux 
pump.  Additionally the transcription of ramA, romA and acrA was shown to be 
downregulated in the ramR complemented strain relative to its parental counterpart.  
This suggests that RamR acts as a negative regulator of RamA and the deletion 
observed in its gene sequence is responsible for the over-expression of ramA and 
subsequently acrA, resulting in reduced susceptibility to several classes of antibiotics 
that are substrates of the AcrAB efflux pump.  The deletion suggests that efflux is an 
essential mechanism for survival in Kp342, possibly as a means to cope with toxic 
substrates encountered in its environmental niche.  The MDR phenotype exhibited by 





infection models have shown that Kp342 is of lower virulence than its clinical 
counterparts, suggesting it is adapted specifically as an endophyte (Fouts et al, 2008).  
It was also observed that in this particular strain the complementation of a wild-type 
ramR resulted in a significant increase in biofilm production, suggesting a role for 
RamA in virulence. 
 
Further investigation into the ramR gene sequences in a panel of K. pneumoniae 
containing both expressers and non-expressers showed a correlation between 
mutations within ramR and the over-expression of ramA.  This suggests that RamR is 
involved in the negative regulation of RamA, and mutations within the ramR gene 
sequence are adequate to result in ramA over-expression.  It was shown that CPZ, 
ciprofloxacin and tigecycline mutants of sensitive K. pneumoniae strain Ecl8, 
contained mutations within their ramR gene sequences.  These mutants exhibited 
elevated MICs across several antibiotic classes correlating with an efflux mutant 
phenotype.  The apparent targeting of these mutations towards the ramR gene is 
significant as both ciprofloxacin and tigecycline are known substrates of the AcrAB 
efflux pump, and CPZ is also likely to be subject to efflux.  Complementation with a 
wild-type ramR in the mutant strains resulted in a decrease in MICs to the tested 
antibiotics, however not to the parental phenotype in all strains.  These results 
suggest that although RamR is an important factor in the regulation of RamA, there 
are also other mechanisms involved in its regulation that remain to be identified.   
 
The final study in this PhD focussed on the mechanisms of carbapenem resistance in 





pneumoniae, obtained from the urine of a single hospitalised patient on separate 
occasions, were isogenic.  The patient had been treated with meropenem between the 
isolation of each of the strains.  The strains differed only by their susceptibilities to 
the carbapenem antibiotics.  The first obtained strain, K1 was carbapenem sensitive, 
and the subsequently obtained strain, K2, exhibited reduced susceptibility to the 
carbapenems.  Analysis of the OMP profiles of both strains revealed that K2 lacked a 
protein of ~38kDa.  Carbapenem mutation studies in K1 showed that the 
susceptibility phenotype and OMP profile exhibited by K2 could be achieved in K1 
via a single step mutation using either ertapenem, imipenem or meropenem.  This 
suggest that K1 was the progenitor of K2 following the in vivo exposure to 
meropenem during therapy.  PCR analyses revealed that both strains contained the β-
lactamases OXA-1, SHV-1 and TEM-1 and the ESBL - CTX-M-15.  Importantly 
neither strain contained any genes encoding carbapenemases or AmpC enzymes, 
both of which are commonly associated with reduced susceptibility to the 
carbapenem antibiotics.  Further analysis of the OMPs showed the porin found 
lacking in K2 was OmpK36 and additionally both K1 and K2 lacked OmpK35.  
Susceptibility profiling identified that the loss of OmpK36 corresponded to reduced 
susceptibility to both ertapenem and meropenem, suggesting that OmpK36 acts as a 
point of entry for these antibiotics in to the cell.  RT-PCR analysis showed that in 
both strains ramA and acrA was over-expressed suggesting the involvement of active 
efflux in the MDR phenotype.  Comparative susceptibility testing in β-lactamase 
containing control strains in the presence of clavulanic acid showed that the ESBL 
CTX-M-15 may have a role in conferring resistance to the carbapenems.  It was 





and that the reduced susceptibility to carbapenem phenotype was conferred by a 
combination of mechanisms including porin loss, active efflux and the  presence of 
CTX-M-15.  This study indicated the plethora and complexity of mechanisms that 
can be employed by a single strain to confer an MDR phenotype. 
 
The following conclusions were made with regard to the results of these studies. 
 
• RamA over-expression correlates with the upregulation of the efflux pump 
AcrAB and subsequently a MDR phenotype in agreement with previous 
literature (Schneiders et al, 2003; Ruzin et al, 2005; Kallmann et al, 2008; 
Zheng et al, 2009). 
 
• RamR acts as a negative regulator of RamA and subsequently plays a pivotal 
role in the regulation of AcrAB mediated efflux. 
 
• Carbapenem resistance can be conferred in the absence of carbapenemase or 
AmpC enzymes.   
 
• The ESBL CTX-M-15 plays a contributory role in conferring resistance to 
ertapenem when coupled with porin loss and active efflux. 
 
The results of these studies show the multitude of mechanisms that can be employed 
by K. pneumoniae to become resistant to antibiotics.  K. pneumoniae, similar to 





through a number of mechanisms when challenged.  The acquisition of resistance 
genes such as β-lactamases, qnr genes, aminoglycoside resistance determinants, 
alteration of the permeability of the outer membrane through either porin loss or 
downregulation, and active efflux mechanisms are but a few mechanisms by which 
K. pneumoniae can confer resistance to most antibiotics.  For example, National 
Nosocomial Infections Surveillance data reported that in 1986 that ~2% of K. 
pneumoniae strains isolated from ICU patients exhibited resistance to third-
generation cephalosporins, and in 2003 this number was reported to have risen to 
~20% (Gaynes and Edwards, 2005).  This rapid increase is undoubtedly as a result of 
the evolution and dissemination of ESBLs amongst K. pneumoniae strains.  Since the 
first identification of carbapenemases in the early 1980’s, dozens of new enzymes 
and variants have been identified in Gram-negative organisms, particularly in the 
Enterobacteriaceae, exhibiting the rapid rate at which these enzymes can evolve 
(Queenan and Bush, 2007).  There has been a marked increase in the frequency of K. 
pneumoniae UTIs between 1975 and 2003 where incidences were reported as 4.6 and 
9.8% respectively, where the increase in antibiotic resistance in K. pneumoniae is 
undoubtedly a major contributing factor (Gaynes and Edwards, 2005).  The existence 
of several of these resistance mechanisms in a single strain can render that strain 
MDR or even PDR, leaving clinicians in a quandary in deciding how to treat these 
infections.  Such infections, not only K. pneumoniae but also those caused by other 
Gram-negative organisms including A. baumannii and P. aeruginosa, has led to an 
increased demand for the development of new antimicrobials and also the revival of 






The constant and fluid evolution of this bacterium in response to antibiotic exposure 
has resulted in the emergence of strains that are almost untreatable and consequently 
are capable of causing significant mortality.  This bacterium has undoubtedly 
progressed and evolved to become a dangerous pathogen, one which we are 
struggling to combat and control in the clinical setting and which necessitates urgent 
attention.  It is almost inevitable that for some species of bacteria we will witness a 
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The Effect of Chlorpromazine on Multidrug Resistance Regulator RamA 
 
Findlay J, Schneiders T, Amyes SGB 





RamA is an AraC/XylS family transcriptional activator found in Klebsiella 
pneumoniae, Salmonella spp. and Enterobacter spp., where its over expression has 
been shown to confer a multidrug resistant (MDR) phenotype via the upregulation of 
the efflux pump acrAB. In previous work, the phenothiazine, chlorpromazine (CPZ), 
has been shown to exhibit increased antimicrobial activity against ramA-deleted 
Salmonella enterica serovar Typhimurium. Thus the aim of this study was to 
characterise the antimicrobial properties of CPZ and its effect on the expression of 




A variety of clinical and environmental strains of K. pneumoniae which had been 
previously characterised as either ramA non or over expressers were used in this 
study. MIC and synergy testing was performed in the presence or absence of 
chlorpromazine according to the BSAC guidelines. RT-PCR was used to determine 
differences in gene transcription levels and these results were quantified using Bio-




CPZ treatment increased the expression of ramA, acrA, romA and tetR in all strains 
tested. The ranges of fold expression increases were as follows: ramA, 1.6-6.4, romA, 
1.9-4.1, tetR 0.8-2.3, and acrA 0-0.7. CPZ was found to act in synergy with certain 




This study identified that CPZ acts as an inducer of ramA and its associated genes 
(acrA, romA and tetR). MIC testing showed that CPZ was able to act synergistically 














RamR: A Dual Regulator of Antibiotic Susceptibility and Biofilm Formation in 
Klebsiella pneumoniae Kp342 
 
Findlay J, Schneiders T 




RamA is an AraC/XylS family transcriptional activator found in Klebsiella 
pneumoniae, Salmonella spp. and Enterobacter spp., the over-expression of which is 
associated with an MDR phenotype.  Recently a tetR-like gene that lies upstream of 
ramA,  known as ramR, has been identified as a repressor of ramA.  K. pneumoniae 
Kp342 is a diazotrophic endophyte strain which has been reported to exhibit notable 
resistance to antibiotics.  Despite its MDR phenotype Kp342 has been shown in 
animals to be attenuated in comparison to clinical K. pneumoniae strains.  The aims 
of this study were to: determine the levels of ramA expression and establish its role 
in Kp342’s MDR phenotype; determine the effect of ramR complementation on 




Genome and sequence analysis performed in K. pneumoniae strain Kp342 
demonstrated a 96bp deletion within the ramR gene. Cloning and complementation 
with full size wild type ramR was performed in Kp342 (hereby known as 
Kp342/ramR). RT-PCR was used to assess levels of gene expression which were 
subsequently quantified using Bio-Rad Quantity One software. MIC testing was 
performed against chloramphenicol (Cm), norfloxacin (Nor) and tetracycline (Tet) 
according to BSAC guidelines. Biofilm formation was measured using a modified 




Kp342 containing the mutated ramR gene (96bp deletion) was shown to over-express 
ramA and the putative outer membrane protein romA.  Complementation of the ramR 
gene resulted in the repression of both ramA and romA transcription by 3-4 fold. 
Interestingly, the ramR complemented strains were shown to have increased biofilm 
formation (up to 9-fold increase) over a 72 hour period in both LB and M9 medium 
after static growth at 37°C. MICs of the tested antibiotics were reduced up to 16-fold 




This result demonstrates that ramR acts as a repressor of both ramA and putative 
outer membrane protein romA and as a result the bacterium becomes more 
susceptible to antibiotics. However the restoration of a functional ramR in Kp342 
increases biofilm formation significantly, suggesting that ramR plays a role in the 





The Differential Effect of Mutations in RamR, in Mediating Antibiotic 
Susceptibility in Klebsiella pneumoniae 
 
Findlay J, Schneiders T 




The transcriptional activator RamA confers an antibiotic resistance phenotype in 
Klebsiella pneumoniae when over-expressed.  Recently a tetR-like gene that lies 
upstream of ramA,  known as ramR, has been identified as a repressor of ramA.  
Correspondingly clinical isolates of K. pneumoniae with mutations within ramR have 
been shown to over-express ramA; however ramA over-expresssing clinical isolates 
with no changes within the repressor ramR or within the associated promoter regions 
have also been found.  Thus the aims of this study were: to firstly determine whether 
ramA over-expression mediated through ramR-derepression was dependent on the 
selective agent and secondly to determine whether mutations within the ramR gene 




Laboratory mutants from K. pneumoniae Ecl8 were selected for by the culturing of 
exponential growth phase bacterial cultures on ciprofloxacin or chlorpromazine 
plates at four times the MIC. The ramR gene was amplified from a selection of the 
mutants and was sequenced.  The subsequent MICs to chloramphenicol (Cm), 
norfloxacin (Nor) and tetracycline (Tet) of the selected mutants with changes within 
the ramR gene were then determined.  ramR mutants were complemented with a 
plasmid containing the wild-type ramR, pACramR, and their subsequent MICs were 




Four of the selected mutants were revealed to harbour mutations resulting in amino 
acid changes within the ramR gene. The mutations (G96D, S137Stop, E175K) found 
in the ramR gene appeared to favour the C-terminus region.  The mutants exhibited 
32-4 fold increases in MICs compared to the parental strain depending on which 
mutations were sustained within ramR. Complementation with the wild-type ramR 




All the mutants appeared to sustain ramR changes regardless of the compound used 
in the selection, indicating that ramR is a critical factor in mediating ramA over-
expression. The partial restoration of the parental phenotypes in the ramR-mutants 
indicates the MDR phenotypes are attributable to mutations within the RamR protein 





mutations identified within RamR protein are clustered around the C-terminus 



















































Mechanisms of Carbapenem Resistance Emerging During Therapy in a Strain 












Centre For Infectious Disease, The University of Edinburgh, Scotland, 
2
Hairmyres 





A clinical strain Klebsiella pneumoniae (K1), with reduced susceptibility to 





MIC testing of K1 and K2 was performed by agar dilution. Strains were typed by 
PFGE with XbaI. Outer membrane proteins were extracted and separated by SDS 
PAGE. Mutation studies were performed with the carbapenems; ertapenem, 
imipenem and meropenem. PCR was used to amplify the ompK35 and ompK36 
genes, which were sequenced. PCR was performed to detect the common β-
lactamases and all known carbapenemases. RT-PCR was performed to assess 




Both strains were resistant to all antibiotics tested except only K2 was resistant to 
ertapenem and meropenem, with intermediate resistance to imipenem. Both strains 
contained the CTX-M-15 β-lactamase and were indistinguishable by PFGE. OMP 
profiling revealed both strains lacked an OMP of around 40kDa but K2 also lacked a 
major OMP of around 36kDa. Carbapenem mutation studies on K1 showed that the 
porin loss and resistance phenotype observed in K2 could easily be selected in vitro 
in K1. Carbapenem MICs performed with clavulanic acid showed inhibition of 
ertapenem resistance suggesting a contribution by the CTX-M-15 β-lactamase. None 
of the known carbapenemases were detected by PCR. RT-PCR showed the 
upregulation of ramA, romA and acrA, and no expression of ompK35 as well as 




PFGE showed K1 and K2 are isogenic, the main difference between them is porin 
loss which appears to have been selected for directly during meropenem therapy. It is 
likely that the carbapenem resistance phenotype is due to three contributing factors; 
the presence of CTX-M-15 and upregulation of efflux pumps to give reduced 
ertapenem susceptibility in K1 followed by porin loss, resulting in  







The Epidemiology of Acinetobacter baumannii of Animal Origin 
 
Hamouda A, Findlay J, Al Hassan L, Amyes SGB 




The aim of this study was to determine whether A. baumannii strains collected from 
animals slaughtered for human consumption from Scottish abattoirs possessed major 




Sixteen A. baumannii isolates (8 from cattle and 8 from pigs) obtained from 1381 
animal samples, collected between the period February 2006 to August 2007, were 
used in this study. For species identification, blaOXA-51-like genes were amplified 
by the polymerase chain reaction (PCR) and confirmed by sequencing. Minimum 
inhibitory concentration (MIC) of antibiotics was performed according to the BSAC 
guidelines. PCR was also used to amplify sections of DNA that harboured resistance 
islands (RIs), blaampC and the insertion sequence ISAba1. All strains were 





All isolates were confirmed as A. baumannii using blaOXA-51-like genes and, 
interestingly, many harboured the blaOXA-51 gene itself. The PFGE profile of the 
animal isolates showed some genotypic diversity and a very different profile from A. 
baumannii European clone I, II, and III. All isolates lacked any evidence of 
resistance islands and ISAba1 but every strain harboured blaampC genes. All 16 
isolates were sensitive to imipenem (MIC ≤4mg/L), meropenem (MIC ≤4mg/L), 
ciprofloxacin (MIC ≤0.5mg/L) and piperacillin/tazobactam (MIC ≤16mg/L) but they 
were all (100%) resistant to ceftazidime (MIC >2mg/L). When animal isolates were 





All isolates were confirmed as A. baumannii using blaOXA-51-like genes and, 
interestingly, many harboured the blaOXA-51 gene itself. The PFGE profile of the 
animal isolates showed some genotypic diversity and a very different profile from A. 
baumannii European clone I, II, and III. All isolates lacked any evidence of 
resistance islands and ISAba1 but every strain harboured blaampC genes. All 16 
isolates were sensitive to imipenem (MIC ≤4mg/L), meropenem (MIC ≤4mg/L), 
ciprofloxacin (MIC ≤0.5mg/L) and piperacillin/tazobactam (MIC ≤16mg/L) but they 
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